

INNOVATION AND INTEGRATION OF LABORATORY AND CLINICAL SYSTEMS

Reshaping the Future of HIV, TB, Malaria, Flu, Neglected Tropical Diseases and Emerging Pathogens in Africa CAPE TOWN
INTERNATIONAL
CONVENTION CENTRE
Cape Town, South Africa



You are invited to attend the ASLM2014 Awards Ceremony and Reception!

WHEN: Wednesday, 3 December, 18:30

WHERE: CTICC Auditorium 1, Cape Town, South Africa

The biennial ASLM Awards Ceremony recognises individuals and laboratories committed to strengthening laboratory medicine in Africa.

"ASLM honours the dedication, innovation and perseverance of professionals who have overcome and addressed laboratory medicine challenges to make significant contributions," says ASLM CEO, Dr. Tsehaynesh Messele.

The ASLM2014 Awards Ceremony will be held in the Cape Town International Conference Centre (CTICC) main auditorium on Wednesday evening, 3 December, to publicly honour the winners of four categories:

ASLM Certificate of Recognition for Accreditation of Government Laboratories

Recognises newly-accredited government laboratories in Africa

Best Laboratory Practice Award

Encourages and recognises a sustainable laboratory improvement or best practice leading to tangible and replicable outcomes for enhanced quality in laboratory systems and patient care

Best Laboratory Champion Clinician Award

Promotes and recognises clinicians in the field of laboratory science with profound impact and benefit to public health

ASLM Lifetime Achievement Award

Recognises an individual playing an exceptional leadership role in the laboratory sciences



AWARDS CEREMONY & RECEPTION SPONSORS





TABLE OF CONTENTS

Weld	come Letters
	South Africa Minister of Health, Dr. Aaron Motsoaledi
	ASLM Chief Executive Officer, Dr. Tsehaynesh Messele
	ASLM2014 Co-Chair, Dr. Amadou Sall
	ASLM2014 Co-Chair, Mr. Sagie Pillay
ASL	M2014 Organising Committee
	Scientific Committee
	Executive Committee
Gen	eral Conference Information
	General Information
	NHLS Laboratory Tours
	Young Professionals
	CTICC Floor Plans and Room Locations
Prog	ramme Summary
	Agenda at a Glance
Scie	ntific Sessions
	Monday, 1 December
	Tuesday, 2 December
	Wednesday, 3 December
	Thursday, 4 December
Supp	porters and Sponsors
	Supporters and Sponsors Descriptions
	Scholarship Sponsors
Exhi	bitors
	Exhibitor Descriptions and Booth Numbers
	Exhibitor Directory





• Supports the National Department of Health in

delivering laboratory services

to South Africans

• Provides **training** in health sciences

in partnership with universities and universities of technology

Promotes and undertakes relevant and innovative health related

research

At the core of the NHLS is next generation pathology excellence

National Health Laboratory Service
Supporting national health and the wellbeing of all South Africans

Tel: 011 386 6000 www.nhls.ac.za

WELCOME

AARON MOTSOALEDI

SOUTH AFRICA MINISTER OF HEALTH



Dear participant,

On behalf of the South African people and the National Department of Health, I welcome you to the second African Society for Laboratory Medicine (ASLM) conference, to be held in Cape Town, South Africa on 30 November-4 December 2014. This conference is hosted by ASLM and supported by the South African National Health Laboratory Service.

The theme of this second international conference is "Innovation and Integration of Laboratory and Clinical Systems: Reshaping the Future of HIV, TB, Malaria, Flu, Neglected Tropical Diseases and Emerging Infections in

Africa". This is a theme which is very close to the heart of South Africa's healthcare policies and strategies. It mirrors the Republic of South Africa and our neighbours' efforts to improve the health services provided to our people through national and regional strategies and agreements.

ASLM is a much needed organisation, one which will help the development of integrated and holistic laboratory services. ASLM is filling a huge gap in Africa: it supports the development of laboratories and those professionals that make for quality and accurate diagnostics. It serves to unite laboratory services in Africa, which we all know, are the cornerstone of any public health system.

I welcome participants from all over the world to our beautiful city of Cape Town. We encourage delegates to participate in this invaluable conference, but also to take the opportunity to experience the culture and history of the city of Cape Town.

We welcome you and look forward to your participation at this conference.

Dr. Aaron Motsoaledi

Minister of Health, South Africa

TSEHAYNESH MESSELE

CHIEF EXECUTIVE OFFICER, AFRICAN SOCIETY FOR LABORATORY MEDICINE



Welcome to the second international conference of the African Society for Laboratory Medicine (ASLM)!

ASLM2014 is pleased to provide you with a comprehensive programme focusing on current scientific, programmatic and policy-related issues, with more than 40 seminar sessions and 700 plenary, symposia, roundtable, oral and poster presentations.

ASLM2014 offers unique roundtable and plenary sessions, where successes and challenges of laboratory medicine in Africa, as well as the latest developments of technologies, practices and policies, are to be addressed.

The conference schedule also covers diverse topics such as laboratory quality improvement, point-of-care diagnostics, drug resistance, biosafety, laboratory networking and surveillance. ASLM looks forward to fostering this week's invaluable scientific discussions across a wide range of disease areas and building upon these conversations to offer sustainable solutions to advance laboratories across the continent.

ASLM2014 also brings renewed attention to the ASLM2020 strategic vision which focuses on the following objectives:

- >> Strengthen the laboratory workforce to meet international targets
- >> Transform the quality of laboratory testing in preparation for achieving accreditation by international standards
- >> Develop strong, harmonised regulatory systems for diagnostic products to ensure patient safety and laboratory result accuracy
- >> Strengthen national laboratory networks to improve early disease detection and collaborative research

Quality laboratories save lives and ensure positive health outcomes. ASLM commits to build on knowledge and experiences shared at ASLM2014 to further enhance quality laboratory systems throughout the continent.

I hope best practices and experiences shared at this conference are inspiring and will be useful to enrich and improve works in your respective countries. I also hope the conference will give an opportunity for networking and new partnerships. ASLM extends its appreciation to the various governments, regional bodies, Ministers of Health, partner organisations, as well as ASLM Ambassadors and members for their support towards making this conference a success.

Tsehaynesh Messele

ASLM Chief Executive Officer (CEO)

AMADOU SALL

CO-CHAIR, AFRICAN SOCIETY FOR LABORATORY MEDICINE 2014 CONFERENCE



Following on the success of the ASLM2012 conference, it is with great pride and enthusiasm that I welcome you to the second international conference of the African Society for Laboratory Medicine (ASLM). ASLM2014 is being held in a particular context as West Africa and the world experience the worst Ebola virus disease (EVD) epidemic in history which has led to exceptional mobilisation globally. The unprecedented magnitude of this epidemic and its devastating impact on health, economies and societies in West Africa not only sound an alarm on the need to reinforce health systems in most African countries but also call to rethink the model in each of its components.

In that perspective, the EVD epidemic in West Africa emphasises the need for the laboratory to be innovative in its approach to deliver and deploy appropriate tools and services at the point-of-care and be fully integrated with clinical management systems for an efficient response and control. For that reason, the theme for ASLM2014 "Innovation and Integration of Laboratory and Clinical Systems" is very much relevant and timely, and should be an opportunity to discuss how we can "reshape the future" of emerging and neglected diseases that are threatening African development.

ASLM2014 is Africa's leading technical conference and exposition for laboratory medicine professionals, and brings together global leaders from more than 50 countries to address the role that professionals, systems and emerging technologies must play in the laboratory services revolution within Africa. ASLM is uniquely positioned to lead efforts to optimise and standardise the laboratory services experience throughout the continent and, in this particular context, has an historical opportunity to make a major difference.

I hope that participants at this conference will not only contribute to this challenging but exciting endeavour by actively participating in the proceedings, but also take the best practices presented here to our respective countries and areas of work. We look forward to your participation and support to help us continue to make this the most successful and premier meeting for laboratory professionals.

Amadou Alpha Sall

ASLM2014 Conference Co-Chair

SAGIE PILLAY

CO-CHAIR, AFRICAN SOCIETY FOR LABORATORY MEDICINE 2014 CONFERENCE



Following on the success of the ASLM2012 conference, it is a privilege and an honour to welcome you to the second international conference of the African Society for Laboratory Medicine (ASLM). We are proud to gather laboratory professionals from across Africa, to share their insights and knowledge on improving laboratory diagnostics, accreditation successes and workforce development efforts. This conference is Africa's leading technical conference and exposition for laboratory medicine professionals. The theme for this second conference is "Innovation and integration of Laboratory and Clinical Systems: Reshaping the future of HIV, TB, Malaria, Flu, Neglected Tropical Diseases and Emerging Pathogens in Africa."

ASLM continually aims to strengthen laboratories and networks throughout Africa. In December 2012, at the inaugural conference of ASLM in Cape Town, an important milestone was achieved to accomplish the strategic vision of ASLM. Six African Ministers of Health from South Africa, Côte d'Ivoire, Kenya, Mozambique, Nigeria, and Tanzania developed and signed a consensus ASLM2012 Ministerial Call for Action. This move outlined specific commitments and tangible steps that would be taken to improve laboratory systems on every level.

The Ministerial Call for Action reinforced an existing commitment from multiple governments to laboratory medicine. This commitment was entered into with the aim to encourage governments to adopt goals and strategies.

The four strategic goals which comprise the ASLM2020 strategy are:

- >> To strengthen the laboratory workforce by training and certifying 30,000 laboratory professionals and clinicians by 2020 through standardised frameworks.
- >> To transform laboratory testing quality by enrolling 2,500 laboratories in accreditation and quality improvement programmes, enabling 250 laboratories to achieve accreditation by international standards before 2020.
- >> To work with Africa's seven regional economic communities, to ensure patient safety by developing strong, harmonised regulatory systems for diagnostic products as defined by the Global Harmonization Taskforce in at least 25 countries by 2020.
- >> To strengthen national laboratory networks and promoting South-South collaboration by developing laboratories that participate in an African network of national public health reference laboratories in at least 30 countries by 2020.

In the interim several other exciting global initiatives were launched with ASLM being a key partner. This included the 90-90-90 campaign and the Diagnostics Access Initiative. ASLM has entrenched itself as truly a pan-African organisation in the forefront to support Health Ministries' in strengthening health systems on the continent. It must be noted that ASLM has, in a short period of 3 years, built its global credibility.

We look forward to a conference that reviews progress to date, then comes up with practical Plans of Action and mobilising resources to effect the plans that will fast track ending the AIDS epidemic by 2030. As we engage and discuss at ASLM2014, we need to assess and measure the ASLM achievements so far, look for solutions to the existing and potential challenges, and ultimately craft the roadmap to 2020. My call to you is to build on the momentum created from the first conference, to pool our scarce resources and expertise, and to work together to build an affordable and effective laboratory medicine environment that supports a better, affordable, accessible health service for all African people.

Sagie Pillay

ASLM2014 Conference Co-Chair

ASLM2014 ORGANISING COMMITTEE

ASLM2014 CO-CHAIRS

Dr. Amadou Sall

Institut Pasteur De Dakar, Senegal

Mr. Sagie Pillay

ASLM2014 Conference Co-Chair

EXECUTIVE COMMITTEE

Executive Committee Members

Dr. Amadou Sall

Institut Pasteur De Dakar, Senegal

Sagie Pillay

ASLM2014 Conference Co-Chair

Lauren Deaton

Courtesy Associates, USA

Graham Garrard

National Health Laboratory Service, South Africa

Dr. Elizabeth Luman

Centers for Disease Control and Prevention, USA

Dr. Tsehaynesh Messele

African Society for Laboratory Medicine, Ethiopia

Dr. Trevor Peter

African Society for Laboratory Medicine, Ethiopia

Kaamini Reddy

National Health Laboratory Service, South Africa

Corey White

African Society for Laboratory Medicine, Ethiopia

Dr. Katy Yao

Centers for Disease Control and Prevention, USA

ASLM2014 Media Officer

Kaamini Reddy

kaamini.reddy@nhls.ac.za +27-72-620-6146

SCIENTIFIC COMMITTEE

Scientific Committee Chair

Dr. Rosanna Peeling

London School of Hygiene and Tropical Medicine, UK

Scientific Committee Deputy Chair

Dr. John Nkengasong

Centers for Disease Control and Prevention, USA

Scientific Committee Members

Pr. Alash'le Abimiku

Institute of Human Virology, Nigeria University of Maryland, USA

Dr. Ousmane Diop

World Health Organization, Switzerland

Dr. Ogobara Doumbo

Malaria Research & Training Centre, Mali

Mackenzie Hurlston

Centers for Disease Control and Prevention, USA

Pr. Robert Marks

Biotechnology Ben Gurion University, Israel Nanyang Technological University, Singapore

Pr. Souleymane Mboup

Cheikh Anta Diop University, Senegal

Pr. Stephen Morse

Columbia University, USA

Pr. Iruka Okeke

Haverford College, USA

Pr. Wendy Stevens

University of the Witwatersrand, South Africa

Pr. Oyewale Tomori

Redeemer's University, Nigeria

Dr. Karin Weyer

World Health Organization, Switzerland



YOU'VE ONLY JUST ARRIVED & ALREADY WE'RE THINKING OF YOUR NEXT TRIP

As the official airline network for ASLM2014, we'd like to thank you for choosing the Star Alliance network and hope that all goes really well for you here today.

Whilst you concentrate on the day's events, we hope you'll consider us the next time you need to attend a conference.

With over 18,500 flights a day to 1,316 airports across 192 countries, our 27 member airlines will extend a wide choice of flights to any future conference you're planning to attend. And no matter which of those airlines' frequent flyer programmes you belong to, you can earn and redeem miles across all of them.

So the next time you want to concentrate all your energies on your conference, we hope you'll decide to leave the travel arrangements to us.



ADRIA

GENERAL CONFERENCE INFORMATION

PARTICIPATING IN ASLM2014

Registration Times

Registration and check-in will be at Cape Town International Convention Centre (CTICC) at the following times and locations:

- >> Saturday, 29 November 2014: 07:30 17:00 Strelitzia Foyer, CTICC Ground Floor
- >> Sunday, 30 November 2014: 07:30 19:00 Strelitzia Foyer, CTICC Ground Floor
- >> Monday, 1 December 2014: 07:00 16:30 Prefunction of Ballroom East/West, CTICC First Floor
- >> Tuesday, 2 December 2014: 07:00 16:30
 Prefunction of Ballroom East/West, CTICC First Floor
- >> Wednesday, 3 December 2014: 07:00 16:30 Prefunction of Ballroom East/West, CTICC First Floor
- >> Thursday, 4 December 2014: 07:00 14:00
 Prefunction of Ballroom East/West, CTICC First Floor

Certificate of Attendance

Certificate of attendance will be available electronically for individuals who complete the ASLM2014 post conference survey. Please check your email post conference for the link.

Name Tags

Name tags must be worn at all times during official meetings in the conference centre. Lost name tags may be replaced at the registration desk. Please bring your ID for verification.

Attire

Conference attire is business casual for all days.

Transportation

Most conference hotels are within walking distance, and some conference properties offer a complimentary shuttle to the famed Victoria & Albert Waterfront district, featuring numerous dining and shopping options.

Additionally, public transport options around Cape Town include city buses, taxis, Rikkis, commuter trains and minbuses. The way most South Africans get around is by minibus taxi. They are cheap, efficient and plentiful. You can hail them like you would a cab anywhere in the world. You'll also see Rikkis (www.rikkis.co.za) in the centre of Cape Town. Rikkis are small brightly colored vans that operate like taxis. Metro Trains (www.metrorail.co.za) run to all the suburban areas and they go as far as Stellenbosch and Paarl in the Winelands.

MyCiTi bus is another option to navigate Cape Town. MyCiTi operates bus routes in a number of areas across Cape Town. For more information, including route options visit their website: http://myciti.org.za/en/home/.

Several taxi companies operate in and around Cape Town.

Two such companies include:

- >> Excite Taxis +27 21 448 4444
- >> Sport Taxis +27 21 447 4444

Parking

CTICC offers over 1,300 secure, easily accessible on-site parking bays to visitors.

The 740 bays on P1 are accessed via the Buitengracht or Walter Sisulu Avenue/Long Street entrance and require a short walk across Convention Square to enter the CTICC.

The 250 bays on P2 are located in the Westin Cape Town hotel basement.

The 350 bays on P3 are situated in the CTICC basement.

Guests are required to use the convenient pay-on-foot parking ticket kiosks to pay for their parking on an hourly basis.

Money

The local currency is the South African Rand. ATMs are available throughout the city including two in the CTICC.

Please remember to advise your credit card and banking institutions that you will be travelling in South Africa. You should also plan to carefully review all banking statements and receipts to ensure accuracy.

Meals

Please check with your hotel to confirm if breakfast is included in your room rate. Lunch and morning/afternoon tea breaks will be available for purchase within the ASLM Exhibit Hall (Ballroom East/West) from 1-4 December (except 4 December will not have an afternoon break option). In addition, the Opening Reception (17:00 Sunday, 30 November) and the Awards Reception (19:30 Wednesday, 3 December) will offer light fare.







Commitment and Care

Making a world of difference in HIV/AIDS

People living with HIV are in need of care and treatment and are often too poor to access it. This lack of access is aggravated by weak health-care infrastructure. Today, thanks to recent advances in therapeutic drugs and treatment programmes, as well as the commitment of national governments to prioritise treatment, many people living with HIV/AIDS harbour a newfound hope.

Through the AmpliCare Initiative, Roche expands access to laboratory tests for diagnosis and monitoring of those on therapy – a necessary component of HIV/AIDS treatment and management programmes. The Roche AmpliCare Initiative remains at the forefront of action and innovation in addressing the HIV/AIDS pandemic – making care possible for people affected by HIV.

Speaker Ready Room

All speaker presentations should be submitted to the Speaker Ready Room, Room 1.51 in the CTICC. You will need to upload your presentation one day prior to your presentation day in Room 1.51. Please do not plan to take your presentation directly to your presentation room.

The **Speaker Ready Room** hours are as follows:

>> 30 November: 8:00 – 17:00

>> 1 December: 8:00 – 18:00

>> 2 December: 8:00 – 18:00

>> 3 December: 8:00 - 18:00

>> 4 December: 8:00 – 16:00

Poster Session/Oral Poster Setup & Teardown Times

Poster presenters will have a poster displayed in the poster area outside of Ballroom East/West (Oral Poster Presenters) and Foyer of Auditorium 1 (Poster Presenters).

Posters should not exceed the size of vertical A1.

Poster session setup will take place on 30 November from 11:00-17:00 and poster teardown will take place on 4 December from 14:00-15:00. Following the designated tear down times, remaining posters will be discarded.

Camera & Record Devices Notice

The use of cameras and/or recorders is strictly prohibited during the oral and poster sessions. Limited use is allowed for Exhibitors in their own booth area. Personal photography is allowed at social functions.

*Consent to Use of Photographic Images: Registration and attendance at, or participation in ASLM2014 constitutes an agreement by the registrant to ASLM's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions and audiotapes of such events and activities.

First Aid

If you are in need of emergency services, medical staff are located on the Lower Level of the CTICC. If you need a hospital, one hospital option is below.

Christiaan Barnard Memorial Hospital Address: 181 Longmarket Street, Cape Town, 8001 Phone:021 480 6262

Internet Access

Internet access: Basic, complimentary internet access is available at the CTICC in designated areas. To access this select "CTICC Open Wi-Fi" and open your browser then follow the instructions.

Simultaneous Translation

French translation is available in Auditorium 1. Please secure your headset at the translation desk outside of Auditorium 1 and plan to return the headset at the conclusion of each day.




NHLS LABORATORY TOURS

The National Health Laboratory Service (NHLS) is hosting Lab Tours during ASLM2014 where you can see the operations of a diagnostic pathology laboratory at Groote Schuur Hospital and also the GeneXpert at Khayelitsha, the latest in TB diagnostics.

These tours will take place on Tuesday, 2nd December and Wednesday, 3rd December. Transportation buses for the tour will depart the Cape Town International Convention Centre promptly at 10:00 and return at 13:00 each day. Pre-registration was required. If you pre-registered, check your email for additional logistical details.

Discover HUMAN

Solutions for Every Laboratory





HUMAN assays validated and preprogrammed

*introduction in 2015







YOUNG PROFESSIONALS

Space is limited at each session and will be filled on a first come, first serve basis at the time of the event. Food and Beverages will not be provided at any of the sessions. Please feel free to bring your own.

Abstract Writing

- >> Part 1: Sunday, 30 November, 09:00-12:00, Room 1.4
- >> Part 2: Monday, 1 December, 13:00-14:30, Roof Terrace Room

A powerful abstract is key to getting your manuscript published or being invited to present at an important conference. This two day course will teach the do's and don'ts of abstract writing, focusing on how to clearly and succinctly communicate your important messages. The hands-on session will give participants the opportunity to work in groups to edit their own abstracts. Homework will be assigned to be completed between sessions.

Sharing Success: Writing News Articles and Award Nominations

- >> Part 1: Wednesday, 3 December, 13:00-14:30, Auditorium 2
- >> Part 2: Thursday, 4 December, 13:00-14:30, Room 1.6

Congratulations — you have done great work! Now it's time to let the world know. This workshop will teach you how to publicize your success stories by writing newsletter articles and award nominations. Participants will be mentored on how to transform their scientific work into a success stories that will appeal to a non-scientific audience. Bring your stories and we'll help you write them! Homework will be assigned to be completed between sessions.

Young Professionals Forum with Leaders

- >> Tuesday, 2 December, 07:00-08:30, Room 2.64/65
- >> Tuesday, 2 December, 13:00-14:30, Room 2.64/65
- >> Wednesday, 3 December, 13:00-14:30, Room 2.64/65

Join some of the top leaders in Laboratory Medicine today! High-level leaders will meet with small groups of 15-20 participants to share their experiences and discuss career paths and opportunities. The small group setting will ensure individual attention and plenty of time for questions in an informal atmosphere.

Developing Killer Presentations

- >> Part 1: Monday, 1 December, 07:00-08:30, Room 1.4
- >> Part 2: Wednesday, 3 December, 07:00-08:30, Room 1.6

Learn how to engage your audience to give effective and memorable presentations. This workshop will cover crafting effective messages, designing engaging and relevant slides, creating useful templates, honing PowerPoint technique, and improving delivery skills. Homework will be assigned to be completed between sessions.



Free Educational Opportunities Online

>> Thursday, 4 December, 07:00-08:30, Room 1.6

Online education is growing exponentially, and many organizations are offering learning material free of charge. Learn how to tap into the limitless online resources available today! Explore options such as TED talks, Kahn academy, and university-level courses that are available free of charge.


Statistical Secrets Revealed: Analysis and Presentation of Data


>> Tuesday, 2 December, 13:00-14:30, Auditorium 2

How can I best present my data? What does this p-value really mean? How big of a sample do I need? This course will focus on some common misconceptions and errors in interpretation of data. We will provide simple explanations of some common statistical concepts, and discuss ideas for how to better display various types of data in tables and graphs.


FLOOR PLAN - ROOM LOCATIONS


CAPE TOWN INTERNATIONAL CONVENTION CENTRE





FIRST FLOOR







Abbott RealTime mSystems

The right solutions for your growing lab

- Broad Menu
- Increased Flexibility
- High Confidence
- High Efficiency



The performance you need. Now.



CONFERENCE AGENDA AT A GLANCE

The detailed descriptions for all seminars can be found at www.aslm2014.org under the Conference Programme tab.

Friday, 28 November 2014

	Saturday, 29 November 2014
	Seminars
07:30 - 17:00	Registration
08:00 - 12:00	AfBSA Pre-conference Workshop
08:00 - 17:00	SLMTA/SLIPTA Symposium 2014

		Sunday, 30 November 2014	1					
07:30 – 19:00	Registration		STRELITZIA CONSERVANCY, CTICC GROUND FLOOR					
		Seminars						
ROC	DM 2.4	R00M 1.6	R00M 1.4					
African Reg 3rd African Reg	0 –12:00 ulatory Forum: julatory Forum for Diagnostics	08:00 –12:00 Beckman Coulter: Innovations in Flow Cytometry and Routine CD4 Testing in HIV	09:00 -12:00 Young Professionals: Abstract Writing (Part 1 of 2)					
	Opening of ASLM2014							
14:00 – 17:00	Opening Ceremony							
17:00 – 19:00 Opening Reception								



			Mon	day, 1 De	ecember	2014				
07:00 - 16:30	Regis	tration				F	OYER OF BALLF	ROOM EAST/	WEST, CTICC FIRST FLOO	
			Mo	rning Seminar	s 07:00 – 08	8:30				
R00M 2.4		R00M 1.6		R001	M 1.4	А	UDITORIUM 2		ROOM 2.64/65	
Africa Experience with Harmonization		Roll Back Mala Harmonization of Rapid Diagnostic	k Malaria: Young Proi ion of Malaria Developi inostic Tests Presen		rifessionals: Therm ing Killer Innovatations in the 1 of 2) of M		rmo Fisher Ethiopia: ovative Biomarkers the Management Malignancies and nergency Medicine		ASM: Sharing Success: Laboratory Mentoring Program 2.0	
10:00 - 17:00	Exhib	it							BALLROOM EAST/WES	
		Plenary 1: Labo	ratory Me	edicine and Inf	ectious Disea	se Contro	l 09:00 – 10	0:30		
				AUDITO	ORIUM 1					
Informing P Microbiologis Pete				ctice of Laborator strong Institutions Alex Co				l Clinical Res	Sanctuary of Scientific search Discovery Karim	
10:45 – 11:00	Break	((on your own)							BALLROOM EAST/WES	
			(Oral Sessions	l 11:00 – 12:4	5				
R00M 1.4		ROOM 1.6	R	00M 2.4	AUDITORIU	JM 1	ROOF TERRA	ACE ROOM	AUDITORIUM 2	
Oral Session 1.1: HIV Diagnosis and Viral Load Testing	Streng	ral Session 1.2: thening Laboratory agement Systems		Session 1.3: Ig Resistance	Oral Sessio Malaria and Parasitic Di	l Other	Oral Sess External Assurance P	Quality	Oral Session 1.6: Partnership and Laboratory Network	
12:45 – 14:15	Lunch	n (on your own)							BALLROOM EAST/WES	
13:00 – 14:15	Poste	ers							AUDITORIUM 1 FOYE	
				Oral Posters	13:00 - 14:30)				
BALLROOM	EAST/W	VEST	BALLROOM EAST/WEST			BALLROOM EAST/WEST				
Oral Pos Evaluating			Oral Posters 1.2: HIV and Co-Infections			Oral Posters 1.3: Laboratory Quality Improvement				
Evaluating	NOVCIT	10010	Mid	I-Day Seminar		1.30	Lau	oratory qua	nty improvement	
ROOM 2.4		R00M 1.6		ROOM			TERRACE ROO	M	AUDITORIUM 2	
ASLM: Shared Opportunity to Save Lives: Public-Private Partnership Diagnostics Consortium to Tackle Major Health Threats in Africa Hologic: Analy Performance of the HIV-1 Quant Dx on the Fully Auto on the Fully Auto with Tools to En Laboratory Mana of Viral Load Te			Aptima ssay nated mbined ance ement		on and Asset at Principles, ed Forecasting ant and Vendor	Ab	g Professional stract Writing Part 2 of 2)		USAID: Filling in the Gaps: Understanding the HRH nd Lab needs to expand pediatric ART	
				Symposia I	14:45 – 16:15					
ROOF TERRACE RO	MOC		ROOM 1.	.6	AU	DITORIUM 2			R00M 1.4	
Scaling up Access to TB (Viral Load in Africa: Init			Symposium 2: Symposium 3: Global Laboratory Accrediting Clinical and Laboratory Systems ance to Implementation and Services: Need to Tie the Two		ical stems :	Symposium 4: Partnerships in Strengthening Laboratory Capacity in Africa				
	Specia	l Session: Frontli	ne Exper	ience with the	Ebola Outbrea	ak in Wes	t Africa 16	6:30 - 18:0	0	
					ORIUM 2					
				Round Tables						
ROOF TERRACE RO		ROOM 1.6			ROOM 1.4			ROOM 2.4		
Round Table 1 An Update on Progress the ASLM2020 Goals for Strengthening in Africa	ds Strengthen	Round Table 2: Round Tab ning Laboratory Networks ic Health Laboratories in Africa for Diagnos Resource-Limite		ivate Partn ort Connec Diagnostics e-Limited S	erships tivity in	Labo	Round Table 4: ratory Supply Chain agement Challenges in Africa			
			Eve	ening Seminar		0:00				
	M 1.6				M 1.4				M 2.4	
KNVC: Practical Mod Use of XpertMTB TB Case Detecti	o Increase		WHO: Assuring the Quality of Diagnostics Used at Point-of-Care; Pre-Market Assessment and Post-market Surveillance Hologic: Field Performance Data of the HIV-1 Quant Dx Assay on the Fully At Panther System: Global Customer Events and Post-market Surveillance			on the Fully Automated				

			Tueso	day, 2 De	ecembe	r 2014				
07:00 - 16:30	Registration	1				F	OYER OF BALL	ROOM EA	ST/WEST, CTICC FIRST FLOO	
			Mo	rning Seminar	s 07:00 – 0	8:30				
ROOM 1.6			R00M 1.	4		ROOM 2.4			ROOM 2.64/65	
Support – The Lasec Strategy New			Sysmex-Partec: New Perspectives in Malaria Diagnostics		Bio-Rad: Geenius HIV1/2 Confirmatory Assay: a Step Forward in HIV Confirmatory and Differentiation Testing; Improving Serological Qualification Goals in Blood Banks: New Bio-Rad HCV Combo Test		Young Professionals: Forum with Leader			
10:00 – 17:00	Exhibit								BALLROOM EAST/WES	
		Plena	rv 2: Labo	ratory Medici	ne and Policy	1 09:00 -	- 10:30			
				AUDITO						
Global Health Role of Labora Shanno			l	Jniting Laborator and Imple		cy,		ling Trust	cy and Clinical Medicine: and Measuring Impact anna Peeling	
10:45 – 11:00	Break (on ye	our own)							BALLROOM EAST/WES	
			C	Oral Sessions	l 11:00 – 12:4	15				
R00M 1.4	AUDITO	RIUM 1	R	OOM 1.6	ROOM	2.4	ROOF TERR	ACE ROOM	AUDITORIUM 2	
Oral Session 2.1: Point-of-Care Diagnostics	HIV Co-i (Hepatitis I	sion 2.2: infection 3, STIs, and coccus)		Session 2.3: g TB Diagnosis	Oral Sessi Monitoring F and Enteric I	Rotavirus	Improvem	ratory	Oral Session 2.6: d Human Resource Development for Laboratory	
12:45 – 14:15	Lunch (on y	our own)							BALLROOM EAST/WES	
13:00 – 14:15	Posters								AUDITORIUM 1 FOYE	
				Oral Posters	13:00 – 14:3	0				
BALLROOM	EAST/WEST			BALLROOM	EAST/WEST			BALLRO	OOM EAST/WEST	
Oral Posters 2.1: Lal Manageme		mation	0		s 2.2: Role of Laboratory Epidemiology			Oral Posters 2.3: HIV-Related Diagnostics		
			Mic	I-Day Seminar	s 13:00 – 1	4:30				
ROOF TERRACE ROOM	ROOI	M 1.6	R	OOM 1.4	AUDITORI	UM 2	ROOM	Л 2.4	ROOM 2.64/65	
Roche: DBS Collection: A Practical Approach	Load on H Already on	itoring Viral IV Patients Treatment: g Challenge		: Shaping the Future iagnostics	Young Profes Statistical S Revealed: And Presentation	Secrets alysis and	and Imple of New D Technologi SLM Coll	Evaluation Young Professiona Forum with Lead Diagnostic plies in Africa: Illaborating Intres		
				Symposia I	14:45 – 16:15					
ROOF TERRACE RO	OM		R00M 1.	4		R00M 1.6			AUDITORIUM 2	
The Changing Fac Laboratory Quality Mar	Symposium 5: S The Changing Face of Strength			Symposium 6: thening the Practice of Medicine and Pathology in Africa		Symposium 7: Cryptococcal Rapid Diagno Testing: Lessons Learned Programme Implementation Diagnostic Access Issue			Symposium 8: The Diagnostics Access Initiative	
			R	ound Tables	16:30 – 18:0	0				
ROOM 2.4		AUDITORIUM	2	AUDITO	RIUM 1		R00M 1.6		ROOF TERRACE ROOM	
Round Table 5: uality Assurance Strategies to Accelerate Uptake of HIV-Related Diagnostics in Africa Round Table 0 Update on the Ste Process Towards La Quality Systems Accreditation in A		epwise Laboratory boratory Development: H and & Comp		y Workforce Diag		Round Table 8: Diagnostics Market Intelligence in Africa		Round Table 9: Promising Point-of-Care Viral Load and Early Infar Diagnosis Technologies		
			Eve	ening Seminar	s 18:30 – 2	0:00				
ROOF TERRACE RO	DOM		R00M 1.	6		R00M 1.4			ROOM 2.4	
Roche: Lessons Learnt – The The Laboratory Response Harn to HIV in Africa Revol			n to Impro	n Network: ital Sharing ve Research Laboratories	Médecins Sans Frontières: Implementing Viral Load in Resource Limited Settings: Having the Test is Not Enough		in Resource	BD: BD FACSPresto™ Near-patient CD4 Counter		


		weane	sday, 3 l	Decemb	er 20	14		
07:00 – 16:30	Registration				F	OYER OF BALLROOM E	AST/WEST, CTICC FIRST FLOO	
		Мо	rning Seminar	s 07:00 – 08	3:30			
ROC)M 2.4		ROOM :	2.64/65			ROOM 1.6	
Alere CANCELLED			ory Information	HL: Systems (LIS) Meessment	onitoring	Developing	g Professionals: g Killer Presentations Part 2 of 2)	
10:00 – 17:00	Exhibit						BALLROOM EAST/WES	
		Plenary 3: Ir	novation in Di	iagnostics 0	9:00 – 10	:30		
			AUDITO					
Regulation I	g the Path for Harmonisation I Tanui			ference with e Diagnostics Chiller		in the Contex African Tra What Role Innovati	ica's Health Challenge kt of the African Union's Insformation Agenda: Ions and Health Technologie Iasirim Nwuke	
10:45 – 11:00	Break (on you	ır own)					BALLROOM EAST/WES	
		(Oral Sessions	l 11:00 – 12:4	5			
R00M 1.4	ROOM		ITORIUM 1	ROOM 2		ROOF TERRACE ROOF	M AUDITORIUM 2	
Oral Session 3.1: Antimicrobial Resistance	Oral Sess Advan in CD4 T	ces A esting in E	Session 3.3: dvances arly Infant iagnosis		Session 3.4: Oral Session 3.5 tic Innovations The Journey to Laboratory Accreditation		Oral Session 3.6: The Role of Laborate in Outbreak Respon	
12:45 – 14:15	Lunch (on yo	ır own)					BALLROOM EAST/WES	
13:00 – 14:15	Posters						AUDITORIUM 1 FOYE	
			Oral Posters	13:00 – 14:30				
BALLROOM	M EAST/WEST		BALLROOM	EAST/WEST		BALLR	OOM EAST/WEST	
Testing and	sters 3.1: Health System athenina		Oral Posters 3.2: Drug Resistance			Oral Posters 3.3: Laboratory-Based Surveillance and Epidemiology		
		Mic	d-Day Seminar	s 13:00 – 14	4:30			
ROOF TERRACE ROOM	И	ROOM 1.6	R00M 1.4		AUDITORIUM 2		ROOM 2.4	
Cepheid: Overall Theme: Power of the Platforn	n	BD	and Syphilis		Young Professionals: Sharing Success: Writing News Articles and Award Nominations (Part 1 of 2)		ASLM: African Public Health Laboratory Netwo Collaborating Centres	
		ASLM and	I APHL Trainin	g Course 14:	45 - 17:4	5		
			AUDITO	ORIUM 1				
		Laboratory Tools to S	Stop Ebola: Detec	ction, Response	Strategies a	and Safety		
			Symposia I	14:45 – 16:15				
AUDITORIUM 2		ROOM 2.4	ROOI	M 1.4		ROOM 1.6	ROOF TERRACE ROOM	
Combating Solutions		tions for HIV Diagnosis The and Monitoring Path		e of Anatomic Evide		mposium 12: ence to Support enza Vaccination in Africa	Symposium 13: Update on Vaccine Preventable Diseases Laboratory Networks in Africa	
		ı	Round Tables	l 16:30 – 18:0	0			
ROOM 1.6		ROOM 1.4	ROOF TERF	RACE ROOM	A	UDITORIUM 2	ROOM 2.4	
A Roadmap The Role of Rapi or Laboratory Strengthening in Africa Management of I Presenting with Chr Intestinal and Neu		ound Table 11: hole of Rapid Tests broving the Clinical gement of Patients ng with Chronic Fever, hal and Neurological Disorders	Tests Ensuring the Quality of linical Point-of-Care Testing: Need titents for Innovative Approaches nic Fever,		Round Table 13: A Collaborative Approach to Market Entry and Procurement of Diagnostic Products		Round Table 14: The Changing Role of the Laboratory in Support Sexually Transmitted Infection Control Programmes in Africa	
		ASLM	2014 Awards	Ceremony & R	eception			
18:30 – 19:30	Awards Cerei						AUDITORIUM	

			hurs	day, 4 D	ecembe	r 2014	4		
07:00 - 14:00	Registration	1				F	OYER OF BALLE	ROOM EAST/	WEST, CTICC FIRST FLOO
			Мо	rning Seminar	s 07:00 – 08	3:30			
ROOF TERRACE ROOM		R00M 1.4		R00	M 2.4	А	UDITORIUM 2		ROOM 1.6
Daktari: Point-of-Care Solutions for Anyone, Anywhere	lmį	Sysmex-Part CD4 Testing pacting Efficie Service Delive e Technology, Uses	ı: ncy of ry –	Good Labora Start with a G	tical Systems: atory Results ood Specimen - ical Variable Resolutions	Hain Lifescience TB Diagnostics: Now The Near Future			Young Professionals: Exploring Free Educational Opportunities Online
10:00 – 14:30	Exhibit								. BALLROOM EAST/WES
		Ple	nary 4: D	isease-Specif	ic Threats 0	9:00 – 10	:30		
				AUDITO	RIUM 1				
Global Heal and Laborato Jordan	ory Medicine			Companion in Vi of Pediatri	Medicine: rtual Elimination c HIV/AIDS re Luo		Frontli	in A	ce in Fighting Ebola frica lou Sall
10:45 - 11:00	Break (on y	our own)							.BALLROOM EAST/WES
			C	ral Sessions	l 11:00 – 12:4	5			
R00M 1.4	ROOI	M 1.6	RO	OOM 2.4	ROOF TERRACE	E ROOM AUDITO		RIUM 2	AUDITORIUM 1
Oral Session 4.1: npact of Surveillance				ssion 4.3: HIV ency Testing	Oral Session 4.4: Sustainable Laboratory Information Systems Biosafe Laboratory		oving ty And	Oral Session 4.6: Return on Investme in Laboratory	
12:45 – 14:15	Lunch (on y	our own)							.BALLROOM EAST/WES
13:00 – 14:15	Posters								AUDITORIUM 1 FOYE
				Oral Posters	13:00 – 14:30				
BALLROOM	EAST/WEST			BALLROOM	EAST/WEST			BALLROOM	EAST/WEST
Oral Pos Diagnostic			Oral Posters 4.2: Policy and Networking Extern			Externa	Oral Posters 4.3: rnal Quality Assurance Programmes		
			Mid	-Day Seminar	s 13:00 – 14	:30			
R00M 2.4		ROC	F TERRACE	ROOM	F	ROOM 1.4			ROOM 1.6
				Global Health Update on the WHO a		agnostics	FIND Ebola	S Writing N	ing Professionals: haring Success: lews Articles and Awar nations (Part 2 of 2)
				Symposia I	14:45 – 16:15				
ROOM 1.4			R00M 2.4		ROOF TERRACE ROOM		MOO	ROOM 1.6	
Advancing Towards Role HIV Drug Resistance Monitoring in Resource-Limited Settings: Field Epide				boratory Laboratory N		ratory Networks Advance al Health Security Qu		Symposium 17: ces in Implementing Quality Assured nt-of-Care Testing	
		Trainii	ng Progran	ı (FELTP)					

16:30 -18:00

BD FACSPresto™ Near-Patient CD4 Counter

Now CE-IVD marked and WHO prequalified





BD Biosciences is delivering an entirely new menu of clinical products designed to precisely match the budget, throughput, and workflow requirements of clinical labs wherever they are found.

The BD FACSPresto™ Near-Patient CD4 Counter, for example, is designed to meet the needs of resource-limited settings. It weighs just under 7 kilos, can handle extreme temperature environments, can be run off AC or battery power, and is operated using graphics, making it language independent. It allows CD4 and %CD4 monitoring and hemoglobin quantification in a single test.

The BD FACSPresto performs system selfdiagnosis at each startup, which takes just a few minutes. The system is designed to eliminate the need for preventive maintenance.

Our clinical solutions are designed to deliver dependable outcomes while speeding workflow, easing operation, and reducing training requirements. They reflect our commitment to live by, reach to, and measure our products and services by ever higher standards.

To learn more about the BD FACSPresto, visit **bdbiosciences.com/eu/go/presto**.

BD Biosciences 2350 Qume Drive San Jose, CA 95131 bdbiosciences.com

14:00-17:00 - Auditorium 1

Invited Speakers:

- H.E. Dr. Khaliru Alhassan, State Minister of Health, Nigeria
- * H.E. Prof. Awa Marie Coll-Seck, Minister of Health and Social Welfare, Senegal
- H.E. Dr. Nkosazana Dlamini-Zuma, African Union
- * H.E. André Mama Fouda, Minister of Public Health, Cameroon
- H.E. Patrick H. Gaspard, US Ambassador to South Africa
- H.E. Dr. Aaron Motsoaledi, Minister of Health, South Africa
- * H.E. Dr. Seif Seleman Rashidi, Minister of Health and Social Welfare, Tanzania
- * Dr. Luis Gomes Sambo, World Health Organization, Regional Office for Africa
- ❖ Dr. Douglas N. Shaffer, Chief Medical Officer, US Office of Global AIDS Coordinator
- H.E. Dr. Kebede Worku, State Minister of Health, Ethiopia

Special Guests:

- Mr. Thierry Bernard, Daktari Diagnostics
- Dr. Tsehaynesh Messele, African Society for Laboratory Medicine
- Dr. Trevor Peter, African Society for Laboratory Medicine, Board of Directors
- Mr. Sagie Pillay, ASLM2014 Conference Co-Chair, Sakhile Development and Research, South Africa
- ❖ Dr. Amadou Sall, ASLM2014 Conference Co-Chair, Institut Pasteur, Dakar, Senegal

Keynote Address

Dr. John Nkengasong, US Centers for Disease Control and Prevention
"A Decade of Strengthening Laboratory Medicine in Africa: Then, Now, and Future"



Dr. Nkengasong is the current Associate Director for Laboratory Science at the Division of Global HIV/AIDS, Center for Global Health, CDC Atlanta. He is also the Chief of the International Laboratory Branch and co-chairs the President's Emergency Plan for AIDS Relief's (PEPFAR) Laboratory Technical Working Group. He joined CDC in 1995 as Chief of the Virology Laboratory, CDC Abidjan, Ivory Coast, and became Chief of the International Laboratory Branch, Global AIDS Program in 2005. He has received numerous awards for his work including, but not limited to, the US Secretary of Health and Human Services Award for excellence in Public Health Protection Research, the Sheppard Award, and

Director's Recognitions Award. He is the founding chair of the board of directors of the African Society for Laboratory Medicine.

Join us for a light reception following the ASLM2014 Opening Ceremony in the ASLM2014 Exhibit Hall, Ballroom East/West from 17:00 – 19:00.

MONDAY, 1 DECEMBER 2014

PLENARY 1

LABORATORY MEDICINE AND INFECTIOUS DISEASE CONTROL

DATE: Monday, 1 December

TIME: 09:00 - 10:30

LOCATION: Auditorium 1

SESSION CO-CHAIRS: **Trevor Peter,** African Society for Laboratory Medicine, Ethiopia


Alex Opio, Ministry of Health, Uganda

Peter Piot, London School of Hygiene & Tropical Medicine, UK

Informing Policy from a Microbiologist's Perspective

Peter Piot, MD, PhD is the Director of the London School of Hygiene & Tropical Medicine, and Professor of Global Health. In 2009-2010 he was the Director of the Institute for Global Health at Imperial College, London. He was the founding Executive Director of UNAIDS and Under Secretary-General of the United Nations from 1995 until 2008, and was an Associate Director of the Global Programme on AIDS of WHO. Under his leadership UNAIDS became the chief advocate for worldwide action against AIDS, also spearheading UN reform by bringing together 10 UN system organizations.

Dr. Piot co-discovered the Ebola virus in Zaire in 1976, and led research on AIDS, women's health, and public health in Africa. He was a professor of microbiology



He is a member of the Institute of Medicine of the US National Academy of Sciences, of the Académie Nationale de Médicine of France, and of the Royal Academy of Medicine of his native Belgium, and a fellow of the Academy of Medical Sciences, UK, and the Royal College of Physicians. In 2008-2011, he was the President of the King Baudouin Foundation and was knighted as a Baron in 1995. He has published over 500 scientific articles and 16 books, including his memoir "No time to lose". In 2013 he was the laureate of the Hideyo Noguchi Africa Prize for Medical Research.



Alex Coutinho, Infectious Diseases Institute, Uganda

Practice of Laboratory Medicine in Africa: Strong Institutions and Partnerships

Dr. Coutinho held the position of Executive Director of the Infectious Diseases Institute in Kampala, Uganda from 2007 - 2014. Previously, he was the Executive Director of the largest HIV civil society organization, the AIDS Service Organization (TASO) from 2001 - 2007. In both roles, he supported and implemented numerous studies in HIV and related co-infections. His interests are in studies that have both policy and practical significance. As an organization, the IDI continues to build best-practice models of HIV prevention care and treatment through iterative improvements and implementation excellence. Dr. Coutinho was also part of the transitional working group to set up the Global Fund to fight HIV, TB, and Malaria which has provided life-saving antiretroviral, anti-tuberculosis and antimalarial medications to millions of people in sub-Saharan Africa. Dr. Coutinho will also serve



as a member of the Training Advisory Committee given his strategic oversight of the IDI, the Research Department, and research capacity building programmes.

Salim Karim, Centre for the AIDS Programme of Research, South Africa

Laboratory Science: Sanctuary of Scientific and Clinical Research Discovery

Salim S Abdool Karim, MBChB, MMed, MS(Epi), FFPHM, DipData, PhD is a South African clinical infectious diseases epidemiologist who is widely recognised for his research contributions in HIV prevention and treatment. He is Director of the Centre for the AIDS Program of Research in South Africa (CAPRISA), President of the South African Medical Research Council (MRC), and Pro Vice-Chancellor (Research) at the University of KwaZulu-Natal in Durban, South Africa. He is also Professor of Clinical Epidemiology at the Mailman School of Public Health at Columbia University, Adjunct Professor of Medicine at Weill Medical College of Cornell University and Associate Member of The Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard University.



His contributions to microbicides for HIV prevention spans two decades and culminated in the CAPRISA 004 tenofovir gel trial which provided proof-of-concept that antiretroviral drugs can prevent sexually transmitted HIV infection and herpes simplex virus type 2 in women. He is co-inventor on patents that have been used in several HIV vaccine candidates. His clinical research on TB-HIV treatment has shaped international guidelines on the clinical management of co-infected patients.

He is the recipient of "TWAS Prize in Medical Sciences" from The Academy of Sciences for the Developing World, the Drug Information Association's "President's Award for Outstanding Achievement in World Health", the Gold Medal Award from the Academy of Science in South Africa and the 2011 Outstanding Senior African Scientist Award.

He is an elected Fellow of the African Academy of Sciences, the Academy of Sciences for the Developing World, the Academy of Science in South Africa, the Royal Society of Science in South Africa and the American Academy of Microbiology. He is a Foreign Associate Member of the Institute of Medicine.

ORAL SESSION 1

DATE: Monday, 1 December

TIME: 11:00 - 12:45

	ion 1.1: HIV Diagnosis and Viral Load Testing S: Sergio Carmona and Laurent Bélec	Monday, 1 December Room 1.4
11:00	Continued Virological Failure and Unnecessary Switching of Antiretroviral Treatment for HIV-1 may Occur D to Viral Load Monitoring Tamara Sonia Boender, Kim CE Sigaloff, Raph L. Hamers, Maureen Wellington, Margaret Siwale, Mariettes Botes, Cissy Kityo, Sula Kishor Mandaliya, Tobias F. Rinke de Wit, Pascale Ondoa	espite Access
11:10	Breaking the Barriers to Antiretroviral Therapy Monitoring: Uganda's Strategy for Public Sector Viral Load Nathering Implementation Victor Bigira, Charles Kiyaga, Meghan Wareham, Isaac Sewanyana, Brian Ngwatu, Judi Lusike, Wilson Nyegenye, Steven Aisu	Nonitoring
11:20	Performance of the Amplix® Real-Time PCR Assay for Plasma HIV-1 (non-B subtypes) RNA Quantification U and Gag Targets to Assess Virological Failure in HIV-infected Treated Children Living in Central Africa Laurent Bélec, Christian Diamant Mossoro-Kpinde, Jean-Chrisostome Gody, Olivia Mbitikon, Jean De Dieu Longo, Gérard Gréseng	·
11:30	Laboratory Validation of Ustar EasyNATTM Diagnostic Test Compared to GeneXpert MTB/RIF for Qualitative Mycobacterium Tuberculosis Using Dried Culture Spots Mokgadi Ruth, Natasha Gous, Wendy Stevens, Lesley Scott	Detection of
11:40	Time for Change? An Evaluation of the Tie-Breaker Algorithm and the Role of Weakly Reactive Test Lines in to a High Rate of False Positive HIV Results Leslie Shanks, Ruby Siddiqui, Jarmila Kliescikova, Neil Pearce, Cono Arti, Libsework Muluneh, Erwan Pirou, Koert Ritmeijer, Johnson	_
11:50	Monitoring the Quality of Rapid HIV Testing Using a National Register: Results from the Initial Implementation Muthoni Junghae, Franklin Kitheka, Samuel Mwalili, Mamo Umuro, Jane W. Mwangi	on Phase in Kenya
	SION 1.2: Strengthening Laboratory Management Systems S: Katy Yao and Giselle Guevara	Monday, 1 December Room 1.6
11:00	Evidence from 501 Laboratories in 39 Countries for SLMTA-Driven Improvement in Quality Management Sy Katy Yao, Elizabeth Luman, The SLMTA Implementation Teams	stems
11:10	Strengthening Laboratory Management Toward Accreditation (SLMTA) – A Systematic Review of Research and Remaining Gaps Elizabeth Luman, Katy Yao, John Nkengasong	Issues, Results,
11:20	Challenges Facing Implementation of Strengthening Laboratory Management Toward Accreditation (SLMTA Blood Transfusion Service in Kenya Eric Wakaria, Charles Rombo, Margaret Oduor, Peter Mwamba, Kimberly Tilock	A) Program in
11:30	The Road to Laboratory Accreditation Through SLMTA: Key Success Factors Thomas Gachuki, Jane Mwangi, Risper Sewe, David Turgeon, Mary Garcia, Elizabeth T. Luman, Mamo Umuro	
11:40	The Impact of the Strengthening Laboratory Management Toward Accreditation (SLMTA) Training Program Laboratory Quality Systems in the Caribbean Region Gisele Guevara, Floris Gordon, Yvette Irving, Ismae Whyms, Keith Parris, Songee Beckles, Talkmore Maruta, Nqobile Ndlovu, Rache	
11:50	Perceptions and Attitudes Towards SLMTA among Laboratory Professionals and Hospital Chief Executive O Adino Desale, Tilahun Muchie Hiwotu, Achamyeleh Mulugeta, Adisu Kebede, Habtamu Asrat, Abnet Abebe, Dereje Yenealem, Ebise Mary Kathryn Linde, Gonfa Ayana	
	SION 1.3: TB Drug Resistance S: Philip Onyebujoh and Hortense Faye-Kette	Monday, 1 December Room 2.4
11:00	Prevalence of TB Infection Among HIV Patients in Association to Drug Resistance at Kenyatta National Hosp Care Clinic Anne Mutsami, Godfrey Jumbe	oital Comprehensive
11:10	Mycobacterium tuberculosis and Anti-Tuberculosis Drug Resistance in HIV Negative and HIV Positive Cases Chisom Ukaegbu, Agatha Ani, Yetunde Isah, Rosemary Pwol, Chindak Lekuk, Godwin Imade, Oche Agbaji	s in Jos, Nigeria
11:20	Evaluation of the FAST Plaque-Response in the Detection of Rifampicin Resistance among Mycobacterium from Egypt Basant Motawi, Zeinab Mostafa, Youssef Soliman	tuberculosis Isolates
11:30	Added Value of Performing a Second Xpert MTB/RIF Test on a Second Sputum Sample to Confirm Rifampic Analysis of Routinely Collected Data in MSF-Supported Sites in Mozambique, Zimbabwe and Kenya Emmanuel Fajardo, Maryam Rumaney, Carol Metcalf, Peter Saranchuk, Marcela de Felo Freitas, Asma Ali, Sandra Simons, Helga Ritte	
11:40	Laboratory Based Second-line Anti-TB Drug Resistance Surveillance in Ethiopia Abebaw Kebede, Zekarias Dagne, Muluwork Getahun, Zelalem Yaregal, Yetnebersh Fisiha, Abyot Meaza, Shewki Moga, Almaz Abebe, I	Eshetu Lemma
11:50	Illumina Technology for Multiples-Amplicon Sequencing can be Used for Identification of Drug Resistant Tu Daniela Maria Cirillo, Andrea Cabibbe, Ilaria Valente, Paolo Miotto	berculosis

	SSION 1.4: Malaria and Other Parasitic Diseases	Monday, 1 December
11:00	RS: Adrian Puren and Lesley Scott Evaluation de l'Efficacité Thérapeutique des Antipaludiques Usuels dans le Traitement du Paludisme Simple falciparum Chez les Enfants de Moins de 5 ans à Bangui, République Centrafricaine Ernest Lango-Yaya, Simon Pounguinza, Jean Pierre Bangamingo, Louis Namboua	Auditorium 1 e à Plasmodium
11:10	Sero-Prevalence of Plasmodium Parasites Amongst Pregnant Women Attending Antenatal Clinic In Sokoto, Hussaini Alhassan Mohammed, Abdullahi Saidu Yaro, Mohammed Danfulani, Egua Maxwell, Nuradeen Mohmammed Bello	Nigeria
11:20	A Study on Malaria Parasitaemia Carried Out in Kibera Community Heath Centre Laboratory Nairobi, Kenya Carolyne Mumo, Gertrude Kitetu	
11:30	CXCL10 Gene Promoter Polymorphism -1447A>G is Associated with Severe Malaria in Ghanaian Children Felix Botchway, Nana Wilson, Adel Driss, Carmen Dickinson_Copeland, Hassana Salifu, Jonathan Stiles	
11:40	Translating Results of Diagnostic Tests into Practice: The Case of Shistosomiasis Eleanor Ochodo, Gowri Gopalakrishna, Mariska Leeflang	
11:50	Is Malaria an Opportunistic Infection Among HIV/AIDS Patients in Nigeria? Joseph Enuma, Bernard Matur	
12:00	Validation and Comparison of Cyscope Microscope, Quantitative Buffy Coat, and Rapid Diagnostic Kit for Mamong Clinic Attendees in Southwest Nigeria Abiodun Ogunniyi, David Dairo, Femi Ajumobi, Patience Ogunjobi, Busola Ojo, Oyetunde Oyebami, Olufunmi Fawole, Hanna Dada-A	•
	SSION 1.5: External Quality Assurance Programmes	Monday, 1 December
	RS: Michael Aidoo and Paula Fernandes	Roof Terrace Room
11:00	Field Evaluation of Dried Plasmodium falciparum Samples for Malaria RDT Quality Control and Proficiency and Ethiopia Michael Aidoo, Afework Tamiru, T. Henry Kohar, Chritie M. Reed, Joseph L. Malone	iesting in Liberia
11:10	Malaria Rapid Diagnostic Tests (RDTs) Field-Level External Quality Assurance (EQA) System: Which Way For Alex Ojaku, Elizabeth Streat, Anthony Nuwa, John Baptist Bwanika, Bosco Agaba, Joseph Nkodyo	rward?
11:20	Microscopist Proficiency Testing as Part of a Comprehensive Program to Assure the Quality of a Multi-Cont Harmonized Malaria Drug Efficacy Trial Paula Fernandes, Ekaterina Milgotina, Mark Fukuda, Jeffrey McCollum, Karen Menge, Peter Obare, Alaina Thomas, James Cummi	
11:30	Piloting External Quality Assurance for TB Line Probe Assay and GeneXpert in Nigeria Susana Oguntoye, Abiola Tubi, Jelpe Tapdiyel, Thor Elliott, Shirematee Baboolal	
11:40	Comparison of Stained versus Unstained Simulated <i>Mycobacterium tuberculosis</i> Microscopy Smears for Proceedings of Stained Viljoen, Marshagne Smith, Olga Perovic	roficiency Testing
11:50	Strengthening National Laboratory Proficiency Testing (PT) in Tanzania Nzovu Ulenga, Aisa Muya, Guerino Chalamilla, Fausta Mosha	
	SSION 1.6: Partnership and Laboratory Networks RS: Patrick Mateta and Jean Sakandé	Monday, 1 December Auditorium 2
11:00	The Role of Associations in Laboratory System Strengthening in Africa: Where Are We? Where Are We Going Talkmore Maruta, Ngobile Ndlovu, Teferi Mekonen, Corey White, Tsehaynesh Messele, Madeline DiLorenzo, Trevor Peter	j ?
11:10	Improving Blood Supply Safety & Adequacy in Developing Countries: Pan-African Blood Safety Perspectives Assah Nkohkwo and Nigel Talboys	S
11:20	Regional Capacity Enhancement in Medical Laboratory Science: The West African Initiative Godswill Okara	
11:30	EID Lab Consolidation Supported by the Sample Transport Network has Improved Access and Program Mor Isaac Ssewanyana, Meghan Wareham, Victor Bigira, Grace Kushemererwa, Christine Namulindwa, Iga Tadeo, Steven Aisu, Charles	
11:40	Improving Patient Referral Linkages Through Implementation of a National Sample Transportation Program in Malawi Carol Porter, Kundai Moyo, Wainings Manda, Mphatso Kachule, Kameko Nichols, Abdoulaye Sarr, James Kandulu, Reuben Mwenda Agnes Thawani	
11:50	Building a Sustainable Team for Tanzania's Hospital Laboratories Patrick Mateta and Charles Massambu	

ORAL POSTER 1

DATE: Monday, 1 December

TIME: 13:00 - 14:30

ORAL	POSTER 4
	STERS 1.1: Evaluating Novel Tests IS: Moses Joloba and George Alemnji Ballroom East/West
13:00	1.11 Using Laboratory Data to Predict which Districts to Prioritize the Implementation of Cryptococcal Antigenaemia Detection Using a Combination of Automated EIA and a Manual Lateral Flow Assay South Africa Nassim Cassim, Lindi Marie Coetzee, Deborah K. Glencross
13:10	1.12 Serum Hyaluronic Acid as a Non-Invasive Tool to Diagnose Schistosomal Periportal Fibrosis in <i>Schistosoma mansoni</i> Endemic Areas of Ethiopia CANCELLED Filimon Mitiku Halle, Elsa Hagos, Nega Berhe, Bjørn Myrvang, Svein G. Gundersen
13:20	1.13 Laboratory Validation of SD BIOLINE HIV/Syphilis Duo Rapid Test Natasha Gous, Lesley Scott, Tintswalo Mavutani, Norma Bosman, Wendy Stevens
13:30	1.14 Malaria Test Performance During an Outbreak in Kenya, 2012 Emmanuel Okunga, Waqo Boru, Gura Zeinab, Galgalo Tura, Amwayi Samuel, Wences Arvelo
13:40	1.15 Validation of Multiplex PCR for Detection and Differentiation of Salmonellas Iryna Gerilovych, Borys Stegniy, Andrii Zavgorodnii, Anton Gerilovych, Vasyl Arefiev
13:50	1.16 Implementation and Evaluation of the Presto Combined Qualitative Real Time CT/NG Assay in Rwanda Irith De Baetselier, Lambert Mwambarangwe, Vicky Cuylaerts, Viateur Musengamana, John Rusine, Claude Mambo Muvunyi, Agrippine Mukarurangwa, Janneke van de Wijgert, Evelyne Kestelyn, Tania Crucitti
	STERS 1.2: HIV and Co-Infections SIS: Charles Kiyaga and Teri Roberts Monday, 1 December Ballroom East/West
13:00	1.21 CD4 Point of Care Testing (POCT) at Household-level in Kenya: Added Novelty from a Nationally-Representative Based Cross-Sectional Survey Kepher Otieno, Ernest Makokha, Caleb Ogada, Grace Bartonjo, Mamo Umuro, Jane Mwangi
13:10	1.22 Dried Blood Spot (DBS) Validation in Viral Load Measurement using Abbott System m2000 in HIV Positive Patients Under Antiretroviral Treatment in DREAM Malawian and Mozambican Cohorts Davide Brambilla, Richard Luhanga, Haswel Jere, Susanna Ceffa, Zita Sidumo, Tatiana Aidé, Erasmo Fernando, Remigio José Mugunhe, Fulvio Erba, Leonardo Palombi
13:20	1.23 Evaluation of CD4 Enumeration by Non-Laboratory Personnel Using PIMA Point of Care (POC) Instruments in Rural Clinics in Tutume Sub-District in Northern Botswana Lucy Mupfumi, Madisa Mine, Mulamuli Moyo, Timothy Matsuokwane, Tuelo Mogashoa, Kennethe Mugisha, Lesedi Tsalaile, Lesego Busang, Frank Mwangemi, Tendani Gaolathe
13:30	1.24 Taux de Séroconversion au VIH, VHB, VHC et Syphilis Chez les Donneurs Bénévoles Fidélisés de Sang de 2012 à 2013 au Centre National de Transfusion Sanguine, à Kinshasa/ République Démocratique du Congo CANCELLED Cleophas Kalala, Eddy Sokolua, Viviane Munyemba Kasende, Huguette Kabulo Nday, Lilas Kongolo Mwamba, Pacifique Misingi Aye, Jean Baptiste Shuli Tchomba, Sylvain Yuma Ramazani
13:40	1.25 Can Dried Blood Spots or Whole Blood Liquid Transport Media Extend Access to HIV Viral Load Testing? Natasha Gous, Lesley Scott, Wendy Stevens
13:50	1.26 HIV Passivity Rate Among Vertically Exposed Infants in Uganda is Steadily Declining and is Associated with the Increased Percentage of Mothers on ART During Antenatal CANCELLED Isaac Ssewanyana, Proscovia Nambuya, Meghan Wareham, Victor Bigira, Grace Kushemererwa, Christine Namulindwa, Iga Tadeo, Steven Aisu, Charles Kiyaga
14:00	1.27 Determination of the Magnitude of Hepatitis B Viral Infection in Healthcare Workers, Addis Ababa, Ethiopia CANCELLED Gizachew Taddesse Akalu, Kassu Desta Tulu, Addis Tamire Woldemariam, Abate Bane Shewaye
	SETERS 1.3: Laboratory Quality Improvement SE: Lynee Galley and Varough Deyde Ballroom East/West
13:00	1.31 Remarkable Reduction in Downtime Following Implementation of Laboratory Equipment Maintenance Strategy in FHI-360-Supported Hospitals in Nigeria Humphrey Musuluma, Ndubueze Eigbe
13:10	1.32 Building Effective Onsite Laboratories in Developing Countries: A Case Study of Rinda Ubuzima Lambert Mwambarangwe, Vicky Cuylaerts, Viateur Musengamana, Stephen Agaba, Evelyne Kestelyn, Tania Crucitti, Irith De Baetselier, Jennifer Van Nuil, Janneke van de Wijgert, Ndagijimana J. Claude
13:20	1.33 Quantification of Microbiology Laboratory Mentoring Progress in Tanzania Lynee Galley, Douglas Abbott, John Aldom, Janet Maleski, Lilian Shija
13:30	1.34 Improvement of the Quality Management System at Mafikeng Laboratory: Benefits of SLMTA Improvement Projects Stephina Nyoka, Nodathini Nazo, Tebogo Tjale, Richard Mareletse, Mankwana Titus, Frederick Lwanga
13:40	1.35 Innovative Improvements in Biosafety Practices Following Biosafety Skill-Based Trainings in Kenya Angela Amayo, Doris Bota, Albert Bunyasi, Mamo Umuro, Jedida Wachira, Jacob Okello
13:50	1.36 Training-of-Trainers: A Strategy to Build Country Capacity for Effective SLMTA Expansion and Sustainability Talkmore Maruta, Katy Yao, Sikhulile Moyo, Nqobile Ndlovu

SYMPOSIUM 1

SCALING UP ACCESS TO VIRAL LOAD IN AFRICA: PROGRESS AND CHALLENGES

SESSION OBJECTIVES:

The objective of this session is to provide an overview of progress to date in scaling up viral load capability in Africa, and highlight approaches taken by different actors to improve access.

DATE: Monday, 1 December

TIME: 14:45 - 16:15

LOCATION: Roof Terrace Room

SESSION OVERVIEW:

Overview of Viral Load Capacity Across Africa

Jonathan Lehe, Clinton Health Access Initiative, Kenya

 Country Case Studies of MSF Support to Viral Load Scale Up in Sub-Saharan Africa

Tom Ellman, Médecins Sans Frontières, South Africa

Taking Viral Load to Scale in Kenya

Matilu Mwau, Kenya Medical Reseach Institut, Kenya

The Global Fund's Support to Viral Load Scale-Up in Africa

Martin Auton, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland

CO-CONVENERS:

Madisa Mine, Botswana/Harvard Partnership, Botswana



Madisa Mine, an ASLM Ambassador to Botswana, serves as a consultant virologist and as Technical Director at the Botswana Harvard HIV Reference Laboratory in Gaborone. Dr. Mine was previously a I ecturer in genetics, molecular genetics and biotechnology at the Botswana College of Agriculture, Gaborone. He earned his doctor of philosophy degree in molecular biology from Murdoch University in Perth, Australia.

Mireille Dosso, Institut Pasteur, Côte d'Ivoire



Mireille Dosso is a medical doctor, a microbiologist and researcher currently serving as the Director of the Institut Pasteur in Cote d'Ivoire. She is also the head leader of the Microbiology Department at the University of Côte d'Ivoire (CAMES) and the Director of Bacteriology, Virology Specialized Training Certificates (SEC). Throughout her career, she has supervised 125 publications and 85 theses. Dr. Dosso has received many prizes over the years including the UNESCO Institut Pasteur medal and the Chevalier de l'ordre merite national (Côte d'Ivoire).

SPEAKERS:

Jonathan Lehe, Clinton Health Access Initiative, Kenya



Jonathan Lehe is the Senior Programme Manager for Point-of-Care (POC) Diagnostics at the Clinton Health Access Initiative (CHAI), and a member of CHAI's global Laboratory Services Team. He is responsible for managing CHAI's work supporting Ministries of Health in Africa, Asia, and the Caribbean to improve access to innovative POC HIV diagnostics, bringing healthcare closer to the patient, especially in rural and low-resource settings without access to labs. He joined CHAI in 2008 and lived in Nairobi, Kenya for 5 years, focusing on expanding access to diagnostics services in East and Southern Africa. In 2013, he returned home to the United States and is currently based in Chicago. Prior to joining CHAI, he worked

in the management consulting industry, advising pharmaceutical companies on strategies to improve their marketing and procurement practices. He holds a degree in Economics from Harvard University.

Tom Ellman, Médecins Sans Frontières, South Africa



Tom Ellman is director of the Southern Africa Medical Unit (SAMU). Since first working for MSF in Rwanda in 1995, he has over 15 years of experience in humanitarian medical work mostly with Médecins Sans Frontières. His focus has been on HIV, TB, and malaria in Africa and South-East Asia, apart from a three-year 'break' working on Chagas disease – the 'AIDS of the Americas' – in Bolivia.

Tom received his medical training in Edinburgh, has a Diploma from the School of Tropical Medicine and Hygiene (Liverpool), and a Masters in Communicable Disease Epidemiology from the School of Tropical Medicine and Hygiene (London). He is a member of the Royal College of Physicians, UK and a beekeeper.

Matilu Mwau, Kenya Medical Reseach Institue, Kenya



Matilu Mwau is an Infectious Diseases Specialist. He holds associate professorships at the College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, and at Nagasaki University, Institute of Tropical Medicine. He is also a Principal Research Officer at the Kenya Medical Research Institute. His current research interests include HIV, novel diagnostic approaches, arboviruses, Immunology, and hepatitis. He has extensively published in these fields. Prof. Matilu Mwau holds a Medical degree from the University of Nairobi, a Master's degree in Tropical Medicine from Nagasaki University in Japan and a Doctorate in Molecular Medicine from Oxford University.

Martin Auton, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland



Martin Auton, Lead for the Sourcing of HIV Products, The Global Fund to Fight AIDS, TB and Malaria. Martin is a member of the Global Fund's Sourcing Department responsible for the Sourcing of HIV products — treatment, diagnostics and prevention. He is a pharmacist, who after working for seven years in the private sector in the United Kingdom, has worked for the last 20 years on access to health products in international public health including for the last 4 years at the Global Fund.

SYMPOSIUM 2

TB GLOBAL LABORATORY INITIATIVE FOR AFRICA: FROM GUIDANCE TO IMPLEMENTATION

SESSION OBJECTIVES:

Strengthening tuberculosis (TB) diagnostic services is crucial to achieving a world without TB. TB laboratory diagnostic services are weak globally, making it challenging to achieve the global tuberculosis control targets set by the WHO and the Stop TB Partnership. The success of the Stop TB Partnership's Global Laboratory Initiative (GLI), hosted by WHO Global TB Programme in Geneva, to

DATE: Monday, 1 December

TIME: **14:45 – 16:15**LOCATION: **Room 1.6**

drive the laboratory strengthening process, TB detection and control will ultimately be dependent on well-equipped and properly staffed laboratories at country level. These laboratories also need context-specific policies and operational standards tailored to managing each region's specific problems, ranging from HIV-associated TB to multi- and extensive drug-resistant TB. To ensure that the articulation and implementation of country-specific policies is well-supported, the guidance of an Africa-based body is essential, hence the establishment of the Global laboratory Initiative for Africa.

The session's first objective is to discuss why GLI-AFRICA, specifically the objectives and conceptual framework, planning, and budgeting for GLI-AFRICA. Secondly, the role of partnerships to promote coordination and sustainability as well as modalities and approaches for strengthening TB Lab services in Africa. We will also discuss the strengths and weaknesses associated with integration of TB lab services with public health lab infrastructure as well as provision and development of human resources to optimise TB Lab services in Africa. Provision of quality assurance and performance monitoring mechanisms for National TB Reference Labs and supply chain management and biosafety considerations will also be covered. Lastly, the session will discuss the implementation of laboratory quality management systems using the GLI stepwise process towards accreditation and the SLIPTA checklist.

SESSION OVERVIEW:

• Why GLI-AFRICA: The Objectives/Conceptual Framework, Planning and Future Role for GLI-AFRICA

Tsehaynesh Messele, African Society for Laboratory Medicine, Ethiopia

 Coordination and Sustainability: The Role of GLI Partnerships in Optimising TB Lab Services in Africa

Thomas M. Shinnick, Centers for Disease Control and Prevention, United States of America

 Provision and Development of Human Resources to Optimise TB Lab Services in Africa: Operational Requirements for Optimising TB Lab Services in Africa

Jean de Dieu Iragena, World Health Organization, Switzerland; Moses Joloba, Makerere University, Uganda

- Implementation of Quality Management Systems Using GLI Stepwise Process Towards TB Laboratory Accreditation; the SLIPTA Checklist Teferi Mekonen, African Society for Laboratory Medicine, Ethiopia
- Provision of Quality Assurance and Performance Monitoring Mechanisms for National TB Reference Labs in Africa: Role of the SRLN; Success and Challenges

Jean Iragena, World Health Organization, Switzerland; **Moses Joloba**, Makerere University, Uganda; and **Teferi Mekonen**, African Society for Laboratory Medicine, Ethiopia

CO-CONVENERS:

Philip Onyebujoh, World Health Organization Regional Office for Africa, Zimbabwe



Philip Onyebujoh is a senior level international health expert with extensive experience in health systems delivery; clinical, operational and basic science research; and health policy development and advocacy. He is currently the focal person for TB Laboratory services strengthening for WHO's Regional Office for Africa. He coordinated TB/HIV research for WHO/TDR 2003-2013 and developed evidence for policy in TB/HIV care. Honours: the Welcome Clinical Felowship1992-5. Scientific interest: Determinants of T cell regulation and the effect of immunotherapy on TB/HIV immunopathogenesis. Publications: Author/Coauthor of several peer-reviewed publications including WHO guidelines and policy documents.

Jean de Dieu Iragena, World Health Organization, Switzerland



Jean de Dieu Iragena holds a Master's degree in Biomedical Sciences. He is currently working with the World Health Organization, Global Tuberculosis Programme, in the unit called Laboratories, Diagnostics and Drug Resistance, Geneva, in Switzerland. Since the end of his studies in Free University of Brussels followed by a training in Tropical Medicine (on diagnostic of TB and HIV) in the Institute of Tropical Medicine of Antwerp in Belgium, Jean de Dieu has gained several experiences in the work of Medical NGO (Médecins Sans Frontières), Pharmaceutical Company (Eli Lilly) and WHO. He has expertise in assisting WHO member states to evaluate and implement the new and WHO endorsed diagnostic technologies in

their TB laboratory network (especially in Africa). He is now dealing with Global Laboratory Initiative (GLI) Secretariat, housed by WHO Global TB Programme, Geneva and aims at strengthening the TB laboratory activities in coordination with the WHO/GLI TB Supranational Reference Laboratory network and also Jean de Dieu has a seat on the GLI-AFRICA Core Group as a liaison between the GLI-AFRICA and GLI Headquarters, Geneva. Jean de Dieu is one of the founder members of the GLI-Africa, whose the secretariat is hosted by the ASLM Addis Ababa in Ethiopia.

SPEAKERS:

Tsehaynesh Messele, African Society for Laboratory Medicine, Ethiopia



Tsehaynesh Messele is currently the CEO of the African Society for Laboratory Medicine, a Pan-African organization working to advance laboratory medicine across the continent. Her broad career in public health has involved research, public health laboratory system development and management, public health emergency management and high-level leadership in the public sector. As the Director General of the Ethiopian Health and Nutrition Research Institute, currently Ethiopian Public Health Institute, she led the national public health protection and promotion mandates in Ethiopia. She also served as National Programme Manager for Ethio-Netherlands AIDS Research Project (ENARP) from Sept. 2001 — Sept. 2004

assuming responsibility for leading a big bilateral collaboration project. From Oct. 2000 – Sept. 2004 she served as a Team Leader for the Immunohaematology/ Pathology Research Team. Prior to that, she worked as Head of National Referral Laboratory for AIDS; Head of Immunohaematology Division; Head of Virology and Rickettsiology Division at Ethiopian Public Health Institute. In her broad and significant career, Dr. Messele has performed numerous researches and has published numerous publications in peer-reviewed journals and as book chapters. She also served as chair and member of different International executive boards and committees.

Thomas M. Shinnick, Centers for Disease Control and Prevention, United States of America



Thomas Shinnick is the Associate Director for Global Laboratory Activities, Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention; Adjunct Professor, Emory University. Education: B.S., University of Wisconsin-Madison; Ph.D., Massachusetts Institute of Technology; Postdoctoral Training, Research Institute of Scripps Clinic. Honors: Arthur S. Flemming Award, 1990; Fellow, American Academy of Microbiology, 1994; Senior Biomedical Research Service, 1997. National activities: Chairman, Division U, American Society for Microbiology, 1994; National Tuberculosis Task Force; Scientific Advisory Board for the Heiser

Programme. International activities: Board of Directors of the African Society for Laboratory Medicine, Chair of the Global Laboratory Initiative of the Stop TB Partnership, Secretary of TB and Immunology Subsection of the International Union Against TB and Lung Diseases. Editorial activities: Associate Editor of International Journal of Tuberculosis and Lung Diseases and Current Microbiology, Editorial Board of African Journal of Laboratory Medicine, Emerging Infectious Diseases, and Tuberculosis, Scientific interests: Understanding the biology and genetics of pathogenic mycobacteria, elucidating mechanisms of pathogenicity and drug resistance of Mycobacterium tuberculosis, developing rapid methods for the diagnosis of mycobacterial infections. Publications: Author/co-author of more than 175 publications, editor of one book.

Moses Joloba, Makerere University, Uganda



Moses L. Joloba, MBChB, MS, PhD is an Assoc. Professor of Molecular Biology, Immunology and Microbiology in the School of Biomedical Sciences, College of Health Sciences at Makerere University. He is the director of the Uganda TB Supra National Reference Laboratory that has attained ISO 15189 accreditation. Since his training in Makerere University (MBChB) and Case Western Reserve University (Ms and PhD), Dr. Joloba has developed skills in setting up standard laboratories, supporting TB laboratory networks, developing training programmes, starting graduate and short courses, initiating and participating in successful North to South and South to South collaborations, conducting laboratory-based research

as well as training of graduate students. Dr. Joloba has trained 33 Masters and 14 Doctoral students and many non-degree students from the African region and internationally. Dr. Joloba has won over 12 grants and published over 120 peer-reviewed papers, he is a reviewer for 6 journals and a book author. Dr. Joloba, a previous and founding member of the core group of the Global Laboratory Initiative (GLI), is very excited and optimistic to be part of the GLI- AFRICA.

Teferi Mekonen, African Society for Laboratory Medicine, Ethiopia



Teferi Mekonen is currently working at the African Society for Laboratory Medicine (ASLM) as a Senior Programme Specialist since February 2012. Before joining ASLM, Teferi has been working as a Director of Laboratory Strengthening Programme for International Clinical Laboratories, where he has been mentoring five medical laboratories for accreditation, two of them were TB-specialized Hospital Laboratories. He also served in the Centres for Disease Control and Prevention in Ethiopia for six years as a Laboratory Project Coordinator; in the School of Medical Laboratory Sciences, Faculty of Medicine, Addis Ababa University as a Lecturer for nearly two years; in Comp Pro Med Inc. as a Consultant of Polytech Laboratory Information

System Implementation for two years; and as a Research Fellow in the Ethio-Netherlands AIDS Research Project.

Teferi did his Master's Degree in Medical Microbiology in Addis Ababa University and his thesis was on HIV-1 DNA PCR to detect the risk on HIV-1 transmission from blood donors in the National Blood Transfusion Centre. He also did his second Master's Degree in Public Health in Mekelle University and his thesis was on the magnitude and causes of drug resistant tuberculosis (MDR and XDR-TB) and preventive efforts in developing countries.

SYMPOSIUM 3

ACCREDITING CLINICAL AND LABORATORY SYSTEMS AND SERVICES: NEED TO TIE THE TWO

SESSION OBJECTIVES:

The ASLM symposium is an opportunity to bring together continental leaders who are focussed on improving the clinic-laboratory interface. The enhancing of the clinic-laboratory-interface is central to achieving better patient outcomes, both in acute diagnostic settings as well as the monitoring of long term patient care.

DATE: Monday, 1 December

TIME: **14:45 - 16:15**

LOCATION: Auditorium 2

Accreditation is a central platform upon which to ensure better patient care. This involves a rigorous process of evaluations within clinical facilities and laboratories. The session will provide insights into how the Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA) programme and clinical accreditation processes are progressing in different parts of the continent.

The objectives of this session include an introduction to the breadth of the value chain of a fully integrated clinic-laboratory interface, experiences from accredited laboratories of the processes involved, and data from clinical facility accreditation. The session will also discuss an improved understanding of the possibilities for improved patient outcomes if there is improved clinic-laboratory functioning, case studies of the process of accreditation, and finally models for trying to improve the linkages between clinics and laboratories.

SESSION OVERVIEW:

 Healthcare Accreditation as an Enabler to Health Systems Strengthening

Sylvia Sax, University of Heidelberg, Germany

Improved Patient Care through Improved Laboratory Interface in Hospitals

Stuart Whittaker, Council for Health Service Accreditation of Southern Africa, South Africa

 Does Accreditation of Medical Laboratories Benefit Patients in the South Africa Public Healthcare Facilities?

Patience Dabula, National Health Laboratory Service, South Africa

Same Goal, Same Client

Alash'le Abimiku, Institute of Human Virology, University of Maryland School of Medicine, United States of America

CO-CONVENERS:

Tim Tucker, Strategic Evaluation Advisory & Development Consulting (Pty) Ltd, South Africa



Tim Tucker is a senior leader, strategist and clinician-scientist in the South African health and research sectors, with a significant academic and programmatic track record in HIV, hepatitis viruses, vaccines and public health programmes in Africa and beyond. He founded his mid-sized public health organization in 2005, after an earlier career encompassing clinical medicine; clinical research and laboratory research; Clinical Virology specialization; significant vaccine experience; and leadership of South Africa's largest R&D programme, the South African AIDS Vaccine Initiative (SAAVI). Tim is registered with the Health Professionals Council of South Africa as a specialist Clinical Virologist. He obtained a PhD in molecular

virology. He has trained in business strategy (Wits).

Tim's company, Strategic Evaluation Advisory & Development Consulting (Pty) Ltd — "SEAD Consulting" — is a public health strategy consultancy dedicated to improving the health of poor communities. He has led the development of critical health strategies and interventions for public and private sector-funded activities in HIV, TB, research programmes, and biotechnology programmes. SEAD has a specific interest in improving the "clinic-laboratory-interface." Tim has played leadership roles in vaccine R&D programmes in SA and internationally. As Director of the SAAVI, he led the consortium to become a leading player in the laboratory development and clinical testing of HIV vaccines globally. Under his leadership, SAAVI was the first developing country initiative to research, develop, manufacture, and perform pre-clinical analysis of a novel HIV vaccine. Tim has been a long standing honorary member of staff at UCT, during which time he has taught annually within two faculties.

Charles Nde Awasom, Bamenda Regional Hospital, Cameroon



Charles Awasom was born in Bamenda Cameroon. He trained as medical doctor at the University of Ibadan Nigeria, and then as a general surgeon at the University of Nairobi. He has taught short courses in quality improvement and Consultancy skills in the University of Heidelberg, Global Health at Imperial College, as well as District Health Management at Swiss Tropical and Public Health institute, Global Health at Imperial College. Dr. Awasom has worked as surgeon and Hospital Director for the Government of Cameroon and has had extensive experience in HIV management, care and support. Throughout his career he has been a quality improvement champion, lecturer in applied anatomy, surgery and bioethics. Currently he serves as

an International Health Consultant with Médecins Sans Frontières.

SPEAKERS:

Sylvia Sax, University of Heidelberg, Germany



Sylvia Sax is a public health scientist with nursing degrees (Canada and USA), a Master in Public Health (New Zealand) and a PhD in International Public Health from Heidelberg University in Germany. She specializes in quality management and improvement at all levels in the health system. She has over forty years of experience working within health services as a clinician and at national and international levels in various projects and a programmes; her work experiences include developed (e.g. Canada, New Zealand and USA) and developing countries (e.g. India, Tanzania, Pakistan, Bangladesh, Malawi, Kazakhstan). Her areas of work have included evaluation, project management, planning, strategy development, curriculum

and training design and facilitation. She currently lectures on quality management, proposal writing, evaluation, leadership, and consultancy skills and also supervises theses and undertakes consultancies and research in various countries.

Stuart Whittaker, Council for Health Service Accreditation of Southern Africa, South Africa



Stuart Whittaker is the founder and CEO of the Council for Health Service Accreditation of Southern Africa (COHSASA). He is recognised internationally as a leader in the field of healthcare quality improvement and accreditation and is a member of the Board Advisory Committee and the Expert Group of the International Accreditation Programme of the International Society for Quality in Health Care (ISQua). He is also an international surveyor for ISQua. He is a Visiting Professor at the School of Public Health and Medicine at the Faculty of Health Sciences at the University of Cape Town. He holds Board positions on both the South African healthcare regulatory body the Office of Health Standards Compliance and the Regional Centre for

Quality in Health Care (RCQHC) which aims to advance the quality of health care in the East, Central and Southern (ECSA) regions of Africa. He has researched and is widely published in peer review journals on the subject of quality improvement, accreditation and patient safety.

Patience Dabula, National Health Laboratory Service, South Africa



Patience Dabula is a National Quality Assurance Manager of the South African National Health Laboratory Service (NHLS) since March 2011. She is a Medical Technologist with a Master's in Biomedical Technology. She worked as a Medical Technologist for more than 10 years. Patience worked as a Manager in a Clinical Trial Laboratory, a part time Lecturer in a University of Technology, a Training and Quality Assurance Officer supporting laboratories in several African Countries and India, a Quality Assurance Manager in a Clinical Trial Laboratory, an Analytical Project Manager in another Clinical Research Unit and a Branch Manager for Quality Assurance in the NHLS. In 2004 she was trained by the South African National Accreditation

Systems (SANAS) as a Technical Assessor; she has been a Lead Assessor since 2006 and is also a member of the Advisory Approval's Committee. She serves as a member of the South African Bureau of Standards (SABS) Technical Committee TC180. Her present responsibilities include implementing QMS, Compliance and Monitoring, Proficiency Testing Schemes and Health Technology Assessment. She is a member of the NHLS Microbiology Advisory Committee. Patience is a SLMTA (Strengthening Laboratory Management Towards accreditation) Trainer and also the Principal Investigator for several projects. She represents South Africa in a Pan African Harmonisation Working Party (PAHWP).

Alash'le Abimiku, Institute of Human Virology, University of Maryland School of Medicine, United States of America



Alash'le Abimiku, is an Associate Professor at the Institute of Human Virology, University of Maryland School of Medicine, Baltimore; and a the Director of office of Laboratory diagnostics and research at the Institute of Human Virology Nigeria. She has spent over 2 decades establishing laboratory infrastructure and science in Nigeria with long-term collaborations with the USA. Dr. Abimiku's research focuses on the role of HIV subtypes in disease pathogenesis using mother to child model to investigate the transmitting subtype/s and studying effects of co-infections on HIV pathogenesis. Dr. Abimiku's more recent grant funding allows Nigeria to epidemiologically characterize different cohorts and build capacity of government officials and

Nigerian researchers in preparation for the future conduct of HIV vaccine clinical trials. Dr. Abimiku also joined the effort by scientists in Africa in the field of genomic science through the NIH's H3Africa initiative. Dr. Abimiku has trained a cadre of pre and post doctoral Nigerian students who are engaged in advanced research as collaborators. She is internationally recognized for her leadership in HIV research and in her role as a member of the WHO Vaccine Advisory Committee and as a board member the African Society for Laboratory Medicine.

SYMPOSIUM 4

PARTNERSHIPS IN STRENGTHENING LABORATORY CAPACITY IN AFRICA

SESSION OBJECTIVES:

The current Ebola virus disease outbreak in West Africa has demonstrated once again that laboratory systems are essential to a well-functioning health care system. The strengthening of healthcare systems in Africa must include the strengthening of laboratories. Currently, laboratories in Africa fall far short of the current need. Labs need to be strengthened, both in capacity and in number. Governments alone are not able to meet the growing health demands of their populations and are

DATE: Monday, 1 December

TIME: **14:45 – 16:15** LOCATION: **Room 1.4**

particularly unable to meet the demands of laboratory capacity development in many resource-constrained countries in Africa. Enhanced partnerships with governments, multilateral organizations, and the private sector will be important to further strengthen laboratory systems. Both physical infrastructure and human capacity development are essential to building strong laboratory systems. Many donors fund different aspects of laboratory capacity building; bringing them all together creates an opportunity for a more comprehensive approach to solving the needs. This session will examine current and future opportunities for partnerships to strengthen laboratory capacity in Africa, the strengths of current models of partnerships (e.g. disease-specific model) and how these models can be used to inform future partnerships to enhance laboratory capacity on the continent. Finally in this session, speakers will explore the role of basic research funding in developing laboratory capacity.

CO-CONVENERS:

Samuel Adeniyi-Jones, Office of Global Affairs, US Department of Health and Human Services



Samuel Adeniyi-Jones is the Director of the Africa Region in the Office of Global Health Affairs, Office of the Secretary, US Department of Health and Human Services, a position he has held since January 2005. Prior to this, he held several positions at the National Institutes of Health (NIH) from 1981-2005.

As a medical scientist with NIH and a consultant to organizations such as the World Bank, United Nations Development Programme, and World Health Organization, Dr. Adeniyi-Jones worked on HIV/AIDS, nutrition and health research in Africa. At the dawn of the HIV/AIDS epidemic, he worked closely with governments of several African countries to help develop their national AIDS control programmes. For over 25 years,

Dr. Adeniyi-Jones has been an advocate, advisor and technical expert for scientific institutions, governments and health care organizations throughout Africa.

Dr. Adeniyi-Jones received his medical degree from Leningrad Pediatric Medical School in St. Petersburg, Russia and his Ph.D. in Nutritional Biochemistry from the Massachusetts Institute of Technology. Dr. Adeniyi-Jones was a fellow at Harvard Medical School from 1975-1978 and later became a faculty member at Harvard Medical School, Departments of Pediatrics and Biochemistry, and an attending physician at Harvard's Children's Hospital in Boston from 1978-1981.

Aggrey Ambali, African Union, New Partnership for Africa's Development (NEPAD)



Aggrey Ambali is currently serving as Advisor and Head of Science, Technology and Innovation Hub (NSTIH) at the New Partnership for Africa's Development (NEPAD) Agency, where he oversees development and implementation of programmes in education, health, and science and technology. He has also served in other positions at the NEPAD Agency during the past 10 years, including Director of Policy Alignment and Programme Development Directorate, Coordinator of the African Biosciences Initiative, and Coordinator of Science and Technology for the Southern Africa region. Prof. Ambali has wide experience in the operations of the African Union (AU) and its economic development programme, NEPAD as well as collaborating

organisations. He recently coordinated the work of the African Union High Level Panel on Science, Technology and Innovation which was appointed in July 2012 and mandated to prepare a ten year Science, Technology and Innovation strategy for Africa (STISA 2024).

SPEAKERS:

William Ampofo, Noguchi Memorial Institute for Medical Research



William Ampofo is Head of the Virology Department, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Accra, Ghana. His research interests include molecular and serological investigations of viruses, prevention of viral infections, anti-viral therapy and viral disease burden.

Career milestones include the laboratory discovery of the first Ghanaian case of HIV in 1986, first isolation of wild type poliovirus in Ghana, confirmation of first cases in 2007 of highly pathogenic avian influenza H5N1 virus in Ghanaian poultry and establishment of the National Influenza Centre in Ghana 2007. In

December 2011, he supervised the laboratory detection of the first ever cases of Lassa fever virus infection in humans and rodents in Ghana. He is also the focal point for HIV Drug Resistance Genotyping and Emerging Dangerous Pathogens Reference laboratories.

Recent collaborations include studies on Influenza, HIV, Viral Hemorrhagic fevers and investigations of plant extracts for antiviral activity. He has teaching responsibilities in the University of Ghana with about 50 publications covering medicine, immunology and microbiology.

Prof. Ampofo is a member of the WHO Global Action Plan for Influenza Vaccines Advisory Group and is the current chair of the WHO Pandemic Influenza Preparedness Framework Advisory Group. He is the Ambassador in Ghana for the African Society for Laboratory Medicine and the American Society for Microbiology and is also the President of the Ghana Cricket Association.

Kathleen Victoir, Institut Pasteur, Paris



Kathleen Victoir, is a project manager at the International Division of the Institut Pasteur in Paris. She is involved in the set up and coordination of laboratory and related surveillance networks (including training modules) within the Institut Pasteur International Network and in the Mediterranean Region. Since August 2014 she is the coordinator of the Institut Pasteur International Network "Ebola Taskforce" together with Prof. F. Rey. Prior joining the Institut Pasteur International Network she worked as a consultant for MSF, and a European Network in the field of technology transfer. Kathleen has a scientific background with PhD in molecular genetics.

Gary Cohen, Global Business Coalition – Health (GBC)



Gary M. Cohen is the Executive Vice President of BD (Becton, Dickinson & Co.), a global medical technology company with over \$7 billion revenues and 29,000 employees in 50 countries. He is board chair of the CDC Foundation and a board director of the Perrigo Company, the US Fund for UNICEF, GBC Health and the Accordia Global Health Foundation. He also serves as a Commissioner for the UN Commission on Life Saving Commodities for Women and Children, chair of the CDC/Corporate Roundtable on Global Health Threats and an advisor to the Clinton Global Initiative. Gary and the BD team are extensively engaged in collaborations across the public, private and NGO sectors to address health needs in developing and

emerging countries. He has served as an advocate, speaker and expert panelist on global health, child immunization, HIV/ AIDS and health system strengthening, in venues including the United Nations, World Bank, World Economic Forum (Davos), US Department of State and Council on Foreign Relations. Gary founded Together for Girls, a new partnership to address the human rights and public health impacts of sexual violence against girls, comprised of UNICEF, UNAIDS, UNFPA, UN Women, the World Health Organization, the CDC, the US Department of State — Office of the US Global AIDS Coordinator (PEPFAR) and Office of Global Women's Issues (GWI), the Nduna Foundation, BD and other partners. He has been honored for his humanitarian work by MESAB (Medical Education for South African Blacks), B'nai B'rith International, the US Fund for UNICEF, the Nyumbani Home (an orphanage in Kenya for HIV positive children) and the Dikembe Mutombo Foundation. He earned a BA from Rutgers College and a MBA from the Rutgers Graduate School of Management, and previously served on the university's Board of Trustees.

SPECIAL SESSION

FRONTLINE EXPERIENCE WITH THE EBOLA OUTBREAK IN WEST AFRICA

DATE: Monday, 1 December

TIME: 16:30 - 18:00

LOCATION: Auditorium 2

SESSION OBJECTIVES:

Ebola virus disease (EVD) was first identified in 1976 during outbreaks in Sudan and Democratic Republic of Congo. The first cases of the current West Africa outbreak were reported in March 2014. It has since sickened more than 9200 people—killing more than 4500—across 7 countries, becoming the largest outbreak of EVD in history. A second, unrelated outbreak is being monitored in the Democratic Republic of Congo. The current epidemic is concentrated in three countries: Guinea, Liberia, and Sierra Leone.

Organizations from around the world including Médecins Sans Frontières, the World Health Organization, the African Union, the US Centers for Disease Control and Prevention, and the European Union, among many others, are contributing manpower, technical assistance, clinical and logistical help, and much-needed supplies to stricken areas. Donors are also rising to the challenge; the United Nations has requested nearly US\$1 billion for the Ebola response and funds are beginning to arrive. With numerous projections suggesting tens of thousands of deaths should the response not escalate, continued and even increased support is necessary to contain the epidemic. Successful efforts in Nigeria show that this can be done.

Laboratories play a critical role in controlling this epidemic. Accurate, timely, and reliable EVD diagnosis is not be possible without quality-assured laboratories and strong lab networks. In the case of EVD, standardized lab processes spanning from proper supply inventory to safe laboratory practices become essential in not only producing accurate test results but also in keeping lab workers safe. Lastly, point-of-care diagnostics and other innovative solutions may play an important role in outbreak response.

SESSION OVERVIEW:

- Laboratory Networks and Systems in the Recent Ebola Outbreak
 Jean-Bosco Ndihokubwayo, WHO Regional Office for Africa
- National Leadership and Response to the Recent Ebola Outbreak
 Austin Demby, US Department of Health and Human Services
- Role of Point-of-Care Diagnostics and Appropriate Responses
 Amadou Sall, Institut Pasteur de Dakar, Senegal
- Health Systems and International Response to the Recent Ebola Outbreak

Shannon Hader, Centers for Disease Control and Prevention, United States of America

 Controlling Ebola in the Democratic Republic of the Congo Jean-Jacques Muyembe Tamfum, University of Kinshasa, Democratic Republic of the Congo

MODERATOR:

Peter Piot, London School of Hygiene & Tropical Medicine, United Kingdom



Peter Piot MD PhD is the Director of the London School of Hygiene and Tropical Medicine, and Professor of Global Health. In 2009-2010 he was the Director of the Institute for Global Health at Imperial College, London. He was the founding Executive Director of UNAIDS and Under Secretary-General of the United Nations from 1995 until 2008, and was an Associate Director of the Global Programme on AIDS of WHO . Under his leadership UNAIDS became the chief advocate for worldwide action against AIDS, also spear heading UN reform by bringing together 10 UN system organizations.

Dr. Piot co-discovered the Ebola virus in Zaire in 1976, and led research on AIDS, women's health, and public health in Africa. He was a professor of microbiology, and of public health at the Institute of Tropical Medicine, Antwerp, the Free University of Brussels, and the University of Nairobi, was a Senior Fellow at the University of Washington, a Scholar in Residence at the Ford Foundation, a Senior Fellow at the Bill and Melinda Gates Foundation, and held the chair "Knowledge against poverty" at the College de France in Paris.

He is a member of the Institute of Medicine of the US National Academy of Sciences, of the Académie Nationale de Médicine of France, and of the Royal Academy of Medicine of his native Belgium, and a fellow of the Academy of Medical Sciences, UK, and the Royal College of Physicians. In 2008-11, he was the President of the King Baudouin Foundation and was knighted as a Baron in 1995. He has published over 500 scientific articles and 16 books, including his memoir "No time to lose". In 2013 he was the laureate of the Hideyo Noguchi Africa Prize for Medical Research.

SPEAKERS:

Jean-Bosco Ndihokubwayo, WHO Regional Office for Africa



Jean-Bosco Ndihokubwayo is a Medical Doctor specialized in Clinical Pathology and Public Health. Before joining WHO in 2001, Dr. Ndihokubwayo was Dean of School of Medicine of Bujumbura, University of Burundi. In his capacity as WHO staff Member in the Regional Office for Africa, based in Brazzaville, Congo, Dr. Ndihokubwayo coordinates the laboratory programmes for their coherent contribution to the strengthening of national health laboratory capacity through setting norms and standards, including national laboratory policies and plans and the provision of support to countries to implement the WHO/ AFRO Stepwise Laboratory Quality Improvement Process Towards Accreditation among others.

Dr. Ndihokubwayo also coordinates the strengthening of the integration of laboratory services in the African region to support countries in their efforts to move away from a disease-specific laboratory focus towards an integrated, coordinated health laboratory system, one that promotes efficient use of resources and improved laboratory service delivery, and ensures laboratories at all levels of the health system contribute to national disease prevention and control including biosafety and laboratory biosecurity. Dr. Ndihokubwayo spent 2 months (April and May 2014) on the ground in Guinea trying to coordinate the international ongoing efforts to control the Ebola virus disease outbreak.

Austin Demby, US Department of Health and Human Services



Austin Demby began his career as a research scientist with CDC in 1980. He went on to be country director of the CDC field station and director of the Lassa fever research programme in Sierra Leone (1987-1989). He served as a research scientist at the Special Pathogens Branch, Virus Reference Laboratory, Central Public Health Laboratory Services, Colindale, United Kingdom, 1990-1993; as a research scientist, Division of Pathology, Centre for Applied Microbiology and Research, Porton Down, United Kingdom, 1993-1994; research scientist, Special Pathogens Branch, CDC; and senior staff Fellow, Diagnostic Mycobacteriology, CDC, 1998-1999. From 1999 – 2005 Dr. Demby served as the Team Leader

for the laboratory services of the CDC Global AIDS Programme (GAP), of which he was a founding member. Dr. Demby served as the Director of the CDC Malawi programme and as the HHS country representative from 2006-2011. He had oversight for the HIV/AIDS prevention, treatment and care activities of CDC and facilitated other major programmes funded through HHS Agencies HRSA and NIH in Malawi. In his current position as the Director and Deputy Principal for PEPFAR, Office of Global Affairs at HHS, Dr. Demby coordinates the Department's global HIV/AIDS portfolio implemented by CDC, NIH, FDA, SAMHSA, and HRSA. Dr. Demby holds a doctorate degree in Clinical Microbiology from the University of London, England and a master's degree in public health-epidemiology/biostatistics from the University of Michigan.

Amadou Sall, Institut Pasteur de Dakar, Senegal



Amadou Sall is currently the head of the Arboviruses and viral hemorrhagic fever unit, director of the WHO collaborating centre and member of the governing board at Institut Pasteu de Dakar. He is also the director and founder of the international course on "arboviruses and viral hemorrhagic fever diagnosis, prevention, control, and outbreak management" organized by Institut Pasteur Dakar in partnership AMP, Ministry of Health of Senegal and University Cheikh Anta Diop Dakar.

Dr. Sall is a virologist and has a PhD in Public Health. He received his scientific education at Universities Paul Sabatier at Toulouse, Paris Orsay and Pierre et Marie Curie in France.

Dr. Sall's research focused primarily on ecology and evolution of arboviruses and viral hemorrhagic fever and diagnostics of the latter viruses is a priority in his laboratory. He has published more than 60 papers and book chapters and given more than 80 scientific communications in international meetings.

Shannon Hader, Centers for Disease Control and Prevention, United States of America



Shannon Hader currently serves as the Director of the Division of Global HIV/AIDS (DGHA) at the US Centers for Disease Control and Prevention. Throughout her career, she has served in key health leadership roles both internationally and domestically. Dr. Hader has served as an Epidemic Intelligence Service Officer for CDC and a Commander in the Commissioned Corps of the U.S. Public Health Service, assigned to CDC. She worked as a medical epidemiologist, CDC Country Director and DGHA lead in Zimbabwe, and Senior Scientific Advisor to the President's Emergency Plan for AIDS Relief (PEPFAR) at the Office of Global AIDS Coordinator. In 2007, she served as the Director of the HIV/AIDS, Hepatitis, STD, and TB Administration for three years.

Just prior to joining CDC as the Division Director, Dr. Hader served as Vice President and Director for the Center for Health Systems and Solutions. In addition to her work at Futures Group, Dr. Hader spent the past year as a Robert Wood Johnson Foundation Health Policy Fellow, where she served on the health policy staff of Senator Edward J. Markey of Massachusetts, chair of the Sub-committee on International Development and Foreign Assistance, Economic Affairs, International Environmental Protection, and Peace Corps, of the Senate Foreign Relations Committee.

Board-certified in Internal Medicine, Pediatrics, and Infectious Diseases, Dr. Hader earned her medical degree and Masters of Public Health from Columbia University and her BS in biological sciences from Stanford University. She completed a combined medicine/pediatrics residency at Duke University, and an infectious diseases fellowship at Emory University. She has served as a clinical assistant professor of medicine at Emory University, and was a Katherine Houghton Hepburn Fellow at Bryn Mawr College.

Jean-Jacques Muyembe Tamfum, University of Kinshasa, Democratic Republic of Congo



Jean-Jacques Muyembe Tamfum, MD, PhD is a professor of microbiology at University of Kinshasa and Director General of the Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo. Professor Muyembe is most known throughout the region for his research and leadership role in control of multiple viral hemorrhagic fever outbreaks (Ebola and Marburg). Muyembe led the response in the 1995 Ebola outbreak in Kikwit General Hospital in DRC, one of the largest Ebola outbreaks in DRC with 315 reported cases. His work over the past decades has led to increased community knowledge of viral hemorrhagic fever infection control, enhanced laboratory procedures and diagnostics, and improved outbreak control processes.

NOTES		

ROUND TABLE 1

AN UPDATE ON PROGRESS TOWARDS THE ASLM2020 GOALS FOR LABORATORY STRENGTHENING IN AFRICA

SESSION OBJECTIVES:

This session will provide an overview of the ASLM2020 Goals for laboratory strengthening in the context of Africa's healthcare development objectives and landscape. The Goals include:

Workforce Development: 30,000 laboratory workers will be trained by governments and partners across Africa.

DATE: Monday, 1 December

TIME: **16:30 - 18:00**

LOCATION: Roof Terrace Room

Laboratory Accreditation: 2,500 laboratories will enroll in the WHO-AFRO SLIPTA programme and 250 laboratories will achieve international accreditation.

Regulatory Strengthening: Regulatory systems for in vitro diagnostics will strengthen and achieve greater harmonisation in each of the economic zones of Africa.

Laboratory Networks: Leading public health reference laboratories in at least 25 countries will form networks across Africa.

The ASLM2020 goals were launched in December 2012 in Cape Town at the first ASLM international conference and to date have been endorsed by a Call for Action signed by Ministers of Health from 12 countries across Africa. Over the past two years there has been significant progress by governments and partners towards achieving these targets.

During the session, a panel of leading international experts will provide presentations on the current status within each of these key areas. Progress towards the ASLM2020 goals and the future outlook will be presented.

SESSION OVERVIEW:

 Relevance of the ASLM2020 Goals in the Context of Africa's Healthcare Development

Tsehaynesh Messele, African Society for Laboratory Medicine, Ethiopia

 Situational Analysis and Progress with Laboratory Workforce Development in Africa

Anthony Emeribe, Medical Laboratory Science Council of Nigeria (MLSCN), Nigeria

Situational Analysis and Progress with Laboratory Accreditation in Africa

Talkmore Maruta, African Society for Laboratory Medicine, Ethiopia

 Situational Analysis and Progress with Diagnostics Regulation and Harmonisation in Africa

Rosanna Peeling, London School of Hygiene & Tropical Medicine, United Kingdom

 Situational Analysis and Progress with Strengthening Laboratory Networks in Africa

Ilesh Jani, National Health Institute, Mozambique

CO-CONVENERS:

Trevor Peter, African Society for Laboratory Medicine, Ethiopia



Trevor Peter is the Chair of the Board of the African Society for Laboratory Medicine and is based in Botswana. He is also the Senior Scientific Director, Diagnostics at the Clinton Health Access Initiative where he has worked since 2005. Dr. Peter has over 20 years experience in the fields of diagnostics and infectious diseases research and public health. He has provided technical guidance in public laboratory strengthening across Africa, Asia, Eastern Europe, the Caribbean and South America. Before 2005, Dr. Peter was laboratory director at Botswana-Harvard HIV Reference Laboratory and conducted infectious disease epidemiology research.

Tsehaynesh Messele, African Society for Laboratory Medicine, Ethiopia



Tsehaynesh Messele is currently the CEO of the African Society for Laboratory Medicine, a Pan-African organization working to advance laboratory medicine across the continent. Her broad career in public health has involved research, public health laboratory system development and management, public health emergency management and high-level leadership in the public sector. As the Director General of the Ethiopian Health and Nutrition Research Institute, currently Ethiopian Public Health Institute, she led the national public health protection and promotion mandates in Ethiopia. She also served as National Programme Manager for Ethio-Netherlands AIDS Research Project (ENARP) from Sept. 2001 — Sept. 2004

assuming responsibility for leading a big bilateral collaboration project. From Oct. 2000 – Sept. 2004 she served as a Team Leader for the Immunohaematology/ Pathology Research Team. Prior to that, she worked as Head of National Referral Laboratory for AIDS; Head of Immunohaematology Division; Head of Virology and Rickettsiology Division at Ethiopian Public Health Institute. In her broad and significant career, Dr. Messele has performed numerous researches and has published numerous publications in peer-reviewed journals and as book chapters. She also served as chair and member of different International executive boards and committees.

SPEAKERS:

Anthony Emeribe, Medical Laboratory Science Council of Nigeria (MLSCN), Nigeria



Anthony Emeribe is currently the Registrar/Chief Executive of the Medical Laboratory Council of Nigeria (MLSCN). He is also the serving President of the Federation of African Associations of Medical Laboratory Scientists and a board member of the African Society for Laboratory Medicine (ASLM). In his broad career, he has served as a Professor of Laboratory Hematology and Blood Transfusion Science at the College of Medical Sciences, University of Calabar. He is also a Member of the New York Academy of Science and an Honorary Consultant Haematologist with the University of Calabar Teaching Hospital.

Pr. Emeribe has served as a Laboratory Consultant to the Global HIV/AIDS in Nigeria (GHAIN) and played a key role in enhancing quality improvement and standardization of laboratory services in various GHAIN facilities in Nigeria. He has served as a Member in the Presidential Project Implementation Committee on the FGN/Vamed Re-Equipping of Teaching and Military Hospitals and in the Board of Management Sciences for Health on the PEPFAR Fellowship for Health Professionals amongst several other community services. Pr. Emeribe is a motivational academic with several peer reviewed scientific publications in local and international journals. He has received over twenty awards from the academia, church, social and community based organizations.

Talkmore Maruta, African Society for Laboratory Medicine, Ethiopia



Talkmore Maruta is a Zimbabwean citizen and Medical Laboratory Scientist holding Bsc (Hons) Degree in Medical Laboratory Sciences, a Masters in Public Health degree, and currently studying for a PhD in Public Health. Mr. Maruta has worked for different international organizations in Laboratory System strengthening including Clinton Health Access Initiative, Foundation for New Innovative Diagnostics, and the African Society for Laboratory Medicine. Over the last 8 years, he has worked with ministries of health in over 20 African countries and the Caribbean, assisting them in implementing several laboratory strengthening activities including accreditation, mentorship, policy, and strategic plan development and review. Mr. Maruta

developed and implemented a laboratory mentorship model and training curriculum which has subsequently been implemented in a number of countries in Africa and the Caribbean. He became one of the 1st three Master Trainers for the Strengthening Laboratory Management Towards Accreditation (SLMTA) programme, and is currently the chairperson of the SLMTA Technical committee, and was awarded a "Distinguished Leadership" award at ASLM 2012 Cape Town Conference. He is a member of the WHO AFRO SLIPTA Expert Committee that reviews and updates the SLIPTA programme and has audited over 25 laboratories across more than 9 countries in Africa under the WHO AFRO SLIPTA programme.

Rosanna Peeling, London School of Hygiene & Tropical Medicine, United Kingdom



Rosanna Peeling is Professor and Chair of Diagnostics Research at the London School of Hygiene and Tropical Medicine (LSHTM) and Director of the International Diagnostics Centre. Trained as a medical microbiologist, she previously served as the research coordinator and head of diagnostics research at the UNICEF/UNDP/World Bank/WHO Special Programme on Research and Training in Tropical Diseases (WHO/TDR) in Geneva, Switzerland, and the Chief of the Canadian National Laboratory for Sexually Transmitted Diseases. Since 2011, she has been funded by the Bill & Melinda Gates Foundation, Grand Challenges Canada and UNITAID to develop mechanisms for streamlining and accelerating the regulatory oversight of

quality-assured diagnostics using harmonized approaches. The Pan-African Harmonization Working Party and the Latin America in-vitro Diagnostic Alliance were established as part of this initiative. These regional working groups will work closely with WHO and technical partners in countries to facilitate the implementation of quality assurance strategies to accelerate the uptake of new diagnostic technologies to improve health outcomes.

She is a member of many international advisory panels and editorial boards, and is the recipient of many awards, including the YM-YWCA Women of Distinction Award. Her research was featured n a Discovery Channel documentary on Chlamydia infection and infertility.

Ilesh Jani, National Health Institute, Mozambique



llesh Jani studied Medicine at the Eduardo Mondlane University in Mozambique (1998), and later received a Ph. D. in immunology from the University of London in the United Kingdom (2003). He has been a researcher at Mozambique's Instituto Nacional de Saúde since 1998, where he also served as the Head of Department of Immunology from 2004 to 2009. Since 2009, he is the Director General of the Instituto Nacional de Saúde (the National Public Health Institute for Mozambique).

During his career, llesh Jani has lead efforts in the areas of research, public health, education and diagnostics with the objective of strengthening the health system in Mozambique. He is currelty part of the the African Society for Laboratory Medicine (ASLM) and a member of the executive board of the International

board of directors of the African Society for Laboratory Medicine (ASLM) and a member of the executive board of the International Association of National Public Health Institutes (IANPHI). His fields of research include diagnostic laboratory technologies and the immunology of HIV/AIDS, and he has authored several publications in peer-reviewed international journals.

ROUND TABLE 2

STRENGTHENING LABORATORY NETWORKS AND PUBLIC HEALTH LABORATORIES IN AFRICA

SESSION OBJECTIVES:

Laboratories play a critical role in providing accurate and timely results for the purpose of diagnosis and disease control and prevention. Laboratory networks ensure that critical public health functions (e.g. diagnosing diseases, identifying public health threats, and conducting surveillance) are performed more efficiently within and across countries. A strengthened laboratory network and continued support and investment can help combat emerging and reemerging diseases. A number of global health initiatives in resource limited settings in sub-Saharan

DATE: Monday, 1 December

TIME: **16:30 – 18:00** LOCATION: **Room 1.6**

Africa have supported the establishment of quality laboratory testing by improving physical infrastructure, equipment, quality management systems and human resource capacity building. The World Bank-funded East Africa Public Health Laboratory Networking Project tackles the historical neglect of public health laboratories. The regional laboratory project aims to establish a network of efficient, high quality, accessible public health laboratories for the diagnosis and surveillance of tuberculosis and other communicable diseases in the East African Community partner states (Kenya, Rwanda, Tanzania, Uganda, and Burundi). The project is rolling out service delivery innovations, promoting client driven knowledge sharing, and fostering an evidence-based approach supporting 32 sites across the five countries. The purpose of this session is to: (i) discuss the pivotal role of laboratory networks and public health laboratories; (ii) share information on investments and innovations to strengthen public health laboratories under the East Africa Public Health Laboratory Networking Project, including key findings in laboratory quality improvements; and (iii) draw lessons on integrated, country driven approaches to laboratory strengthening and networking in the region.

SESSION OVERVIEW:

- Role of Laboratory Networks in Achieving Quality and Efficiency Moses Joloba, Uganda TB Supra National Reference Laboratory, Uganda
- Laboratory Workforce Development through Public Health Laboratory Networking in East Africa

Fausta Mosha, National Public Health Laboratory, Tanzania

 Transforming National Public Health Laboratory Systems in East Africa: Kenya Case Study

Mamo Umuro, National Public Health Laboratory, Kenya

• Integrated Laboratory Systems Improvement: Experience with a Peer Review Laboratory Programme under the East Africa Public Health Laboratory Networking Project

Martin Matu, East African Public Health Laboratory Networking Project (EAPHLNP), Kenya

CO-CONVENERS:

Souleymane Mboup, Cheikh Anta Diop University (CADU), Senegal



Souleymane Mboup received a Pharm D degree a the University of Dakar in Senegal in 1976, an Immunology MS degree at Pasteur Institute in France in 1981 and a PhD in Bacteriology Virology in 1983 in TOURS (France) .

Since 1984, he is the head of the Bacteriology Virology department at the University Hospital Le Dantec, University of Dakar, Senegal Since 1985, Professor Mboup is distinguished for his important contributions to the analysis and control of HIV/AIDS in West Africa, particularly Senegal. He was instrumental in the initial identification of HIV-2 and also contributed to the finding that this virus is less virulent and less

transmissible than HIV-1. He maintains active research collaboration with several academicians in France, the US and the UK. Several of his trainees now hold influential positions at international agencies. He has a growing contribution on malaria and tuberculosis which are like HIV/AIDS major and growing public health problems that are exceedingly difficult to control. He is the chair of the African AIDS Research Network, and also WANETAM (West African Network of Excellence for AIDS, TB and Malaria). He is awarded by CDC for a grant for the Development of a HIV-related Proficiency Testing Programme for African Countries and a Quality Management Systems Programme for African Francophone Countries under the President's Emergency Plan for AIDS Relief (PEPFAR) Professor MBOUP has authored or co-authored 350 publications and 22 books.

Alex Opio, Department of National Disease Control, Uganda



Alex Opio is a Ugandan Medical Doctor specialized in Epidemiology. He has a long national level experience in the provision of health services. He received his medical training from Makerere University, Uganda qualifying as a Medical Doctor in 1980. From 1981 to 1985, he worked at Entebbe Grade "A" Hospital as a medical officer. In 1985, he proceeded for postgraduate training at the University of London where he obtained a Master of Science degree in Maternal and Child Health. In 1987, he became the Assistant Manager of the Uganda National Expanded Programme on Immunization. Later, in 1989, he proceeded again for further studies enrolling for a Ph.D. course at Case Western Reserve University, Cleveland, Ohio,

USA to study Epidemiology and Biostatistics. After obtaining his Ph.D. in 1994, he returned to Uganda to continue with work at the Ministry of Health. Since then, Alex has grown through the ranks to his current position of Assistant Commissioner of Health Services in the Department of National Disease Control.

Alex has been actively involved in policy formulation, development of standards and guidelines, provision of technical support to districts, as well as monitoring and evaluation of health intervention; especially those related to the prevention and control of communicable diseases. He has had particular interest in strengthening laboratory services in Uganda. Currently, he chairs the National Laboratory Technical and Policy Advisory Committee. Under his leadership, the Uganda National Health Laboratory Policy was developed and launched. He is also the Coordinator of the East African Public Health Laboratory Networking Project.

SPEAKERS:

Moses Joloba, Uganda TB Supra National Reference Laboratory, Uganda



Moses L. Joloba, MBChB, M.S., Ph. D is an Assoc. Professor of Molecular Biology, Immunology and Microbiology in the School of Biomedical Sciences, College of Health Sciences at Makerere University. He is the director of the Uganda TB Supra National Reference Laboratory that has attained ISO 15189 accreditation. He is the Chair of the Laboratory Networking Technical Working Group of the World bank funded East Africa Public Health Laboratory Networking Project. Since his training in Makerere University (MBChB) and Case Western Reserve University (Ms and PhD), Dr. Joloba has developed skills in setting up standard laboratories, supporting TB laboratory networks, developing training programmes, starting

graduate and short courses, initiating and participating in successful North to South and South to South collaborations, conducting laboratory-based research as well as training of graduate students. Dr. Joloba has trained 33 Masters and 14 Doctoral students and many non degree students from the African region and internationally. Dr. Joloba has won over 12 grants and published over 120 peer reviewed papers, he is a reviewer for 6 journals and a book author. Dr. Joloba, a previous and founder member of the core group of the Global Laboratory Initiative (GLI), is very excited and optimistic to be part of the GLI-AFRICA.

Martin Matu, East African Public Health Laboratory Networking Project (EAPHLNP), Kenya



Martin Matu is a Laboratory specialist for the East African Public Health Laboratory Networking Project at the East Central and Southern Africa Health Community Secretariat in Arusha, Tanzania. Matu previously worked for the African Medical and Research Foundation, the University of Nairobi and the Kenya Medical Research Institute.

Martin is a laboratory scientist by profession with a background in Medical Laboratory Sciences and he also holds a Master of Science degree in Biotechnology and Molecular Biology from Kenyatta University. He is also pursuing PhD in Public Health (epidemiology) at the Jomo Kenyatta University of Agriculture

and Technology, in Kenya and a Masters in Business Administration (Strategic Management and Leadership) at the Eastern and Southern Management Institute, in Arusha, Tanzania.

He is currently involved coordinating the regional World Bank-funded project being implemented in five countries in East Africa that aims at *Controlling the Spread of Communicable Diseases in Eastern Africa through Improved Diagnostic and Surveillance Capacities*. Matu is involved in providing oversight mentorship for laboratory improvement, laboratory systems auditing, implementing quality systems and capacity building of laboratory professionals in the region.

Fausta Mosha, National Public Health Laboratory, Tanzania



Fausta Mosha, is a medical microbiologist and epidemiologist working for the Ministry of Health and Social Welfare in Tanzania since 2005, currently as a Director for the National Public Health Laboratory since 2010. Before that she has been coordinatinglaboratory based trainings and also a Resident Advisor for the Tanzania Field Epidemiology and Laboratory Training Programme (FELTP). She holds an MD from the University of Dar es Salaam, Msc in Microbiology from the University of Leuven, Belgium, Msc in Epidemiology and Laboratory Management from the Jomo Kenyatta University, Kenya and PhD from the University of Leuven, Belgium. She is a Principal Investigator for the international Co-operative agreement

between the Centers for Disease Control and Prevention, (CDC), Atlanta and African Field Epidemiology Network (AFENET) on a project "Laboratory Biosafety and Quality Assurance involving Several Countries in Africa and the Caribbean Region." She is also a Programme Manager for the East African Public Health Laboratory Networking Project (EAPHLNP) in Tanzania and Secretary for the Board of Directors of African Society for Laboratory Medicine (ASLM).

Mamo Umuro, National Public Health Laboratory, Kenya



Mamo holds a Masters degree in medical microbiology and is currently pursuing a PHD in molecular virology. In addition he has a post graduate diploma in health systems strengthening from Kenya Medical College, Kenya and has attended a strategic laboratory management and leadership course at George Washington University USA and many other technical courses.

Mamo is a laboratory scientist with many years of professional experience in laboratory management, laboratory quality systems and health programme planning and implementation. He has worked in the Ministry of Health in various senior management capacities as a senior laboratory specialist gaining both

local and international exposure in the fields of public health laboratory and quality management system.

He has extensive experience in planning, coordinating and implementation of donor funded projects and grants with several key achievements, among them initiation a national proficiency testing EQA plan for rapid HIV testing programme using dried tube specimens, scaling the programme to over 7000 participants (highest in the region) and the SLIPTA programme, a stepwise laboratory accreditation programme in Kenya where through his able leadership, the National HIV reference laboratory Kenya was ISO 15189 Certified (accredited), becoming the first and the only public laboratory accredited in Kenya. Mamo is the current Head of the National Public Health Laboratory Kenya and Project manager for a World Bank supported East Africa Public Health Laboratory Networking Project, which is supporting a national public health laboratories and regional laboratories in the country. He is a Kenya government gazeted member of Kenya medical laboratory board and registered member of many other local and international associations.

ROUND TABLE 3

PUBLIC-PRIVATE PARTNERSHIPS TO SUPPORT CONNECTIVITY FOR DIAGNOSTICS IN RESOURCE-LIMITED SETTINGS

SESSION OBJECTIVES:

This symposium is being organized as a follow-up to ASLM's Industry Forum that took place in March 2014. One of the discussion topics at that meeting was the potential for public-private partnerships among industry, implementing partners and the public sector to improve the effectiveness of diagnostic delivery in sub-Saharan Africa. In that context, a subject of particular interest to participants was connectivity for diagnostics, especially in light of increased decentralized testing through the use of point-of-care technologies.

DATE: Monday, 1 December

TIME: **16:30 – 18:00**LOCATION: **Room 1.4**

This ninety minute symposium will focus on the connectivity landscape for diagnostics, specifically how the application of technology and process engineering can be used to improve patient flow, increase patient safety and improve patient outcomes, especially for point-of-care technologies. It will consider potential ways that public-private partnerships might help resolve some of the issues surrounding connectivity for diagnostics in resource-constrained settings, including mobile versus Internet-based technologies, interoperability of systems, data management and vendor neutrality, among others.

CO-CONVENERS:

Maurine Murtagh, International Diagnostics Centre, Uganda



Maurine Murtagh is the CEO of the International Diagnostics Centre. She is also a consultant specializing in diagnostics for global health in which capacity she works with UNITAID and the Bill & Melinda Gates Foundation, among others. Previously, Maurine was the Director of Diagnostic Services for the Clinton Health Access Initiative (CHAI), a position she held for almost five years. Prior to joining CHAI, Maurine was a corporate partner at the law firm of Howard Rice Nemerovski Canady Falk & Rabkin in San Francisco, California, where her focus was on mergers and acquisitions and securities law. She graduated from Georgetown University and holds an M.B.A. from the University of Texas at Austin, an M.Phil. in finance from Columbia University and a J.D. from Duke University.

Ben Cheng, Pangaea Global AIDS Foundation, United States of America



Ben Cheng is the Vice President of Technology and Innovation at the Pangaea Global AIDS Foundation. Prior to joining Pangaea, Ben was the Director of Advocacy and Communications at PATH and was the Deputy Director at the Forum for Collaborative HIV Research, a public private partnership housed in the School of Public Health and Health Services at the George Washington University in Washington, DC.

He was responsible for identifying and addressing critical gaps in HIV research and mobilizing key stakeholders. For many years, Ben also served as Director of Antiviral Advocacy for Project Inform, an AIDS Service Organization based in San Francisco. He has extensive experience in building global advocacy

partnerships, has a strong science background, and has worked with many of the global partners from an HIV/AIDS perspective. At Pangaea, Ben's major area of focus is on accelerating access to diagnostics and monitoring technologies.

SPEAKERS:

Brad Cunningham, Lucerae Consulting, South Africa



Brad Cunningham is an engineer who consults as a Solutions Analyst with a specialization in the healthcare and biomedical field. He transitioned from the academic environment where he obtained an MSc. Eng (Biomedical Research Group) and BSc. IT into the medical research and development field. Brad has been involved in the conception, design and implementation of a number of IT solutions in the medical and healthcare field being used both nationally and internationally. Brad has a long-standing relationship with the South African National Priority Programme of the NHLS where he has been involved with the development and evaluation of various IT, middleware and automation systems with a primary focus on point-of-care diagnostics implementation and data management for HIV and TB.

Zelalem Gizachew, Clinton Health Access Initiative, Ethiopia



Zelalem Gizachew is a programme manager for mHealth at Clinton Health Access Initiatives leading the design, development and implementation of mobile based technology solutions for health service delivery. Zelalem Gizachew is a Medical Laboratory Technologies and Computer Programmer, having graduated from Addis Ababa University and HiLCoE School of Computer Science and Technology with B.Sc. in Medical Laboratory Technology and Computer Science, specializing in Health Information Technology Systems. Zelalem worked for various health facilities and institution as a Medical laboratory technologist and as principal advisor on development and adoptions of health information management systems for the past 10 years.

Brenda Waning, UNITAID, Switzerland



Brenda Waning serves as Coordinator of Market Dynamics at UNITAID, a WHO-partnership based in Geneva. She leads UNTAID's technical team responsible for monitoring trends in HIV/AIDS, tuberculosis, and malaria markets; identifying strategic opportunities to intervene in these markets; developing new proposals for funding consideration; and assessing the public health and market impact of UNITAID's interventions. Prior to joining UNITAID, Dr. Waning served as Director of Pharmaceutical Policy at Boston University School of Medicine where she authored numerous peer-reviewed studies on pharmaceutical policy at local, national, and global levels. Dr. Waning serves on many expert advisory groups, including

the UNAIDS Diagnostics Access Initiative Steering Committee United Nations and the Medicines for Malaria Venture Access and Delivery Advisory Committee.

William Rodriguez, Daktari Diagnostics, United States of America



William Rodriguez, MD, trained in medicine and infectious diseases at the Brigham and Women's Hospital, and served as Chief Medical Resident. From 2003-2007, he was the Chief Medical Officer for the William J. Clinton Foundation, where he assisted the South African government with its HIV programme, and helped broker agreements between African and Asian governments and drugs and diagnostics manufacturers. He has consulted for the World Health Organization and the Bill & Melinda Gates Foundation. From 2001-2008, he co-directed a global health diagnostics programme at Massachusetts General Hospital. In 2008, he co-founded Daktari Diagnostics, where he serves as Chief Executive Officer.

ROUND TABLE 4

LABORATORY SUPPLY CHAIN MANAGEMENT CHALLENGES IN AFRICA

SESSION OBJECTIVES:

It is widely recognized that there are significant financial pressures on laboratory services in developing health networks. Since the Maputo Declaration in 2008, many national laboratory programmes are responding to shifting health demands and technology developments but are still plagued with high cost per test, low instrument utilization and sub-optimal instrument placement. In light of flat and reduced laboratory funding streams, countries are faced with the need to seek cost

DATE: Monday, 1 December

TIME: **16:30 – 18:00**LOCATION: **Room 2.4**

efficiencies to meet existing and future demand for laboratory services. At the same time, the Diagnostic Access Initiative (DAI) launched recently by UNAIDS, WHO, CHAI, PEPFAR and other partners in Melbourne (July 2014) express a commitment that by 2020, 90% of all people living with HIV know their serostatus, 90% of all people diagnosed with HIV have ART, and 90% of all those on ART have achieved viral suppression.

Analyzing laboratory procurement and quantification data with greater frequency can enhance network development and identify opportunities to reduce existing instrument diversity and significantly contribute to the achievement of the above targets in a more efficient manner. There is a need to improve sample referral networks and strategically deploy laboratory instruments. These efforts can help develop increased service coverage with greater cost efficiency to maximize current and future instrument investment. In a time where current network instruments may be aged, there is a need to also address instrument replacement strategies and realign instrument coverage with site level demands with best fit instruments. Harmonization, improved coordination and partnership, and evidence based procurement strategies are critical to achieve the Diagnostic Access Initiative 90-90-90 targets by advancing cost efficient laboratory service provision in an effort to improve coverage and the health outcomes of the populations they serve.

The purpose of the roundtable is to give participants an overarching view of the supply chain challenges for diagnostics including procurement strategies, pricing/rental options, and harmonization and placement issues. It is the intent for participants to understand the procurement strategies from the Global Fund and the US Government, have an overview of different strategies related to procurement, pricing and rental agreements from CHAI, and understand the solutions to achieve appropriate harmonization, placement, and distribution of products. This will be followed by a panel discussion with questions and answers.

SESSION OVERVIEW:

- Global Fund and USG Strategies for Procurement of Diagnostics
 - **Jöelle Daviaud** and **Martin Auton**, The Global Fund to Fight against AIDS, Tuberculosis and Malaria, Switzerland; **Joel Kuritsky**, United States Agency for International Development
- Pricing Related Issues with Diagnostics

Zach Katz, Clinton Health Access Initiative, United States of America

Data Driven Harmonization and Lab Network Optimisation Strategies:
 Addressing the 90-90-90 Target

Jason Williams and Peter Smith, Partnership for Supply Chain Management

CO-CONVENERS:

Joel Kuritsky, United States Agency for International Development



Joel Kuritsky is the Medical Advisor for the Supply for Health Division in the Office of HIV/AIDS at USAID. He is trained in infectious diseases and worked for the National Centers for Disease Control in Atlanta for 23 years before joining USAID. Dr. Kuritsky worked in Bolivia for CDC and USAID from 1988 to 1994 on child survival programmes, Chagas' disease and HIV/AIDS. From 1996-2000 he was the Director of the Immunization Services Division in the National Immunization Programme at CDC. From 2003 to 2005 he worked in the Treatment and Care Branch for the Global AIDS Programme at CDC and was co-chair of the Procurement Work Group, which helped design supply chain strategies for the PEPFAR programme. From

2006 to 2009, Dr. Kuritsky was the Deputy Director of the Pediatric Dengue Vaccine Initiative at the International Vaccine Institute in Seoul, South Korea.

Vincent Habiyambere, World Health Organization, Switzerland



Vincent Habiyambere is an expert in PSM system strengthening. He is a medical doctor (MD) with a MPH and a PhD in social and administrative pharmacy with emphasis on pharmacy management and practice. After 5 years of practicing medicine and teaching public health in university and director of the School of Public Health of University of Rwanda, he has been working with the World Health Organization (WHO) for 22 years. His work area includes strategic information on use of HIV drugs and diagnostics, global ARV demand forecast to prevent global ARV shortage, capacity building in PSM and fostering collaboration among AMDS partners.

SPEAKERS:

Jöelle Daviaud, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland



Jöelle Daviaud graduated from France with a Doctorate degree in Pharmacy. She is the Quality Assurance Specialist for Health Products in Grant Management Support within the Grant Management Division at the Global Fund. Since 2006 she has been responsible for providing with expert support and guidance on quality assurance related matters for health products (pharmaceuticals, diagnostics, bednets, insecticides, condoms), throughout the grant lifecycle. She also manages the development, operationalization, and implementation of the Quality Assurance policies developed in close cooperation with technical partners including WHO Prequalification team, National Drugs regulatory authorities, manufacturers' representatives,

as well as with donors, such as UNITAID and USAID, working towards harmonization of policies.

Since the early nineties, she has worked in the field of Health Products Quality Assurance with the following continuous objective: ensuring that the end users receive the most appropriate formulation of safe, efficient and quality-assured products.

She started her carrier in the Quality Control Laboratory at the French Ministry of Health, working on diagnostics, pharmaceuticals, and vaccines dossier assessment and quality control. In 2002 she moved to Geneva to join WHO Headquarters to work with the team in charge of the prequalification of vaccines.

Martin Auton, The Global Fund to Fight against AIDS, Tuberculosis and Malaria, Switzerland



Martin Auton, Lead for the Sourcing of HIV Products, The Global Fund to Fight AIDS, TB and Malaria. Martin is a member of the Global Fund's Sourcing Department responsible for the Sourcing of HIV products — treatment, diagnostics and prevention. He is a pharmacist who after working for seven years in the private sector in the United Kingdom has worked for the last 20 years on access to health products in international public health including for the last 4 years at the Global Fund.

Zach Katz, Clinton Health Access Initiative, United States of America



Zach is the Director of Diagnostic Services for the Clinton Health Access Initiative (CHAI). CHAI works to increase access to drugs and diagnostics for HIV, malaria, tuberculosis and other essential areas. CHAI has played a large role in the introduction of new diagnostics for HIV through extensive partnerships in the public and private sectors.

Previously Zach held a number of in-country roles including as the inaugural Country Director of Papua New Guinea as well as Cambodia, and the Deputy Regional Directorship for Asia-Pacific.

Zach received his BA from Carleton College in the US and received a MPA from the Robert F. Wagner School of Public Service at New York University.

Jason William, Partnership for Supply Chain Management



Jason Williams, the Principal Laboratory Advisor for SCMS (Supply Chain Management System), a project under PEPFAR administered by USAID. Mr. William's serves as a liaison between SCMS country programmes, Ministries of Health, USG (USAID/CDC), and external collaborators. He provides technical leadership and advocacy to promote the advancement of laboratory harmonization, equipment maintenance strategies, best practice logistics and supply chain principles, and laboratory commodity quantifications.

Mr. Williams comes to SCMS with 25 years of clinical, research, and public health-based programmatic laboratory development experience. He has worked on public health issues with a variety of US

Government agencies and has provided HIV and TB laboratory programme management, technical assistance, and programmatic development support to countries across Africa, South America, the Caribbean, India, China, and Southeast Asia. Prior to joining SCMS, Mr. Williams served as the Senior Laboratory Advisor responsible for implementing the operational and programmatic laboratory-based objectives of the CDC's PEFPAR Programme in South Africa. Mr. Williams served as the Lead Laboratory Advisor for a multi-agency mission in South Africa where he coordinated US Government financial and technical assistance for the South Africa National Department of Health, the National Health Laboratory Service, and other NGO laboratory-based activities within South Africa.

Peter Smith, Partnership for Supply Chain Management



Peter Smith currently serves as the Procurement Operations Manager for PFSCM (Partnership for Supply Chain Management) non-pharmaceuticals team. As part of the Global Supply Chain operations, he is responsible for the procurement and on-time delivery of over \$120 million USD in laboratory, medical and infrastructure products to over 30 high needs countries. He has over 34 years' experience in supply chain management specializing in process development and technology implementation with over 16 years in development of end to end logistics systems for medical and laboratory services. He has directed procurement operations for government and commercial facilities including bid development and control, award management and contract execution.

The Panther® System A new era in viral load testing.



Learn how you can monitor HIV-1 treatment with confidence.

Visit Hologic at Booth 34.

Hologic is building on our history of innovation to provide a growing menu of virology and infectious disease assays on the Panther system:

- Our technology has been used to test for HIV in blood screening since 1998.
- The Aptima HIV-1 Quant Dx assay* delivers sensitive, accurate and precise results (submitted for CE mark approval).
- The Aptima family of assays runs on the Panther system a single, sample-to-answer automated platform.

Virology. Panther. Hologic.
Setting the standard for the molecular diagnostics world.

hologic.com | diagnostic.solutions@hologic.com

ADS-01078-001 ©2014 Hologic, Inc. All rights reserved. Hologic, Panther, Aptima and associated logos are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks, and product names are the property of their respective owners. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to diagnostic.solutions@hologic.com.



The Panther System Menu

Current Aptima® Assay Targets

CT/NG

CT NG

Trichomonas

HPV 16 18/45

HPV 16 18/45 (genotyping)

Targets
In Development*

HIV-1 viral load

HBV viral load

HCV viral load

M. genitalium HSV I/II





^{*}Assay currently in development.

TUESDAY, 2 DECEMBER 2014

PLENARY **2**LABORATORY MEDICINE AND POLICY

DATE: Tuesday, 2 December

TIME: **09:00 - 10:30**

LOCATION: Auditorium 1

SESSION CO-CHAIRS: **Brad Hersh**, Joint United Nations Programme on HIV/AIDS, Switzerland

Wendy Stevens, National Health Laboratory Service, South Africa

Shannon Hader, Centers for Disease Control and Prevention, United States of America

Global Health Emergencies: Role of Laboratory Medicine

Shannon Hader currently serves as the Director of the Division of Global HIV/AIDS (DGHA) at the US Centers for Disease Control and Prevention. Throughout her career, she has served in key health leadership roles both internationally and domestically. Dr. Hader has served as an Epidemic Intelligence Service Officer for CDC and a Commander in the Commissioned Corps of the U.S. Public Health Service, assigned to CDC. She worked as a medical epidemiologist, CDC Country Director and DGHA lead in Zimbabwe, and Senior Scientific Advisor to the President's Emergency Plan for AIDS Relief (PEPFAR) at the Office of Global AIDS Coordinator. In 2007, she served as the director of the HIV/AIDS, Hepatitis, STD, and TB Administration for three years.




Just prior to joining CDC as the Division Direction, Dr. Hader served as Vice President and Director for the Center for Health Systems and Solutions. In addition to her work at Futures Group, Dr. Hader spent the past year as a Robert Wood Johnson Foundation Health Policy Fellow, where she served on the health policy staff of Senator Edward J. Markey of Massachusetts, chair of the Sub-committee on International Development and Foreign Assistance, Economic Affairs, International Environmental Protection, and Peace Corps, of the Senate Foreign Relations Committee.

Board-certified in Internal Medicine, Pediatrics, and Infectious Diseases, Dr. Hader earned her medical degree and Masters of Public Health from Columbia University and her BS in biological sciences from Stanford University. She completed a combined medicine/pediatrics residency at Duke University, and an infectious diseases fellowship at Emory University. She has served as a clinical assistant professor of medicine at Emory University, and was a Katherine Houghton Hepburn Fellow at Bryn Mawr College.

Peter Lamptey, Family Health International, Ghana

Uniting Laboratory Science, Policy, and Implementation

Peter Lamptey is a Distinguished Scientist/ President Emeritus at FHI360 and Co-Chair of the FHI 360 Advisory Committee. He is based in Accra, Ghana, and provides technical and strategic leadership to FHI360's public and development programmes in over 65 countries in Africa, Asia, Latin America and the Caribbean. He also holds a part-time position as Professor of Global Non-communicable Diseases at the London School of Hygiene and Tropical Medicine with joint appointments in the Faculty of Epidemiology and Population Health and the Faculty of Public Health and Policy.



Dr. Lamptey is an internationally recognised public health physician and expert in developing countries, with particular emphasis on communicable and non-communicable diseases. With a career at FHI360 spanning more than 30 years, he has been instrumental in establishing FHI360 as one of the world's leading international nongovernmental organisations in implementing HIV/AIDS prevention, care, treatment and support programmes.

Dr. Lamptey received his medical degree from the University of Ghana, and advanced public health education in the US including a Masters in Public Health from the University of California, Los Angeles (UCLA). He also hold a DrPH from the Harvard University School of Public Health and a nutrition fellowship at the Massachusetts Institute of Technology (MIT).

Dr. Lamptey serves on the Lancet Commission on the Future Health of Africa, the Africa Tobacco Control Committee, Global Advisory Group for the new LSHTM Centre for Global NCDs, and is a member of the CSIS Commission on Smart Global Health Policy.

Rosanna Peeling, London School of Hygiene & Tropical Medicine, United Kingdom

Laboratory Policy and Clinical Medicine: Building Trust and Measuring Impact

Rosanna Peeling is Professor and Chair of Diagnostics Research at the London School of Hygiene and Tropical Medicine (LSHTM) and Director of the International Diagnostics Centre. Trained as a medical microbiologist, she previously served as the research coordinator and head of diagnostics research at the UNICEF/UNDP/World Bank/WHO Special Programme on Research and Training in Tropical Diseases (WHO/TDR) in Geneva, Switzerland, and the Chief of the Canadian National Laboratory for Sexually Transmitted Diseases. Since 2011, she has been funded by the Bill & Melinda Gates Foundation, Grand Challenges Canada and UNITAID to develop mechanisms for streamlining and accelerating the regulatory oversight of quality-assured diagnostics using harmonized approaches. The Pan-



African Harmonization Working Party and the Latin America in-vitro Diagnostic Alliance were established as part of this initiative. These regional working groups will work closely with WHO and technical partners in countries to facilitate the implementation of quality assurance strategies to accelerate the uptake of new diagnostic technologies to improve health outcomes.

She is a member of many international advisory panels and editorial boards, and is the recipient of many awards, including the YM-YWCA Women of Distinction Award. Her research was featured n a Discovery Channel documentary on Chlamydia infection and infertility.

ORAL SESSION ${f 2}$

DATE: Tuesday, 2 December

TIME: 11:00 - 12:45

	SSION 2.1: Point-of-Care Diagnostics S: Francois-Xavier Mbopi-Keou and Clement Zeh	Tuesday, 2 December Room 1.4
11:00	Evaluation of a Novel Point-of-Care Test for CD4, %CD4, and Total Hemoglobin (Hb): The BD FACSPresto TM Frank Angira, Clement Zeh, Paul Omolo, Benta Akoth, Valarie Opollo, Beverly Lu, Scott Bornheimer, Henok Tilahun, Laurie Byrne, In	melda Omana-Zapata
11:10	Assessment of a Revised Protocol for Selection of HIV Rapid Tests for the National HCT Programme in South Beverley Anne Singh and Adrian Puren	th Africa
11:20	Dried Blood Spot Samples for Viral Load Testing Vary Significantly in Performance with Each of the Current Viral Load Technologies Lara Vojnov	tly Available
11:30	Connectivity: Instrument and Information Management at Point-of-Care — Experience vs. Expectation Bradford Cunningham, Charlotte Jansen van Rensburg, Edwin Motsoloane, Lesley Scott, Wendy Stevens	
11:40	Positive Control Wells (PCW) for Malaria Rapid Diagnostic Tests (RDT): Training Effectiveness, Impact on RE Health Worker Perceptions in Lao PDR and Uganda Daniel Kyabayinze, Jane Cunningham, Heidi Hopkins, Mayfong Mayxay, Koukeo Phommasone, Elizabeth Streat, Iveth J. Gonzalez,	
	SSION 2.2: HIV Co-infection (Hepatitis B, STIs, and Cryptococcus) S: Souleymane Sawadogo and Rosemary Audu	Tuesday, 2 December Auditorium 1
11:00	Detection of Hepatitis B Virus DNA by Polymerase Chain Reaction (PCR) in Plasma of Blood Donors Negativin Abakaliki, Ebonyi State, Nigeria CANCELLED Chinenye Mbamalu, Ifeoma Ekejindu, Emmanuel Nna	re for HBsAg
11:10	Antibody Response to Hepatitis B Vaccine in Pediatric Patients Attending Rwanda Military Hospital in Octob Judy Orikiiriza, Louis Mujuwisha, Elizabeth Karlsson, Johan Normark CANCELLED	ber-December 2013
11:20	Séroprévalence des Marqueurs Spécifiques de l'Hépatite B Chez les Donneurs de Sang Vénévoles à Kinsha Eric Mukenge, Sylvain Yuma Ramazani, Guy-Olivier Mbensa Kuediasala, Blanchard Malenga Nkanga, Aimé Mbaya Tshiyamu, Fran Muwonga Masidi, Donatien Kayembe Nzongola, Ferdinand Mbayo Kalumbu, Steve Ahuka-Mundeke	
11:30	Prevalence of Cryptococcus Antigenemia (CrAg) among a Sample of HIV-infected Individuals in Namibia Souleymane Sawadogo, Boniface Makumbi, Anne Purfield, Christophine Ndjavera, Gram Mutandi, Andrew Maher, Francina Kaindju Benjamin J. Park, David W. Lowrance	ee Tjituka, Jon Kaplan,
11:40	Molecular Typing of <i>Cryptococcus neoformans</i> and <i>Cryptococcus gattii</i> from Clinical and Environmental Sc Nairobi, Kenya CANCELLED Mourine Kangogo, Christine Bii, Olivier Bader, Hamadi Boga, Wanjiru Wayoike, Michael Weig, Uwe Groß	ources in
11:50	Contribution à l'Amélioration de la Sécurité Transfusionnelle : Diagnostic Moléculaire des Virus d'Epstein I de l'Hépatite G (VHG) par PCR et RT-PCR Chez les Donneurs de Sang au Burkina Faso CANCELLE Issoufou Tao, Cyrille Bisseye, Alice Kiba, Mahmoudou Sanou, Tegwindé Rebeca Compaoré, Lassina Traoré, Jean Baptiste Nikiema, Jacques Simpore)
12:00	The Burden Of Bacterial Vaginosis in Lagos, Nigeria CANCELLED Chinedum Oparaugo, Rosemary Okoye, Adesegun Adesesan, Mariam Adetunji, Samuel Nduaga, Ini-obong Essien	
	SSION 2.3: Improving TB Diagnosis S: Jean de Dieu Iragena and Tom Shinnick	Tuesday, 2 December Room 1.6
11:00	Improving Access to MDR-TB Diagnosis in Africa: EXPAND-TB's Experience of Establishing Laboratories in Jesse Wambug and Kekeletso Kao	12 African Countries
11:10	Improved Laboratory Diagnosis of MDR-TB Cases is Revealing Care and Treatment Scale-Up Needs in Côte Raymond N'Guessan, Mah-Sévé Keita Sow, André Téhé, Alem Sinishaw, Adje-Toure Christiane, Jacquemin Kouakou	e d'Ivoire
11:20	Comparison of Tuberculosis Skin Test and QuantiFERON-TB Gold in Tube Assay for Diagnostic Workup of Cl A Cross-Sectional Study Conducted at Tikur Anbesa Specialized Hospital, Ethiopia Ibrahim Ali, Yimtubeznash Woldeamnuel, Amha Mekasha, Markos Abebe, Liya Wassie, Abraham Aseffa	nildhood Tuberculosis.
11:30	GeneXpert MTB/RIF: Observed Error Rates and Invalid Results After Twelve Months of Regular Use Yetunde Isa, Agatha Ani, Rosemary Pwol, Chindak Lekuk, Tolutope Ashi-Sulaiman	
11:40	Comparison of SpeedOligo Test to Xpert MTB/Rif Test for Detection of Tuberculosis in Smear-Negative HIV- Simon Walusimbi, Alfred Okeng, Edgar Kigozi, Samuel Kyobe	Infected Patients

	ESSION 2.4: Monitoring Rotavirus and Enteric Diseases IRS: Diane Waku and Elisabeth Pukuta Roc	ember om 2.4
11:00	Diversity of Group A Rotavirus Strains Circulating in RDC, January-December 2012 Elisabeth Pukuta, V. Tubijinga, M. Landu, G. Kitambala, D. Monga, M. Essona, S. Mapaseka, A. Nkongolo, D. Waku, V. Ngum, M. Bowen, V. Mondonge, JJ. Muyembe	
11:10	Estimated Rotavirus Gastroenteritis Prevalence in Children Below the Age of 5 Years in Swaziland During Period Jan-Dec 20 Nomcebo Phungwayo and Gugu Maphalala	013
11:20	The Necessity of Full Sepsis Work-Up in Neonatal Sepsis: Experience in a Resource-Limited Setting Kenneth Onyedibe, Bose Toma, Udochukwu Diala, Omini Uket, Ubong Udoh, Okokon Ita, Mark Okolo, Tolulope Afolaranmi, Victor Nwadike	
11:30	Epidemiology and Genotyping Characterization of Rotavirus Strains Detected in Under 5 with Acute Gastroenteritis at 2 Children's Hospitals in Zambia Julia Simwaka, Evans Mpabalwani, Mwaka Monze, Jason Mwenda, Olusegun Babaniyi, Cynthia Phiri Mubanga, Idah Ndumba, Mazyanga Liwewe, Hellen Mutambo	
11:40	Identifying Etiologic Agents of Diarrhoea Through Active Laboratory-Based Surveillance in Dadaab, Kenya, 2011-2013 Fredrick Oyier, Shafe Ali Mowlid, Steve Biko Ochieng, Ahmed Unshur, Charles Okello, Barry Fields, Joel M. Montgomery, Maurice Ope, Nina Marano	
11:50	Strengthening Laboratory Capacity Through the Surveillance of Rotavirus Gastroenteritis in Central Africa: The Surveillance Épidémiologique en Afrique Centrale (SURVAC) Project Diane Waku-Kouomou, Mathew D. Esona, Elisabeth Pukuta, Ionela Gouandjika-Vasilache, Angelina Boula, Kathleen F. Cavallaro, Michael D. Bowen	
12:00	A Comparison of Anatomically Designed Flocked Rectal Swab to Traditional Fibre Swab Samples for the Molecular Detection of Bacterial Enteric Pathogens Margaret Mokomane, Andrew P. Steenhoff, B.A. Gashe, Jeffrey M. Pernica, Loeto Mazhani, Isaac Quaye, Kwana Lechiile, James Mahony, Marek Smieja David M. Goldfarb	
	ESSION 2.5: Improvement Toward Laboratory Accreditation IRS: Eduardo Samo Gudo and Ernest Makokha Roof Terrace	
11:00	The Tipping Point in SLMTA Implementation: Kenya's Experience Ernest Makokha, Daniel Kimani, Mercy Njeru, Jane Mwangi, Omu Anzala	
11:10	Strengthening Laboratory Management Towards Accreditation (SLMTA) as a Practical Tool for Laboratory Quality Improvement Ownership and Sustainability in Ethiopia Achamyeleh Mulugeta, Habtamu Asrat, Adisu Kebede, Dereje Yenealem, Adino Desale, Abinet Abebe, Ebise Abose, Wondwosson Kassa, Amha Kebede, Gonfa Ayana	
11:20	Keeping Pace Towards Accreditation in the Post-SLMTA Phase: Mozambique Experience Eduardo Samo Gudo, Isabel Pinto, Patrina Chongo, Paula Mandlaze, Beth Skaggs, Jessina Massamha	
11:30	Multi-Stakeholder Engagement for Sustainable SLIPTA Initiatives Jane Mwangi, Ernest Makokha, Frank Basiye, Muthoni Junghae,	
11:40	Assessment of Patient Customer Satisfaction at Kitale District Hospital Laboratory 2013 Rosebella Rotich. Ogaro H, Wekesa D, Kutolo E	
11:50	Taking a Laboratory from Zero to Five Stars – The ASM Approach to Mentoring Labs towards Accreditation CANCELL Susana Oguntoye, Sofia Viegas, Nureisha Kadir, Carla Madeira, Khalid Azam, Daisy Nakamura Sato	LED
	ESSION 2.6: Human Resource Development for Laboratory IRS: Isatta Wurie and Rubina Imtiaz Auditor	
11:00	Laboratory Workforce Mapping in 10 PEPFAR-Supported Countries: Major Gaps and Role for a Harmonized Intervention Rubina Imtiaz, Ernest Makokha, Jane Mwangi, Abdulattif Ali, Bernard Nkrumah, Sunita Upadhyaya, Filomena Gomez da Silva, Margarida Rodrigues, Anthony O. Emeribe, Kenneth Iregbuo, Elizabeth Skaggs, Jessima Masamha, Anita Beukes, Bui T.T. Hien, Kyle Bond, Michael Mwasekaga	
11:10	Laboratory Workforce Regulation in Africa's Top Five HIV Burden Countries Andre R. Verani, Rubina Imtiaz, Anthony Emeribe, Fausta Mosha, Sagie Pillay, Abdulatif Ali, Jane Mwangi, Jean-Bosco Ndihokubwayo, Daniel Garcia, Tsehaynesh Messele	
11:20	Building Capacity in Laboratory Medicine in Africa by Increasing Physician Involvement: A Laboratory Medicine Course for Clinicians Jeannette Guarner, Timothy Amukele, Meheretu Mehari, Tufa Gemechu, Yimtubezinash Woldeamanuel, Annie Winkler, Daniel Asrat, Michael Wilson, Carlos del Rio	
11:30	Strengthening Health Laboratory Human Resource Through a Structured Pre-Service Training Program: Sierra Leone Strateger Plan Direction CANCELLED Sahr Gevao, Wendy Arneson, Ralph Timperi, Aji Sanneh, Isatta Wurie	gic
11:40	Improving Service Quality Through Local Capacity Building: Looking Beyond PEPFAR Bernard Nkrumah, Beatrice van der Puije, Veronica Bekoe, Samuel Duh, Nii Akwei Addo, Celia Woodfill	
11:50	Barriers to Uptake of Laboratory Services for Antenatal Care. Findings from a Multilevel Qualitative Study in Senegal Winny Koster, Aicha Sarr, Iyane Sow, Robert Pool, Constance Schultsz, Pascale Ondoa	
12:00	Implementing The Leadership Development Program Challenge Model to Improve Laboratory Services in Four County Refer Hospitals in Kenya Ernest Ruttoh, Joan Wasike, Tobias Nyanjong, Frederick Kobia, Patrick Kamau, Humphrey Aremo	ral

ORAL POSTER 2

DATE: Tuesday, 2 December

TIME: **13:00 - 14:30**

OHAL	POSTER
	OSTERS 2.1: Laboratory Information Management Systems IRS: Amitabh Adhikari and Matilu Mwau Ballroom East/West
13:00	2.11 Strengthening Laboratory Supply Chain Management Systems for Improved Uptake of Prevention of Mother-to-Child Transmission Services in Six States in Nigeria CANCELLED Chioma Nwuba, Ogubuike Inmpey, Vincent Ihaza, Okechukwu Agbo, Sunday Aguora, Innocent Ibegbunam, Elvis Okafor, Theophilus Faruna
13:10	2.12 Tracking ART Initiation with Laboratory Information Systems: The Implementation of HIV-Positive Infant Follow-Up Forms for Improved Retention in Care at Health Facilities in Uganda Meghan Wareham, Victor Bigira, Brian Ngwatu, Betty Mirembe, Charles Kiyaga, Isaac Sewanyana, Peter Elyanu, Eleanor Magongo, Jeff Grosz
13:20	2.13 Review of Laboratory Information Management Systems in Mozambique: Implementation Successes and Challenges CANCELLED Mark DeZalia, Janise Richards, Beth Skaggs
13:30	2.14 Scale-up of Laboratory Network in Support of HIV/AIDS Prevention Care and Treatment: Rwanda Experience CANCELLED Claude Muvunyi, Wangeci Gatei, Edouard Ntagwabira, John Rusine, Eugene Habiyambere, Janvier Seromundo, Laetitia Gahimbare, Baptiste Mazarati
13:40	2.15 Burden of Febrile Illness in Côte d'Ivoire: When Clinical Diagnosis Mismatched with Laboratory-Confirmed Cases in Malaria Control CANCELLED Abdoulaye Ouattara, E.V. Adjogoua, A V Akran, M Kamagaté, G Elia, G T Gueu, M. Dosso
13:50	2.16 Modernization of Laboratory Information Management System at the University Teaching Hospital, Zambia Clement Ndongmo, Esther de Gourville, Victor Mudenda, Hamakwa Mantina, Edward Mwabuka, Charles Nyambe, Clement Phiri, Kenneth Langraaf
	DSTERS 2.2: Role of Laboratory in Epidemiology RS: Namita Singh and Tura Galgalo Ballroom East/West
13:00	2.21 Non-Tuberculous Mycobacteria (NTM) in The Gambia – A Pilot Study CANCELLED Catherine Okoi, Martin Antonio
13:10	2.22 Prevalence and Risk Factors Associated with Intestinal Helminthic Infections with Special Emphasis to <i>Schistosoma mansoni</i> among Fishermen at Lake Hawassa, Southern Ethiopia CANCELLED Tadesse Menjetta, Serkadis Debalke, Daniel Dana
13:20	2.23 TEM, CTX-M and SHV Beta-Lactamases in Clinical Samples of <i>Klebsiella pneumoniae</i> Isolated in OAUTHC, Ile-Ife, Nigeria CANCELLED Adegboyega Oladipo, Adekunle Olowe, Saturday Udoh
13:30	2.24 Microbiological Investigation of the Risk of Nosocomial Infections in Four Services of Aristide Le Dantec Hospital, Dakar, Senegal Seynabou Lo, Papa Amadou Niang Diallo, Awa Ba Diallo, Ndèye Amy Diagne, Aicha Marceline Sarr, Rokhaya Diagne, Mamadou Lamine Dia, Aissatou Gaye Diallo
13:40	2.25 Facteurs de Pronostic de l'Accès Pernicieux Palustre de l'Enfant à Kinshasa Patrick Malumba Kabitantshi
13:50	2.26 Sero-Prevalence and Risk Factors of HBV Infection in Pediatric Patients Attending Rwanda Military Hospital (October-December 2013) CANCELLED Louis Mujyuwisha, Elizabeth Karlsson, Judy Orikiiriza, Johan Normark
14:00	2.27 Newborn Screening Initiatives for Sickle Cell Disease in Africa Jelili Ojodu and Lucy Maryogo-Robinson
	DSTERS 2.3: HIV-Related Diagnostics IRS: Jackson Hungu and Madisa Mine Tuesday, 2 December Ballroom East/West
13:00	2.31 Laboratory Evaluation of the Frequency of CCR2–V64l Polymorphism in an HIV-infected South African Population CANCELLED Nyasha Chin'ombe
13:10	2.32 Effects of Antiretroviral Therapy on Lipid Profile Levels of HIV Positive Patients at the Nylon District Hospital, Douala, Cameroon CANCELLED Ebot Walter Ojong, Eric Akum Achidi, Anna Longdoh Njunda, Henri Lucien F Kamga
13:20	2.33 Serum Levels of Bone Minerals and Alkaline Phosphate Activities in HIV-Seropositive Subjects in Nnewi, Nigeria CANCELLED Chukwuemeka Kennedy Ikechukwu, Adeola Oluboyo, Charles Onyenekwe, Ejeatuluchukwu Obi
13:30	2.34 Intestinal Parasitosis in Relation to CD4+T Cells Levels and Anemia among HAART Initiated and Non-HAART Initiated Pediatric HIV Patients in Zewditu Memorial Hospital, Addis Ababa, Ethiopia CANCELLED Hylemariam Mihiretie, Asaye Birhanu, Bineyam Taye, Aster Tsegaye
13:40	2.35 Life Threatening Elevated Serum Alanine Amino Transferase and Creatinine Levels among HIV-Infected Patients on HAART in Jos, North-Central Nigeria Ekeh Evelyn, Mark Akindigh
13:50	2.36 Assessment of the "Biocentric" and "Nuclisens" Assays Using DBS for HIV-1 Early Diagnosis and Viral Load Quantitation CANCELLED Kwimatouo Lekpa

SYMPOSIUM 5

THE CHANGING FACE OF LABORATORY QUALITY MANAGEMENT SYSTEMS IN AFRICA

SESSION OBJECTIVES:

While the first five to ten years of the US President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund have focused on providing badly needed drugs to dying AIDS patients; the attention in the last few years quite rightly has shifted to ensuring that high clinical and laboratory services are provided for

DATE: Tuesday, 2 December

TIME: 14:45 - 16:15

LOCATION: Roof Terrace Room

the maturing and more complex AIDS and TB treatment programme. The unprecedented zeal and effort thrown into quality improvement of laboratory tests following the 2008 Maputo declaration and the Health Ministers Call to Action in 2012 at the first ASLM conference for National Laboratory Strategic Plans and Policies that strengthen laboratory systems has indeed changed the face of laboratories in Africa for the better. Instrumental to this positive change are the WHO Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA) and CDC's programme on SLMTA. These innovative programmes enabled many laboratories in Africa to improve the quality of their tests and services through incremental steps — each step steadily building on the previous; not overwhelming the staff or the fragile health system. This session presents experiences from countries as they take this bold step; and the reward of doing so as Africa takes its place in genomic science and cope with emerging infectious disease threats.

SESSION OVERVIEW:

• Out With Old; In With New in Tanzania

Fausta Mosha, National Public Health Laboratory, Tanzania

 Ebola Virus Disease in West Africa: Role of Labs in Supporting the Ongoing Efforts to Control the Outbreak

Jean-Bosco Ndihokubwayo, WHO Regional Office for Africa, Republic of Congo

 Role of National Accreditation Agency in Changing the Face of Laboratory Quality Management System in Nigeria

Lawrena Okoro, Medical Laboratory Science Council of Nigeria (MSLCN), Nigeria

 Role of Professional Biobanking in Advancing Research and Laboratory Medicine Health Systems

Akin E Abayomi, Tygerberg Academic Hospital, South Africa

CO-CONVENERS:

Alash'le Abimiku, Institute of Human Virology, University of Maryland School of Medicine, United States of America



Alash'le Abimiku, is an Associate Professor at the Institute of Human Virology, University of Maryland School of Medicine, Baltimore; and a co-founder the Institute of Human Virology Nigeria where she directs Laboratory diagnostics and research. She has spent over 2 decades establishing laboratory infrastructure and science in Nigeria with long-term collaborations with the USA. Dr. Abimiku's research focuses on the role of HIV subtypes in disease pathogenesis using mother to child model to investigate the transmitting subtype/s and studying effects of co-infections on HIV pathogenesis. Dr. Abimiku's more recent grant funding allows Nigeria to epidemiologically characterize different cohorts and build capacity of government

officials and Nigerian researchers in preparation for the future conduct of HIV vaccine clinical trials. Dr. Abimiku also joined the effort by scientist in Africa in the field of genomic science through the NIH's H3Africa initiative. Dr. Abimiku has trained a cadre of pre and post doctoral Nigerian students who are engaged in advanced research as collaborators. She is internationally recognized for her leadership in HIV research and in her role as a member of the WHO Vaccine advisory committee and as a board member the African society of Laboratory medicine.

Daniel Sess. Cote d'Ivore



Professor Daniel Sess has served West Africa's laboratory community through many prominent leadership positions and he has authored more than 60 publications on biochemistry, bioclinical, quality control, and evaluation subjects since 1987. Sess has secured several education degrees, including a Doctorate of Medicine in Lille, France.

SPEAKERS:

Fausta Mosha, National Public Health Laboratory, Tanzania



Fausta Mosha, is a medical microbiologist and epidemiologist working for the Ministry of Health and Social Welfare in Tanzania since 2005, currently as a Director for the National Public Health Laboratory since 2010. Before that she has been coordinating laboratory based trainings and also a Resident Advisor for the Tanzania Field Epidemiology and Laboratory Training Programme (FELTP). She holds an MD from the University of Dar es Salaam, Msc in Microbiology from the University of Leuven, Belgium, Msc in Epidemiology and Laboratory Management from the Jomo Kenyatta University, Kenya and PhD from the University of Leuven, Belgium. She is a Principal Investigator for the international Co-operative agreement

between the Centers for Disease Control and Prevention, (CDC), Atlanta and African Field Epidemiology Network (AFENET) on a project "Laboratory Biosafety and Quality Assurance involving several Countries in Africa and the Caribbean Region. She is also a Program Manager for the East African Public Health Laboratory Networking Project (EAPHLNP) in Tanzania and Secretary for the Board of Directors of African Society for Laboratory Medicine (ASLM).

Jean-Bosco Ndihokubwayo, WHO Regional Office for Africa, Republic of Congo



Jean-Bosco Ndihokubwayo is a Medical Doctor specialized in Clinical Pathology and Public Health. Before joining WHO in 2001, Dr. Ndihokubwayo was Dean of School of Medicine of Bujumbura, University of Burundi. In his capacity as WHO staff Member in the Regional Office for Africa, based in Brazzaville, Congo, Dr. Ndihokubwayo coordinates the laboratory programmes for their coherent contribution to the strengthening of national health laboratory capacity through setting norms and standards, including national laboratory policies and plans and the provision of support to countries to implement the WHO/ AFRO Stepwise Laboratory Quality Improvement Process Towards Accreditation among others.

Dr. Ndihokubwayo also coordinates the strengthening of the integration of laboratory services in the African region to support countries in their efforts to move away from a disease-specific laboratory focus towards an integrated, coordinated health laboratory system, one that promotes efficient use of resources and improved laboratory service delivery, and ensures laboratories at all levels of the health system contribute to national disease prevention and control including biosafety and laboratory biosecurity. Dr. Ndihokubwayo spent 2 months (April and May 2014) on the ground in Guinea trying to coordinate the international ongoing efforts to control the Ebola virus disease outbreak.

Lawrena Okoro, Medical Laboratory Science Council of Nigeria (MSLCN), Nigeria



Lawrena Okoro is the Director Laboratory Accreditation/ Deputy Registrar of Medical Laboratory Science Council of Nigeria. She is a Medical Laboratory Scientist with a Doctor of Philosophy Degree in Medical Microbiology and Parasitology from University of Calabar, Nigeria and a Master of Science Degree in Total Quality management and Organizational Excellence from Sheffield Hallam University United Kingdom. She started her career with the University of Calabar Teaching Hospital. She was a Senior Laboratory Advisor-High Tech/Quality Management in the FHI/ GHAIN, where she was part of the team that established the first locally built Biosafety level-3 TB culture laboratory in Nigeria. She is the technical lead driving policies,

structures and tools for medical laboratory certification and accreditation in Nigeria. She is also involved in efforts to sanitize and strengthen the production, importation, sales and distribution of In-Vitro Diagnostics in Nigeria. She is the Investigator of the US-CDC funded MLSCN/MELTNA project in Nigeria and the Secretary of the Independent Advisory Committee of the Medical Laboratory Science Council of Nigeria.

Akin E Abayomi, Tygerberg Academic Hospital, South Africa



Akin Abayomi is Chief Pathologist and Head of the Division of Haematology and Associate Professor Faculty of Health Sciences, University of Stellenbosch University, Cape Town, South Africa. He is a specialist in internal Medicine and Haematology. He studied at the Royal Medical College of St Bartholomew's Hospital in the University of London where he attained his first graduate degree in Medicine. Specialized in Internal Medicine and Haematology, obtaining fellowships from both Royal College of Medicine in the United Kingdom and the College of Medicine of South Africa. He has worked in several countries around the world in both Internal Medicine and Haematology and has been exposed to a variety of geographical variations

and disease patterns within the discipline of Internal Medicine and Haematology. His focus has mainly been on the complications of HIV and the development of laboratory and clinical capacity to rise to the challenge of the HIV epidemic in the Developing world and Africa.

SYMPOSIUM 6

STRENGTHENING THE PRACTICE OF LABORATORY MEDICINE AND PATHOLOGY IN AFRICA

SESSION OBJECTIVES:

One of the barriers of physician use of pathology and laboratory results in many African countries is their poor quality and unreliability. Significant resources by multiple organizations (ASLM, ASCP, WHO, CDC, and others) are now being invested in the clinical laboratory infrastructure of sub-Saharan Africa to address the underlying quality problem. However, initiatives to improve clinicians trust in, knowledge of and engagement in the clinical laboratory are lacking. In this

DATE: Tuesday, 2 December

TIME: **14:45 – 16:15** LOCATION: **Room 1.4**

symposium, we will discuss: 1. efforts on how to strengthen communication between clinicians and pathologists regarding clinical laboratories; 2. similarities between laboratory medicine and anatomic pathology; 3. the deficit of medical students that choose to pursue a pathology/ laboratory medicine subspecialty in Africa; and 4. a clinician's perspective on how to strengthen pathology and laboratory medicine in Africa. Being able to make specific diagnoses (rather than syndromic diagnoses) by having a well-trained anatomic and clinical pathology work force will enhance patient care at the individual level as well as the community and public health level. Having clinician advocates for the profession will provide the quality specimens that are needed to render adequate diagnoses. Efforts to increase communication between laboratory scientist, pathologists and clinicians is indispensable for better use of resources available, it will improve clinicians trust in, knowledge of and engagement in the clinical laboratory and pathology which is paramount for patient care and public health.

SESSION OVERVIEW:

• Strengthening Communication between Clinicians and Clinical Pathologists

Timothy Amukele, John Hopkins University, United States of America

- Similarities Between Laboratory Medicine and Anatomic Pathology
 Michael Wilson, Denver Health Medical Center, United States of America
- Deficit of Medical Students Choosing Pathology or Laboratory Medicine as a Specialty in Africa

Martin Hale, University of the Witwatersrand, South Africa

• A Clinician's Perspective on How to Strengthen Pathology and Laboratory Medicine in Africa

Doreen Ramogola-Masire, Botswana-UPenn Partnership, Botswana

CO-CONVENERS:

Jeannette Guarner, Emory University, School of Medicine, United States of America



Jeannette Guarner was brought up in Mexico City where she obtained her medical degree from LaSalle University. She did her anatomic and clinical pathology residency training at Emory University in Atlanta, GA. Then she returned to Mexico City where she was the Director of the Clinical Laboratory at the National Cancer Institute. In 1997 she returned to Atlanta and worked at the Centers for Disease Control and Prevention (CDC) in the Infectious Disease Pathology Branch. During her 10-year tenure at CDC she was involved in the histopathologic study of high profile outbreaks including the US anthrax bioterrorism attack, the introduction of West Nile virus to the Americas, and the discovery of SARS coronavirus. In 2007

she joined the faculty at Emory University. She is Professor of Pathology and Laboratory Medicine and is currently the Medical Director of the Clinical Laboratory at Emory University Hospital in Midtown. She teaches medical students, residents and fellows. She has developed a curriculum to teach laboratory medicine to clinicians that has been used at Emory University and Addis Ababa University.

Jeff Jacobs, American Society for Clinical Pathology (ASCP), United States of America



Jeff Jacobs is a Senior Vice President at the American Society for Clinical Pathology (ASCP) where he has worked for more than a decade. He is the director the ASCP's Institute for Science, Technology and Policy which is housed in ASCP's Washington, D.C. office. With over thirty years of experience in public health including over a decade at the American Public Health Association, he has led public health efforts at AIDS Action and at the Association of Public Health Laboratories. His current portfolio includes managing the PEPFAR and international public health programmes housed under the ASCP Institute's Center for Global Health. ASCP's global outreach programme has worked on behalf of Ministries of Health and patients in

more than 20 countries. He has a Master's degree from the American University in Washington D.C. and a Bachelors of Arts from the University of Minnesota.

SPEAKERS:

Timothy Amukele, John Hopkins University, United States of America



Timothy Amukele is an Assistant Professor in the Department of Pathology at Johns Hopkins University; and the laboratory director for the Johns Hopkins Malawi Clinical Trials Units in Blantyre, Malawi, and Kampala, Uganda. His research interests are in the Quality and Impact of Clinical Laboratories in Developing countries, particularly in the monitoring of chronic diseases. He has developed a laboratory Quality Assurance system for hospital laboratories in poor countries, and has implemented this system in Uganda, Eritrea, Bhutan and Malawi. This work is supported by the Beckman-Coulter foundation. His other interests are in the epidemiology of renal disease in sub-Saharan Africa. Dr. Amukele is the Pl of an observational study of acute renal disease prevalence and risk factors in Mulago Hospital in Kampala Uganda.

Michael Wilson, Denver Health Medical Center, United States of America



Michael Wilson is Director of the Department of Pathology and Laboratory Services at Denver Health in Denver, Colorado. He is a Professor of Pathology at the University of Colorado School of Medicine in Aurora, Colorado. He is currently the Editor-in-Chief of the *American Journal of Clinical Pathology*. His academic interests are in the areas of Medical Microbiology, Infectious Diseases Pathology, and Public Health Microbiology. His research focus is in the areas of laboratory detection of bacteremia and fungemia and tuberculosis diagnostics. He is a founding member of InPaLa, a non-governmental organization based in the USA that works to coordinate efforts to build sustainable anatomic and clinical pathology/laboratory

medicine capacity in Sub-Saharan Africa (SSA). Prof. Wilson is currently involved in two major projects to improve anatomic and clinical pathology/laboratory medicine capacity in SSA, one in Eldoret, Kenya and the other in Juba, South Sudan.



Martin Hale, University of the Witwatersrand, South Africa



Martin J Hale attended the Godfrey Huggins School of Medicine at the then University of Rhodesia, now Zimbabwe and graduated with his MBChB in 1977. After working for a number of years as a medical officer at Mpilo Hospital in Bulawayo he elected to specialize in Anatomical Pathology and obtained his specialist qualification from the College of Pathologists in 1984. Since specializing he has devoted his time to practice at Chris-Hani Baragwanath Hospital and has a special interest in the pathology of infectious diseases. He continues to lecture in the Faculty of Health Sciences, University of the Witwatersrand at undergraduate and postgraduate level. Professor Hale is now the Head of the Division of Anatomical

Pathology, School of Pathology, University of the Witwatersrand. He was the Executive Manager of the Quality Assurance Research and Academic Relations at the National Health Laboratory Service in South Africa. He is well known in the International Academy of Pathology as he was the Vice President for Africa in the Society.

Doreen Ramogola-Masire, Botswana-UPenn Partnership, Botswana



Doreen Ramogola-Masire, BMBS, FCOG, was born in Botswana. She graduated with honors from the School of Medicine of the University of Nottingham in the United Kingdom. She specialized in Obstetrics and Gynecology in the United Kingdom then pursued subspecialties in Perinatal Medicine and Cervical Cancer Prevention in the Republic of South Africa at the University of Cape Town. Her experience with the "See and Treat" approach has been instrumental for the success of the implementation of this programme for diagnosis and treatment of pre-cervical cancer lesions in HIV-infected women in Botswana. Her training in Perinatal Medicine has made her a key participant in issues of HIV infected pregnant women. She was

recently nominated to serve in the technical working group for piloting universal ART for pregnant women in Botswana. She was appointed as the In-Country Director of the Botswana-UPenn Partnership in January 2009, and has worked closely with Dr. Friedman on recruiting outstanding faculty, nurses, office staff and auxiliary personnel to the Botswana-UPenn Partnership. She is the Country Director and Lead Physician, Women's Health Program.

SYMPOSIUM 7

CRYPTOCOCCAL RAPID DIAGNOSTIC TESTING: LESSONS LEARNED ON PROGRAMME IMPLEMENTATION AND DIAGNOSTIC ACCESS ISSUES

SESSION OBJECTIVES:

This session will help laboratory medicine professionals gain perspective in the implementation of point-of-care cryptococcal antigen testing as well as a better understanding of how laboratory-based screening can be expanded and improved. Participants will also receive updates on the South African screening programme.

DATE: Tuesday, 2 December

TIME: **14:45 – 16:15** LOCATION: **Room 1.6**

SESSION OVERVIEW:

• Initial Perspectives on the Implementation of the Cryptococcal Antigen Lateral Flow Assay at the Point-of-Care

Teri Roberts, Médecins Sans Frontières, Geneva South Africa

 Concepts and Framework Development for Scaling Up Laboratory-Based Reflex Testing for Early Detection of Cryptococcal Antigenaemia in South Africa

Lindi Coetzee, National Health Laboratory Service, South Africa

• South Africa Cryptococcal Screening Programme Update

Varough Deyde, Centres for Disease Control and Prevention, South Africa

• Building Laboratory Capacity to Improve Access to Effective Diagnostic Tests

Tsehaynesh Messele, African Society for Laboratory Medicine, Ethiopia

CO-CONVENERS:

Tom Chiller, Centers for Disease Control and Prevention, United States of America



Tom M. Chiller, MD, MPHTM, with over 10 years of experience in global health he became the Associate Director for Epidemiologic Science in the Division of Foodborne, Waterborne, and Environmental Diseases at the National Center for Emerging and Infectious Zoonotic Diseases at the Centers for Disease Control and Prevention (CDC) in June, 2007. He is also the Deputy Chief of the Mycotic Diseases Branch, where he oversees many activities involving global fungal diseases. He also serves as CDC's lead for the Global Foodborne Infections Network, a WHO programme to build global capacity for enteric disease surveillance and response.

Prior to joining the Centers for Disease Control and Prevention, Dr. Chiller received his bachelor's degree from Dartmouth College and his medical and public health degrees from Tulane University. After residency Dr. Chiller completed a fellowship in infectious diseases and mycotics at Stanford University and then joined CDC to train in infectious disease epidemiology as an Epidemic Intelligence Service (EIS) officer in the Foodborne and Diarrheal Diseases Branch, where he became chief epidemiologist of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Dr. Chiller is board certified in infectious diseases and is a faculty member in the Division of Infectious Diseases at the Emory School of Medicine.

Nelesh Govender, National Institute for Communicable Diseases, South Africa



Nelesh Govender is a laboratory medicine (pathology) specialist with additional formal training in clinical HIV management, tropical medicine and medical mycology (ongoing). Dr. Govender works in public health mycology and leads a South African population-based surveillance project for cryptococcal meningitis. Dr. Govender has led implementation of the first phase of a cryptococcal screening and treatment programme in South Africa in partnership with the Department of Health. Dr. Govender was co-chair of the South African 2013 cryptococcal guidelines panel and a member of the WHO cryptococcal treatment guidelines panel. For this project, Dr. Govender will lead the South African efforts in collaboration with Dr.

Boulware. Dr. Govender has been involved in the research design; will review data collection instruments and management; and manage field staff.

SPEAKERS:

Teri Roberts, Médecins Sans Frontières, Geneva



After completing a BSc at Rhodes University, South Africa, she moved to Cape Town to complete a Masters in Human Nutrition at the University of Stellenbosch. Through funding from the Action TB initiative, I was then offered a fellowship to complete a PhD in Immunology, also at Stellenbosch University, where she undertook a project to investigate host immune responses during the course of Tuberculosis (TB) disease and treatment. Dr Roberts then moved to the University of Cape Town (UCT) for a second post-doctoral position to focus on the discovery of diagnostic biomarkers for TB using proteomics techniques and immunoassays. Following this she took a position as Scientific Officer at the Desmond Tutu HIV Centre and

helped the organization with their laboratory and epidemiological studies, including database design, management and analysis. Most recently, Dr Roberts moved to Geneva to take up a position with the MSF's Access Campaign as their Diagnostics Advisor. In this position she works on access issues to HIV and hepatitis diagnostics, including improving access to existing diagnostic and monitoring tests and influencing the design of future tests to better suit the needs of resource-limited settings.

Lindi Coetzee, National Health Laboratory Service, South Africa



Lindi Coetzee is a senior medical scientist with a PhD in Haematology and has 20 years experience in flow cytometry and related research activities. Currently, she is employed by the National Health Laboratory Service (NHLS) as the national coordinator for CD4 laboratories under the National Priority Programme (NPP) where her primary function is to ensure capacity for CD4 testing across a network of 60 facilities as well as coordinate training, evaluation and monitoring of laboratory performance together with validation of emerging technologies, including point-of-care. Dr. Coetzee is involved in developing tools for laboratory monitoring and new diagnostics and has a special interest in the economics of providing appropriate and affordable HIV laboratory services to facilitate meaningful patient intervention.

Varough Deyde, Centres for Disease Control and Prevention, South Africa



Varough M Deyde, MS, PhD is a Health Scientist and Laboratory Branch Chief in CDC-South Africa. Prior to this position, he served as Laboratory Services Team Lead with CDC-Nigeria. Varough joined CDC as a postdoctoral fellow with the Special Pathogens Branch- DVRD from 2004- 2006 and worked in the Influenza Division from 2006 to 2010. He holds a PhD in Cellular and Molecular Biology from the University of Nevada, a master's degree in Genetics and Molecular Biology from the Université des Sciences et Médecine de Tunis in Tunisia, and a bachelor's degree in Natural Sciences from the Institut Supérieur de Nouakchott in Mauritania. Varough is currently an Editorial Board member of the Journal of Clinical

Microbiology and an invited reviewer for eight other journals and is well published. He is fluent in English, Arabic, French, and Fulani (Fulfulde).

Tsehaynesh Messele, African Society for Laboratory Medicine, Ethiopia



Tsehaynesh Messele joined ASLM as CEO in March 2011, following an extensive international candidate search. From 2004-2011, she served as Director General of the Ethiopian Health and Nutrition Research Institute. She has also served as Senior Technical Advisor for the Federal HIV Prevention and Control Office of Ethiopia. Over her distinguished career, Dr. Messele has published and co-authored over 60 publications in peer-reviewed journals as well as book chapters. She holds a PhD in Immunology from the University of Amsterdam, Netherlands.

SYMPOSIUM **8**THE DIAGNOSTICS ACCESS INITIATIVE

SESSION OBJECTIVES:

This session will provide an overview of the Diagnostics Access Initiative to achieve the new 90-90-90 HIV treatment goals.

To end AIDS as a public health threat by 2030, UNAIDS has set the following targets to be achieved by 2020 (a) 90% of all people living with HIV know their

HIV status, (b) 90% of all people with diagnosed HIV infection are receiving sustained HIV treatment, and (c) 90% of all people receiving HIV treatment have achieved durable viral suppression.

DATE: Tuesday, 2 December

TIME: 14:45 - 16:15

I OCATION: Auditorium 2

Laboratory medicine plays a pivotal role in the ART response. However current diagnostic access remains inadequate to achieve the new treatment targets. Scaling up HIV diagnosis and viral load testing, deploying innovative and quality-assured diagnostic technologies including at the point-of-care, improving efficiency and lowering the cost of diagnostics, are essential to achieve the new treatment goals.

Recognizing this urgent need, UNAIDS, WHO, UNICEF, African Society for Laboratory Medicine (ASLM), Global Fund for AIDS TB and Malaria (GFATB), UNITAID, US Centers for Disease Control and Prevention (CDC), Clinton Health Access Initiative (CHAI), US President's Emergency Plan for AIDS Relief (PEPFAR), and other partners have joined forces to spearhead the Diagnostics Access Initiative.

During the session, a panel of experts will outline the mission, goals and structure of the Initiative provide an update on its priorities and progress to date. This will be followed by a facilitated panel discussion on key topics such as pediatric needs, Africa priorities, industry and market considerations, and the opportunities for the diagnosis of related infections.

SESSION OVERVIEW:

- Overview of the Diagnostics Access Initiative Badara Samb, Joint United Nations Programme for HIV/AIDS, Switzerland
- Relevance of Diagnostics in the Context of New Treatment Targets
 Jessica Markby, World Health Organization, Switzerland
- A Roadmap for the Initiative: Priorities, Action Steps and Progress to Date
 John Nkengasong, Centers for Disease Control and Prevention, United States of America

CO-CONVENERS:

Badara Samb, Joint United Nations Programme for HIV/AIDS, Switzerland

After beginning his career as a field assistant for UNICEF and a medical doctor in Senegal, Dr Samb worked with WHO and the French Institute for Scientific Research and Development Cooperation (IRD, formerly ORSTORM) studying measles and measles vaccines. From there he moved to the French Institute for Medical Research (INSERM), working as a senior researcher and epidemiologist for much of the 1990s. During this period, he also served as an Associate Professor of Public Health at the University Pierre et Marie Curie in Paris.

Holding dual citizenships of Senegal and France, Dr Samb received his medical degree from the University of Cheikh Anta Diop, in Dakar, and a PhD in Public Health from the Pierre and Marie Curie University in Paris. Dr Samb is fluent in French, English and Wolof. He was granted the 2003 International Health Professional of the Year award by the International Biographical Centre, Cambridge, United Kingdom. He is currently an associate professor of health and international relations at the Geneva School of Diplomacy and International Relations.

Souleymane Mboup, Cheikh Anta Diop University, Senegal



Professor Souleymane Mboup received a Pharm D degree a the University of Dakar in Senegal in 1976, an Immunology MS degree at Pasteur Institute in France in 1981 and a PhD in Bacteriology Virology in 1983 in TOURS (France).

Since 1984, he is the head of the Bacteriology Virology department at the University Hospital Le Dantec, University of Dakar, Senegal Since 1985, Professor Mboup is distinguished for his important contributions to the analysis and control of HIV/AIDS in West Africa, particularly Senegal. He was instrumental in the initial identification of HIV-2 and also contributed to the finding that this virus is less virulent and less

transmissible than HIV-1. He maintains active research collaboration with several academicians in France, the US and the UK. Several of his trainees now hold influential positions at international agencies. He has a growing contribution on malaria and tuberculosis which are like HIV/AIDS major and growing public health problems that are exceedingly difficult to control. He is the chair of the African AIDS Research Network, and also WANETAM (West African Network of Excellence for AIDS, TB and Malaria). He is awarded by CDC for a grant for the Development of a HIV-related Proficiency Testing Program for African Countries and a Quality Management Systems Program for African Francophone Countries under the President's Emergency Plan for AIDS Relief (PEPFAR) Professor MBOUP has authored or co-authored 350 publications and 22 books.

Meg Doherty, World Health Organization, Switzerland



Dr. Meg Doherty is the Coordinator of Treatment and Care in the Department of HIV/AIDS at the World Health Organization (WHO) in Geneva, Switzerland and has been in this role since September 2012. She provides overall technical and managerial support to treatment and care for adults, adolescents, children and pregnant women, as well as, the development of the new consolidated global antiretroviral treatment guidelines. Prior to joining WHO, Dr. Doherty was a an assistant professor of medicine and faculty member of infectious diseases and public health at Johns Hopkins University School of Medicine. She has more than 20 years of experience working in HIV, infectious diseases and in resource limited settings and recent spent

5 years in Ethiopia leading and scaling up a comprehensive ARV programme. Dr. Doherty is a trained epidemiologist, infectious disease specialist and continues to see and care for HIV infected patients.

Dr. Doherty received her MD from Harvard Medical School and her MPH and PhD in Infectious Disease Epidemiology from JHU Bloomberg School of Public Health. She is board certified in internal medicine and infectious diseases.

SPEAKERS:

Jessica Markby, World Health Organization, Switzerland



Dr. Jessica Markby currently holds the position of Diagnostics Advisor at the World Health Organization in Geneva. Her areas of interest include development and capacity building of HIV diagnostic and monitoring programmes in resource constrained countries, translational research of appropriate HIV diagnostics technologies and population health surveillance. Dr. Markby finished her PhD in Immunology and Pathology at Monash University, Australia in 2005, and subsequently obtained her Master of Public and Tropical Medicine. Dr. Markby has nine years post-doctoral field experience most of which was spent living in Papua New Guinea (PNG) and Cambodia. She completed her first post-doctoral fellowship at the University of

Melbourne in the Department of Biochemistry, followed by her first overseas posting at the PNG Institute of Medical Research, where she headed a high throughput molecular malaria laboratory. Subsequently, she worked with the National Institute of Public Health Laboratory (NIPHL) in Cambodia as a Technical Adviser. More recently, she spent four years working with Clinton Health Access Initiative (CHAI) PNG as the laboratory adviser, implementing the national EID programme, coordinating and implementing CD4 monitoring (Lab and POC) and viral load testing. She continued this work with the Burnet Institute managing a Global Fund project and conducting translational HIV research.

John Nkengasong, Centers for Disease Control and Prevention, United States of America



Dr. Nkengasong is the current Associate Director for Laboratory Science at the Division of Global HIV/AIDS, Center for Global Health, CDC Atlanta. He is also the Chief of the International Laboratory Branch and co-chairs the President's Emergency Plan for AIDS Relief's (PEPFAR) Laboratory Technical Working Group. He joined CDC in 1995 as Chief of the Virology Laboratory, CDC Abidjan, Ivory Coast, and became Chief of the International Laboratory Branch, Global AIDS Program in 2005. He has received numerous awards for his work including, but not limited to, the US Secretary of Health and Human Services Award for excellence in Public Health Protection Research, the Sheppard Award, and Director's Recognitions Award. He is the founding chair of the board of directors of the African Society for Laboratory Medicine.

DISCUSSANTS:

Duncan Blair, Alere; Sagie Pillay, ASLM2014 Conference Co-Chair; Chewe Luo, UNICEF; Tsehaynesh Messele, ASLM; Renuka Gadde, Becton Dickinson; Tom Chiller, US CDC; Zachary Katz, CHAI; Philip Onyebujoh, WHO

ROUND TABLE 5

QUALITY ASSURANCE STRATEGIES TO ACCELERATE UPTAKE OF HIV-RELATED DIAGNOSTICS IN AFRICA

SESSION OBJECTIVES:

Quality standard of products is an important consideration across the development, evaluation, manufacturing, supply chain management, and monitoring of global health commodities. Every year, hundreds of millions of US dollars' worth of diagnostics and medicines are purchased by or through international financing or procurement mechanisms. Quality assurance strategy and mechanisms are

DATE: Tuesday, 2 December

TIME: **16:30 – 18:00** LOCATION: **Room 2.4**

needed to sustainably increase access to quality-assured, appropriate diagnostics, thereby improving prevention, diagnosis, and treatment of HIV/AIDS.

The session will look into the different aspects of quality assurance that support an accelerated uptake of HIV-related diagnostics in Africa. The selected speakers will provide an insight on global regulatory, in-country, regional, and procurement related challenges and opportunities.

SESSION OVERVIEW:

 African Union-NEPAD's Strategies for Accelerating the Uptake of Quality-Assured HIV Diagnostics

Paul Tanui, African Union-New Partnership for Africa's Development (NEPAD), South Africa

 Strengthening Laboratories in Africa to Ensure the Quality of Diagnostics

Jean-Bosco Ndihokubwayo, WHO Regional Office for Africa, Republic of Congo

- Quality Assurance of HIV Diagnostics in Tanzania
 Agnes Kijo, Tanzania Food and Drugs Authority, Tanzania
- The Global Fund Quality Assurance Policy on Diagnostics: Principles, 3 Year Implementation, and Impact on Procurement

Jöelle Daviaud, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland

CO-CONVENERS:

Rosanna Peeling, London School of Hygiene & Tropical Medicine, United Kingdom



Rosanna Peeling is Professor and Chair of Diagnostics Research at the London School of Hygiene and Tropical Medicine (LSHTM) and Director of the International Diagnostics Centre. Trained as a medical microbiologist, she previously served as the research coordinator and head of diagnostics research at the UNICEF/UNDP/World Bank/WHO Special Programme on Research and Training in Tropical Diseases (WHO/TDR) in Geneva, Switzerland, and the Chief of the Canadian National Laboratory for Sexually Transmitted Diseases. Since 2011, she has been funded by the Bill & Melinda Gates Foundation, Grand Challenges Canada and UNITAID to develop mechanisms for streamlining and accelerating the regulatory oversight of

quality-assured diagnostics using harmonized approaches. The Pan-African Harmonization Working Party and the Latin America in-vitro Diagnostic Alliance were established as part of this initiative. These regional working groups will work closely with WHO and technical partners in countries to facilitate the implementation of quality assurance strategies to accelerate the uptake of new diagnostic technologies to improve health outcomes.

She is a member of many international advisory panels and editorial boards, and is the recipient of many awards, including the YM-YWCA Women of Distinction Award. Her research was featured in a Discovery Channel documentary on Chlamydia infection and infertility.

Irena Prat, World Health Organization, Switzerland



Irena Prat is the Group Lead for the Diagnostics assessment Team within the WHO Department of Essential Medicines and Health Products (EMP). Ms. Prat has joined WHO in 2008 when she became responsible for product dossier and regulatory work within the WHO Prequalification of diagnostics programme. Since early 2014 she is overall responsible for the WHO Prequalification of In Vitro Diagnostics Programme and is the focal point for all in vitro diagnostics related activities within the department. Before joining WHO she worked as a Counsellor in the field of medical devices, active implantable medical devices and in vitro diagnostic medical devices at the Agency for medicinal products and medical devices of the Republic of

Slovenia (2000-2007). Ms. Prat has contributed to the transposition of the EEC Directives into the national regulations as well as to the establishment of pre- and post-market surveillance procedures for medical devices.

Ms. Prat graduated from the University of Ljubljana (Slovenia), Faculty of pharmacy and holds a post graduate specialization in management from the University of Primorska (Slovenia), Faculty of management.

SPEAKERS:

Paul Tanui, African Union-New Partnership for Africa's Development (NEPAD), South Africa



Paul Tanui is a Senior Programme Officer-Technical Support in the African Medicines Regulatory Harmonization (AMRH) Programme at NEPAD Planning and Coordinating Agency based in Pretoria South Africa. He is a pharmacist and a quality assurance and regulatory affairs professional with over 13 years' work experience in regulatory affairs, the pharmaceutical industry, and pharmaceutical management. He has a strong background in regulatory systems strengthening including medicines assessment and registration systems, pharmaceutical manufacturing processes, and regulatory harmonization. Areas of expertise include medicines regulatory harmonization, risk-benefit analysis, rational use of medicine, and

quality management practices. He holds a master's degree in Business Administration, degree in Pharmacy, and postgraduate qualifications in Business and Healthcare Management.

Jean-Bosco Ndihokubwayo, WHO Regional Office for Africa, Republic of Congo



Jean-Bosco Ndihokubwayo is a Medical Doctor specialized in Clinical Pathology and Public Health. Before joining WHO in 2001, Dr. Ndihokubwayo was Dean of School of Medicine of Bujumbura, University of Burundi. In his capacity as WHO staff Member in the Regional Office for Africa, based in Brazzaville, Congo, Dr. Ndihokubwayo coordinates the laboratory programmes for their coherent contribution to the strengthening of national health laboratory capacity through setting norms and standards, including national laboratory policies and plans and the provision of support to countries to implement the WHO/ AFRO Stepwise Laboratory Quality Improvement Process Towards Accreditation among others.

Dr. Ndihokubwayo also coordinates the strengthening of the integration of laboratory services in the African region to support countries in their efforts to move away from a disease-specific laboratory focus towards an integrated, coordinated health laboratory system, one that promotes efficient use of resources and improved laboratory service delivery, and ensures laboratories at all levels of the health system contribute to national disease prevention and control including biosafety and laboratory biosecurity. Dr. Ndihokubwayo spent 2 months (April and May 2014) on the ground in Guinea trying to coordinate the international ongoing efforts to control the Ebola virus disease outbreak.

Agnes Kijo, Tanzania Food and Drugs Authority, Tanzania



Agnes Sitta Kijo is the Manager-Medical Devices Assessment and Enforcement Department at the Tanzania Food and Drugs Authority (TFDA). Ms. Kijo is a Pharmacist by profession and has also MSc in Pharmaceutical Technology from Kings College London. She has fifteen years work experience in regulatory affairs, five years in quality management and two years in medical devices regulations. She has been involved also in inspection and surveillance, post-market surveillance of medicines and medical devices, medicine dossier evaluation, and has vast experience in Good Manufacturing Practices (GMP). She has participated in a WHO Pregualification inspection in China (a manufacturer of HIV RDTs).

Since 2012 she has been actively involved in a WHO project to strengthen regulation of In Vitro Diagnostics in Tanzania. The main elements of the project are post-market surveillance of rapid diagnostic test kits for HIV and malaria, testing, review of acts and regulations, and preparation of guidelines for assessment of technical files, adverse events monitoring, importation, and PMS.

Jöelle Daviaud, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland



Jöelle Daviaud graduated from France with a Doctorate degree in Pharmacy. She is the Quality Assurance Specialist for Health Products in Grant Management Support within the Grant Management Division at the Global Fund. Since 2006 she has been responsible for providing with expert support and guidance on quality assurance related matters for health products (pharmaceuticals, diagnostics, bednets, insecticides, condoms, throughout the grant lifecycle. She also manages the development, operationalization, and implementation of the Quality Assurance policies developed in close cooperation with technical partners including WHO Prequalification team, National Drugs regulatory authorities, manufacturers' representatives,

as well as with donors, such as UNITAID and USAID, working towards harmonization of policies.

Since the early nineties, she has worked in the field of Health Products Quality Assurance with the following continuous objective: ensuring that the end users receive the most appropriate formulation of safe, efficient and quality-assured products.

She started her carrier in the Quality Control Laboratory at the French Ministry of Health, working on diagnostics, pharmaceuticals, and vaccines dossier assessment and quality control. In 2002 she moved to Geneva to join WHO Headquarters to work with the team in charge of the prequalification of vaccines.

ROUND TABLE 6

UPDATE ON THE STEPWISE PROCESS TOWARDS LABORATORY QUALITY SYSTEMS AND ACCREDITATION IN AFRICA

SESSION OBJECTIVES:

Quality of laboratory testing services has increasingly become a high priority in many countries across Africa. At the ASLM2012 conference the WHO-AFRO Stepwise Laboratory (Quality) Improvement Process Towards Accreditation (SLIPTA) was adopted and endorsed by several ministers of health as framework for

DATE: Tuesday, 2 December

TIME: **16:30 - 18:00**

LOCATION: Auditorium 2

improving the quality of public health laboratories in developing countries to achieve the international accreditation requirements. Many countries in the region have subsequently adopted and have been actively implementing SLIPTA. The African Society for Laboratory Medicine (ASLM) in collaboration with WHO AFRO has been evaluating and providing recognition certificates to laboratories since 2012. The round table discussion brings together countries in Africa to share experience in rolling out SLIPTA.

The objective of the session will be to provide an update on the current status of implementation of SLIPTA in Africa and share experiences in the implementation of Quality Management System towards accreditation using SLIPTA.

SESSION OVERVIEW:

The SLIPTA Process: Its Reach Now and Beyond
 Ndlovu Ngobile, African Society for Laboratory Medicine, Ethiopia

Implementing a Sustainable Quality Management System:
 The Mozambique Experience

Patrina Chongo, National Institute of Health, Mozambique

Old Concepts, Innovative Tools, Evolving Strategies:
 The Cameroon SLIPTA

Judith Shang, Centres for Disease Control and Prevention, Cameroon

• Changing the Culture of Laboratory Quality Practices Through SLIPTA in Tanzania

Fausta Mosha, National Public Health Laboratory, Tanzania

CO-CONVENERS:

Talkmore Maruta, African Society for Laboratory Medicine, Ethiopia



Talkmore Maruta is a Zimbabwean citizen and Medical Laboratory Scientist holding Bsc (Hons) Degree in Medical Laboratory Sciences, a Masters in Public Health degree, and currently studying for a PhD in Public Health. Mr. Maruta has worked for different international organizations in Laboratory System strengthening including Clinton Health Access Initiative, Foundation for New Innovative Diagnostics, and the African Society for Laboratory Medicine. Over the last 8 years, he has worked with ministries of health in over 20 African countries and the Caribbean, assisting them in implementing several laboratory strengthening activities including accreditation, mentorship, policy, and strategic plan development and review. Mr. Maruta

developed and implemented a laboratory mentorship model and training curriculum which has subsequently been implemented in a number of countries in Africa and the Caribbean. He became one of the 1st three Master Trainers for the Strengthening Laboratory Management Towards Accreditation (SLMTA) programme, and is currently the chairperson of the SLMTA Technical committee, and was awarded a "Distinguished Leadership" award at ASLM 2012 Cape Town Conference. He is a member of the WHO AFRO SLIPTA Expert Committee that reviews and updates the SLIPTA programme and has audited over 25 laboratories across more than 9 countries in Africa under the WHO AFRO SLIPTA programme.

Michael Mwasekaga, Centres for Disease Control and Prevention, Tanzania



Michael Mwasekaga is the Laboratory Branch Chief for CDC Tanzania with an oversight on the operations of the Laboratory, Influenza, and Blood Safety support programmes. He holds a higher National Diploma in applied Biology majoring in microbiology from North East Surrey College of Technology, UK.

Prior to joining CDC Tanzania office, Mr. Mwasekaga worked as the Director of the National TB Reference laboratory in Gaborone – Botswana (1993 – 2005) where he successful established the National TB reference laboratory, implemented TB drug resistance surveillance, and the quality assurance programme for AFB smear microscopy. Mr. Mwasekaga returned to Tanzania in October 2005 and worked as the

National Laboratory Quality Systems Coordinator in the Tanzania Ministry of Health and Social Welfare (2005 – March 2007).

In April 2007, he joined CDC Tanzania as Avian Influenza Advisor where he provided technical assistance leading to establishment of the National Influenza Laboratory, implementation of influenza sentinel surveillance in five hospitals, and training of outbreak rapid response teams which were key to the rapid detection and response to the pandemic flu in 2009. From August 2009 to January 2010, Mr. Mwasekaga was the Laboratory Support Program Team Lead; February 2010 to February 2012 the Acting Chief; and from March 2012 to date the Lab Branch Chief. CDC Tanzania supports lab strengthening activities in Tanzania including SLMTA training.

SPEAKERS:

Ndlovu Ngobile, African Society for Laboratory Medicine, Ethiopia



Ndlovu Nqobile is the Senior Program Specialist working for ASLM. He holds a Masters in Public Health and a degree in Medical Laboratory Sciences. Before joining ASLM in April 2013, Mr. Ndlovu served as Laboratory Project Coordinator for the African Field Epidemiology Network (AFENET) in Kampala, Uganda, where he managed laboratory strengthening programmes in many African countries and the Caribbean region. He also served as Assistant Field Coordinator for the Masters in Public Health training programme at the University of Zimbabwe.

Patrina Chongo, National Institute of Health, Mozambique



Patrina Chongo born in Mozambique and qualified as a chemistry teacher at Pedagogic University of Mozambique in 2008. Currently studying for a Post Graduate degree in Quality Management. Qualified as a Master Trainer for the Strengthening of Laboratory Management Towards Accreditation (SLMTA) in 2012 and has subsequently facilitated a number of SLMTA training of trainers workshops in and outside of Mozambique. She currently (since 2011) serves as the Head of National External Quality Assurance at the National Institute of Health in Mozambique, having previously served as a lab technician and also as a quality manager in the Immunology Reference Laboratory from 2009 to 2011.

Judith Shang, Centres for Disease Control and Prevention, Cameroon



Jusirh Shang is the current Laboratory Director for the CDC-Cameroon programme. She received a Masters in Medical Microbiology at the London School of Hygiene and Tropical Medicine, UK, and a Doctorate in Medical Sciences (Microbiology) from the United Medical and Dental Schools of Guy's and St Thomas's Hospitals, London, UK. From 1998-2001, she took up the position of assistant head of the Laboratoire de Santé Hygiene Mobile, Yaoundé, Cameroon. Between July 1999 and February 2000, she also served as an ORISE Fellow in a post-doctoral fellowship programme with the Food and Drug Administration (FDA), Center for Biologics, Evaluation and Research, USA. In 1999, she joined the University of Yaoundé 1, Department

of Biochemistry and Microbiology, as lecturer in Microbiology, Immunology, and Molecular Biology until 2007 when she joined CDC-Cameroon DHAP programme as the laboratory coordinator for the CDC-Cameroon research station in Mutengene. In October 2008, she joined CDC/DGHA-Cameroon. Dr. Shang has received several awards in recognition of her services, including a Centre for Global Health 2011 Director's Leadership Award and a US Department of State Meritorious Honor Award for superior management and leadership of the CDC Cameroon laboratory section resulting in a model laboratory programme under PEPFAR.

Fausta Mosha, National Public Health Laboratory, Tanzania



Fausta Mosha is a medical microbiologist and epidemiologist who has worked for the Ministry of Health and Social Welfare in Tanzania since 2005, and has been working as a Director for the National Public Health Laboratory since 2010. Before that she coordinated laboratory based trainings and was also a Resident Advisor for the Tanzania Field Epidemiology and Laboratory Training Programme (FELTP). She holds an MD from the University of Dar es Salaam, Msc in Microbiology from the University of Leuven, Belgium, Msc in Epidemiology and Laboratory Management from the Jomo Kenyatta University, Kenya, and PhD from the University of Leuven, Belgium. She is a Principal Investigator for the international Co-

operative agreement between the Centers for Disease Control and Prevention, (CDC) Atlanta and African Field Epidemiology Network (AFENET) on a project "Laboratory Biosafety and Quality Assurance Involving Several Countries in Africa and the Caribbean Region." She is also a Program Manager for the East African Public Health Laboratory Networking Project (EAPHLNP) in Tanzania and Secretary for the Board of Directors of African Society for Laboratory Medicine (ASLM).

ROUND TABLE **7**LABORATORY WORKFORCE DEVELOPMENT: HARMONISATION & COMPETENCE

SESSION OBJECTIVES:

Africa is facing a crisis of human resources for health (HRH). This shortage is even more critical for the laboratory field with less than 1 laboratory worker of any kind per 10,000 population (WHO AFRO: 2006 data) and major discrepancies between competencies and regulation of laboratory professionals. There is a great need for harmonization of these approaches across the region with enough flexibility to accommodate national needs and situations.

DATE: Tuesday, 2 December

TIME: **16:30 - 18:00**

LOCATION: Auditorium 1

This Roundtable provides a forum for key implementers of national laboratory workforce development or WFD (leaders and experts from Ministries of Health, training institutes, professional membership organizations, regulatory boards, NGOs, donor and technical partners) to share best practices towards harmonization and standardization of laboratory professionals and trainings as well as related policy and regulatory issues. This will be followed by a facilitated discussion on key lab WFD issues and possible solutions in Africa. Key issues to be discussed are summarized as a) identify process for achieving harmonized policies and regulations to strengthen laboratory workforce and professionals at all levels, b) share experience and resource networks to support quality and accreditation of individuals and training institutes, c) share support and organizational roles for harmonization of these efforts across the region (e.g. ASLM, Regional Economic Committees, WHO, PEPFAR, etc).

SESSION OVERVIEW:

• Status of Laboratory Workforce Competence & Needs in West Africa: Ghana Case Study

Ernest Owusu-Ansah, University of Cape Coast, Ghana

• Role of Countries and Regional Committees in Laboratory Workforce Harmonisation

Kone Sindou, Institute National des Formation des Agents de Stante, Cote d'Ivoire

CO-CONVENERS:

Anthony Emeribe, Medical Laboratory Science Council of Nigeria, Nigeria



Anthony Emeribe is currently the Registrar/Chief Executive of the Medical Laboratory Council of Nigeria (MLSCN). He is also the serving President of the Federation of African Associations of Medical Laboratory Scientists and a board member of the African Society for Laboratory Medicine (ASLM). In his broad career, he has served as a Professor of Laboratory Hematology and Blood Transfusion Science at the College of Medical Sciences, University of Calabar. He is also a Member of the New York Academy of Science and an Honorary Consultant Haematologist with the University of Calabar Teaching Hospital.

Pr. Emeribe has served as a Laboratory Consultant to the Global HIV/AIDS in Nigeria (GHAIN) and played a key role in enhancing quality improvement and standardization of laboratory services in various GHAIN facilities in Nigeria. He has served as a Member in the Presidential Project Implementation Committee on the FGN/Vamed Re-Equipping of Teaching and Military Hospitals and in the Board of Management Sciences for Health on the PEPFAR Fellowship for Health Professionals amongst several other community services. Pr. Emeribe is a motivational academic with several peer-reviewed scientific publications in local and international journals. He has received over twenty awards from academia, church, social and community based organizations.

Rubina Imtiaz, Centers for Disease Control and Prevention, United States of America



An internist by training, Dr. Imtiaz entered public health in 1984 by joining CDC's Epidemic Intelligence Service (EIS). In the past 29 years she has worked on various public health programmes at state, national, and global levels and with several bilateral and multi-lateral partners in the public and private sectors. Her specialized area of expertise is sustainable capacity building with a focus on health workforce development.

She served as a Senior Public Health Physician in New Jersey State Health Department where she helped develop the initial policies on HIV/AIDS and in 1986 moved to Global 2000 Inc., Carter Presidential Center to initiate strategies, surveillance guidelines and operational plans for Guinea Worm Eradication with

subsequent implementation in Pakistan, Ghana, and Nigeria from 1986 to 1992. She later directed the Expanded Program for Immunization for UNICEF in Nepal, 1992 – 1996. From 2001 – 2007 Imtiaz worked as a Branch Chief in the CDC's Global Health Office overseeing Field Epidemiology and Laboratory Training Programs (FELTPs) in 26 countries in Asia, Central Asia, Middle East, and Central/South America. Following that she was appointed as the CDC & DGHA Director to India from 2007 – 2009. She currently serves as the Associate Chief for Program Integration at CDC DGHA's International Laboratory Branch.

SPEAKERS:

Ernest Owusu-Ansah, University of Cape Coast, Ghana



Ernest Owusu-Ansah has been the enthusiastic, driven Head of Department for five years of training Medical Laboratory Technologists. Prof. Ernest Owusu-Ansah, earned his PhD (Chemistry) in 2009 at the University of Bristol, United Kingdom. He is an Associate Professor in Biological Chemistry and Head of Department of Medical Laboratory Technology, University of Cape Coast, Ghana, since 2009.

Prof. Owusu-Ansah restructured the Medical Laboratory Programme to reflect the aims and aspirations of the Medical Laboratory profession. He ensured that all the six core areas of the programme were given

equal attention at the undergraduate level. He equipped the laboratories with the basic instruments, recruited faculty to reflect the six core areas, signed memoranda of understanding MoU with the Regional Hospital and selected District Hospitals for rotational studies during school sessions. He led well-structured vacation training at urban and rural health facilities. Prof. Owusu-Ansah initiated a "sandwich" Post-Diploma in Medical Laboratory Technology to abridge Diploma and Bachelor degrees, as well as introduced postgraduate and 6-year DMLS programmes to meet West Africa Health Organisation standard. He is encouraging Lecturers to develop course materials into textbooks.

Kone Sindou, Institute National des Formation des Agents de Stante, Cote d'Ivoire



Kone Sindou is an Engineer Biologist, bacteriology and virology. In 2012, Sindou received his Diploma in Engineering Design Quality and Environmental Control, specializing in Biomedical Waste Management. In 2007, Sindou received his Diploma as an Engineer Biologist. His studies supported the National Institute for Training of Health Workers (INFAS) and Institut Pasteur de Côte d'Ivoire (IPCI). His work included Diagnosis of Respiratory Syncytial Virus (RSV) by Reverse Transcriptase — Polymerase Chain Reaction (RT-PCR) in nasal secretions of children aged 0-5 years in Abidjan. In 1995, Sindou received a Higher Technician Diploma in Medical Biology.

ROUND TABLE 8 DIAGNOSTICS MARKET INTELLIGENCE IN AFRICA

SESSION OBJECTIVES:

This session will describe relationships between reliable market intelligence and improvements in public health programing. Market intelligence is critical to demonstrate accountability of resources and guide investments, document a country's capability and capacity for improving diagnostic access, and to standardize and systemize practices. Market intelligence is also essential to inform rational and sustained industry investment in diagnostic product development and deployment.

DATE: Tuesday, 2 December

TIME: **16:30 – 18:00** LOCATION: **Room 1.6**

The Diagnostics Access Initiative launched by UNAIDS and partners in July 2014 has highlighted the critical importance of market intelligence and forecasting as one of the key pillars to improving diagnostics access.

The session will provide perspectives on market intelligence need from industry, the WHO and agencies gathering market intelligence data. The latest market intelligence data for TB and HIV diagnostics will also be presented.

SESSION OVERVIEW:

Industry Perspectives on Market Intelligence
 Duncan Blair, Alere, Thailand

WHO AMDS Survey

Vincent Habiyambere, World Health Organization, Switzerland

TB Market Intelligence

Leigh Berrie, National Health Laboratory Service, South Africa

HIV Market Intelligence

Jonathan Lehe, Clinton Health Access Initiative, Kenya

CO-CONVENERS:

Zach Katz, Clinton Health Access Initiative, United States



Zach Katz has been the Senior Director of Diagnostic Services at Clinton Health Access Initiative (CHAI) from 2010 to present. In this position he manages the work of the CHAI Laboratory Services Team, working to address demand and supply-side barriers to access and foster a healthy marketplace to ensure the sustainable supply of essential diagnostic testing. Prior to this he was the Deputy Regional Director of South East Asia and the Pacific at Clinton Health Access Initiative from 2008 – 2010, working in Cambodia, Indonesia, Papua New Guinea, Ukraine and Vietnam. He was also the CHAI Country Director for Cambodia from 2007 – 2010 and the CHAI Country Coordinator for Papua New Guinea in 2006 – 2007. He holds a Masters degree Public Administration from New York University.

Trevor Peter, African Society for Laboratory Medicine, Ethiopia



Trevor Peter is the Chair of the Board of the African Society for Laboratory Medicine and is based in Botswana. He is also the Senior Scientific Director, Diagnostics at the Clinton Health Access Initiative where he has worked since 2005. Dr. Peter has over 20 years experience in the fields of diagnostics and infectious diseases research and public health. He has provided technical guidance in public laboratory strengthening across Africa, Asia, Eastern Europe, the Caribbean and South America. Before 2005, Dr. Peter was laboratory director at Botswana-Harvard HIV Reference Laboratory and conducted infectious disease epidemiology research.

SPEAKERS:

Duncan Blair, Alere, Thailand



Duncan Blair started his career as a basic biomedical scientist having undertaken post graduate studies in neuroscience and post-doctoral research in molecular and cellular biology. After leaving the research bench and moving into public health, Dr. Blair worked in the field with numerous organisations including CHAI, SPC, US-CDC Global AIDS Program, UNICEF, and WHO-WPRO on the implementation, expansion, quality improvement, and evaluation of diagnostic services related to HIV, sexually transmitted infections, tuberculosis, and malaria in low resource settings. Based in South East Asia for many years, Dr. Blair has extensive experience working on the ground with ministry, bi-lateral, multi-lateral and NGO partners in Asia,

Sub-Saharan Africa, the Caribbean and the Pacific Islands. Joining Alere in mid-2011, Dr. Blair took on the role of Director of Public Health Initiatives to help foster collaboration between this major diagnostic industry partner and diagnostics stakeholders in the global health community.

Vincent Habiyambere, World Health Organization, Switzerland



Vincent Habiyambere is an expert in procurement and supply management (PSM) system strengthening. He is a medical doctor (MD) with a MPH and a PhD in social and administrative pharmacy with a specific focus on management of medicines, diagnostics and other health commodities. After 5 years of practicing medicine and teaching public health in university and director of the School of Public Health of University of Rwanda, he has been working with the World Health Organization (WHO) since 1992. His work area in WHO HIV AIDS medicines and diagnostic service (AMDS), includes strategic information on use of HIV drugs and diagnostics, global ARV demand forecast to prevent global ARV shortage, capacity building in PSM and fostering collaboration among AMDS partners.

Leigh Berrie, National Health Laboratory Service, South Africa

Leigh Berrie is currently the Operations Manager for the National Priority Programmes of the NHLS (Sept 2012-current), with a portfolio focusing on HIV viral load and CD4 monitoring, Early Infant Diagnosis, and TB diagnosis through the roll-out of the GeneXpert technology. Her management, coordination and implementations of these programmes has contributed significantly to improving access to these services in South Africa.

Her research efforts have included evaluation of new technologies for HIV viral load and Early Infant Diagnosis which can be supported by various publications and conference presentations. She has vast expertise with current commercial molecular diagnostic technologies available for HIV and TB.

Jonathan Lehe, Clinton Health Access Initiative, Kenya



Jonathan Lehe is the Senior Program Manager for Point-of-Care (POC) Diagnostics at the Clinton Health Access Initiative (CHAI), and a member of CHAI's global Laboratory Services Team. He is responsible for managing CHAI's work supporting Ministries of Health in Africa, Asia, and the Caribbean to improve access to innovative POC HIV diagnostics, bringing healthcare closer to the patient, especially in rural and low-resource settings without access to labs. He joined CHAI in 2008 and lived in Nairobi, Kenya for 5 years, focusing on expanding access to diagnostics services in East and Southern Africa. In 2013, he returned home to the United States and is currently based in Chicago. Prior to joining CHAI, he worked in the

management consulting industry, advising pharmaceutical companies on strategies to improve their marketing and procurement practices. He holds a degree in Economics from Harvard University.

ROUND TABLE 9

PROMISING POINT-OF-CARE VIRAL LOAD AND EARLY INFANT DIAGNOSIS TECHNOLOGIES

SESSION OBJECTIVES:

Point-of-care (POC) Early Infant Diagnosis (EID) and viral load (VL) testing present potential solutions to address some of the limitations and gaps of centralised laboratory based testing. Access to EID/VL testing in rural and remote areas with same day results may enable better linkage to care without relying on weak specimen referral networks. Currently, limited published data is available for new POC EID/VL technologies with a small number of platforms near to

DATE: **Tuesday, 2 December**

TIME: **16:30 - 18:00**

LOCATION: Roof Terrace Room

commercial release offering potential. This session aims to bring together manufacturers to report on POC EID and VL product development as well as researchers to update on field and laboratory evaluations. The most up to date evidence and status of each product will enable the audience to formulate assessments of the relative performance, quality of evidence and readiness for implementation. Taken together with expert review update of these characteristics, this session aims to provide a platform for more accurate and comprehensive assessment of whether these promising technologies are ready for prime time.

SESSION OVERVIEW:

• SAMBA – Product Update

Helen Lee, Diagnostics for the Real World, United Kingdom

The Simple AMplification Based Assay (SAMBA) is being developed by a team led by Dr. Helen Lee, Director of the Diagnostics Development Unit (DDU) at University of Cambridge. Two NAT-based HIV assays are being developed: (i) a semi-quantitative test for monitoring of ART and (ii) a qualitative test for use in EID. The first SAMBA HIV assay to be launched will be the semi-quantitative viral load assay. The SAMBA machine will integrate extraction, amplification and detection into a bench-top analyzer with amplification and detection taking place in a closed cartridge. (Source UNITAID, Diagnostics Landscape 2011)

UPDATE OF FIELD EVALUATIONS

Clement Zeh, KEMRI/Centres for Disease Control and Prevention, Kenya **Teri Roberts**, Médecins Sans Frontières, South Africa

AlereQ – Product Update

Duncan Blaire, Alere, Thailand

The Alere NAT system is a generic platform for the implementation of different nucleic acid tests. The first test to be commercialized will be an integrated test for quantitative measurement of HIV-1 and HIV-2 viral load from approximately 25µL of whole blood. The device on which the assay is run has a small footprint, is portable, contains an integrated UPS, can be run either on mains power or from a dedicated battery pack, and is ruggedized to withstand harsh environments. (Source: UNITAID Landscape Document update, 2013).

UPDATE OF FIELD EVALUATIONS

Ilesh Jani, National Health Institute, Mozambique

Xpert – Product Update

Gwynn Stevens, Cepheid

The Cepheid GeneXpert® System is a fully-automated and integrated system for PCR-based DNA testing. The GeneXpert System integrates and automates sample preparation, amplification and detection in a single-use, self-contained microfluidic cartridge. (Source, modified from UNITAID, Diagnostics Landscape 2011).

UPDATE OF FIELD EVALUATIONS

Sergio Carmona, National Health Laboratory Service, South Africa

Lynx (EID only) – Product Update

Kara Palamountain, Northwestern University, United States of America

The Northwestern Global Health Foundation (NWGHF) is developing a POC rapid "p24 antigen" testing platform that will be both easy to use and low cost. The product design calls for a small device that can hold up to 8 samples at a time, but that could process fewer samples than that, with test results in 60 minutes. (Source, modified from UNITAID, Diagnostics Landscape 2011).

Liat – Product Update: Tri Do-Roche

Robert Luo

The Liat[™] Analyzer manufactured by Roche, is a NAT-based lab-in-a-tube platform using reverse transcription, PCR amplification, and real-time detection to quantify viral load27. (Source: UNITAID Diagnostics Landscape 2011)

CO-CONVENERS:

Sergio Carmona, National Health Laboratory Service, South Africa



Sergio Carmona is a pathologist at the Charlotte Maxeke Academic Hospital in Johannesburg, where he manages one of the largest routine HIV virology laboratories in the region, providing EID PCR, HIV drug resistance testing and over 40000 viral loads per month.

He has been the pathologist at Executive Committee of the National Health Laboratory Service since 2012, an organization with over 7000 employees and 268 labs, that provides diagnostic pathology for 80% of South Africans. In 2010 Dr. Carmona was seconded to the programme for the implementation of new viral load testing platforms in 17 labs across South Africa and this has successfully reached close to 2 million

tests per annum. He is interested in the areas of early infant diagnosis, HIV viral load monitoring evaluation of POC devices, HIV drug resistance, HPV genotyping, and HIV related Monitoring and Evaluation.

Jessica Markby, World Health Organization, Switzerland



Jessica Markby currently holds the position of Diagnostics Advisor at the World Health Organization in Geneva. Her areas of interest include development and capacity building of HIV diagnostic and monitoring programmes in resource constrained countries, translational research of appropriate HIV diagnostics technologies, and population health surveillance. Dr. Markby finished her PhD in Immunology and Pathology at Monash University, Australia in 2005, and subsequently obtained her Master of Public and Tropical Medicine. Dr. Markby has nine years of post-doctoral field experience most of which was spent living in Papua New Guinea (PNG) and Cambodia. She completed her first post-doctoral fellowship at the University

of Melbourne in the Department of Biochemistry, followed by her first overseas posting at the PNG Institute of Medical Research, where she headed a high throughput molecular malaria laboratory. Subsequently, she worked with the National Institute of Public Health Laboratory (NIPHL) in Cambodia as a Technical Adviser. More recently, she spent four years working with Clinton Health Access Initiative (CHAI) PNG as the laboratory adviser, implementing the national EID programme, coordinating and implementing CD4 monitoring (Lab and POC) and viral load testing. She continued this work with the Burnet Institute managing a Global Fund project and conducting translational HIV research.



The Power of the Platform

Cepheid's Xpert® MTB/RIF test is revolutionizing tuberculosis detection, treatment, and prevention around the globe. Our GeneXpert® System is a game-changing molecular platform. And even with 19 CE-IVD tests available today, we are just getting started.

Let us show you how Cepheid is expanding access to quality diagnostics.

Visit www.cepheidinternational.com for more information.

Pending CE-IVD marking. Product distribution outside the United States.

CORPORATE HEADQUARTERS

904 Caribbean Drive Sunnyvale, CA 94089 USA

1.888.336.2743 PHONE 1.408.541.4191 RAX 1.408.541.4192

EUROPEAN HEADQUARTERS

Vira Solelh 81470 Maurens-Scopont, France

PHONE +33.563.82.53.00
FAX +33.563.82.53.01
EMAL cepheid@cepheideurope.fr

CEPHEID RSA

Famous Grouse House Kildrummy Office Park Cnr Witkoppen Rd and Umhlanga Ave Paulshof, 2191 Johannesburg, South Africa

PHONE +27 11 234 9636 FAX +27 11 234 9640 EMAL info-rsa@cepheid.com



WEDNESDAY, 3 DECEMBER 2014

PLENARY 3

INNOVATION IN DIAGNOSTICS

DATE: Wednesday, 3 December

TIME: 09:00 - 10:30

LOCATION: Auditorium 1

SESSION CO-CHAIRS: Alash'le Abimiku, Institute of Human Virology, University of Maryland, United States of America

Tsehaynesh Messele, African Society for Laboratory Medicine, Ethiopia

Paul Tanui, African Union-New Partnership for Africa's Development (NEPAD), South Africa

Facilitating the Path for Regulation Harmonisation

Paul Tanui is a Senior Programme Officer-Technical Support in the African Medicines Regulatory Harmonization (AMRH) Programme at NEPAD Planning and Coordinating Agency based in Pretoria South Africa. He is a pharmacist and a quality assurance and regulatory affairs professional with over 13 years' work experience in regulatory affairs, the pharmaceutical industry, and pharmaceutical management. He has a strong background in regulatory systems strengthening including medicines assessment and registration systems, pharmaceutical manufacturing processes, and regulatory harmonization. Areas of expertise include medicines regulatory harmonization, risk-benefit analysis, rational use of medicine, and quality management practices. He holds a master's degree in Business



Administration, degree in Pharmacy, and postgraduate qualifications in Business and Healthcare Management.

Brenda Waning, UNITAID, Switzerland REPLACED BY TOM CHILLER

Making a Difference with Point-of-Care Diagnostics

Dr. Brenda Waning serves as Coordinator of Market Dynamics at UNITAID, a WHO-partnership based in Geneva. She leads UNTAID's technical team responsible for monitoring trends in HIV/AIDS, tuberculosis, and malaria markets; identifying strategic opportunities to intervene in these markets; developing new proposals for funding consideration; and assessing the public health and market impact of UNITAID's interventions. Prior to joining UNITAID, Dr. Waning served as Director of Pharmaceutical Policy at Boston University School of Medicine where she authored numerous peer-reviewed studies on pharmaceutical policy at local, national, and global levels. Dr. Waning serves on many expert advisory groups, including the UNAIDS Diagnostics Access Initiative Steering Committee United Nations and the Medicines for Malaria Venture Access and Delivery Advisory Committee.



Kasirim Nwuke, UN Economic Commission for Africa, Ethiopia

Meeting Africa's Health Challenge in the Context of the African Union's African Transformation Agenda: What Role Innovations and Health Technologies?

Kasirim Nwuke is currently Chief, New Technologies and Innovation, Special Initiatives Division, United Nations Economic Commission for Africa (ECA), Addis Ababa, Ethiopia. In this role, he leads and oversees activities and programmes aimed at ensuring that ECA's products and services, including the flagship reports, are of the highest standards and reflect best practices at the time they are delivered. Previous to assuming this responsibility, he was Chief of the Quality Assurance Section in which role it was his duty to ensure that ECA's policy and analytical products meet the highest quality at the time they are delivered.



He has served in numerous positions at ECA including as Chief, MDGs/Poverty Analysis & Monitoring Section in which role he initiated and led a number of

innovative products including the annual flagship report "Assessing Progress in Africa toward the MDGs." Mr. Nwuke also led the African Learning Group on Poverty Reduction Strategies and the MDGs. In 2005, he was seconded by ECA to the Government of the Federal Republic of Nigeria to serve as Special Advisor to the then and current Minister of Finance of Nigeria, Dr. Ngozi Okonjo-lweala.

He served on the Steering Committee of the African Economic Research Consortium's (AERC) research project "Understanding the Impact of China and India on Africa", as a member of the Technical Advisory Group (TAG) of the African Monitor's Grassroots Focused Index (GFI), and on the Steering and Selection Committees of the major UNAIDS/ECA/UNDP/Shell Project "AIDS in Africa: Scenarios of the Future." He also served on the Secretary-Generals MDG 8 Task Force.

ORAL SESSION 3

DATE: Wednesday, 3 December

TIME: 11:00 - 12:45

	SSION 3.1: Antimicrobial Resistance IS: William Ampofo and Coumba Touré Kane Wednesday, 3 December Room 1.4		
11:00	Prevalence, Antimicrobial Susceptibility Pattern and Clinical Predictors of Group A Streptococci among Children with Pharyngitis Getnet Tesfaw Tadege, Alemseged Abdissa Lencho, Gebre Kibru Tiga, Demeke Mekonnen Mengistie		
11:10	Molecular Characterisation of Methicillin-Resistant <i>Staphylococcus aureus</i> Isolated at the University Teaching Hospital, Lusaka, Zambia Mulemba Samutela, James C.L. Mwansa, Chileshe Lukwesa-Musyani		
11:20	Risk Factors Associated with Antiretroviral Therapy Failure and Acquiring Drug Resistance Mutations among HIV-1 Adult Patients on ART — Results from a Nationwide Cross-Sectional HIV Drug Resistance Survey in Kenya Guoqing Zhang, Lucy Nganga, Joshua DeVos, Evelyn Ngugi, Francesca Odhiambo, Irene Mukui, Abraham Katana, Lucy Kanyara, Elliot Raizes		
11:30	Dried Blood Spot Specimens are a Vital Alternative Specimen Type for HIV Drug Resistance Surveillance and Monitoring in HIV-1-infected Patients Initiating Antiretroviral Therapy in Nigeria Rachel Suzanne Beard		
11:40	Evaluation of Antibiogram Techniques in some Laboratories in Cameroon Tchoula Mamiafo Corinne		
11:50	The Need for Genotypic Antiretroviral Resistance Testing for Children in Developing Countries Annette Donnelly and Ellen HopeKearns		
ORAL SESSION 3.2: Advances in CD4 Testing CO-CHAIRS: Larry Westerman and Matilu Mwau Room 1.6			
11:00	Can CD4 Monitoring be Stopped Among Virologically Suppressed Patients: a Systematic Review and Meta-analysis CANCELLED Nathan Ford and Andrew Hill		
11:10	Predictors of CD4 Count Changes after Initiation of Antiretroviral Treatment in Gondar University Hospital, Gondar, Ethiopia CANCELLED Mihiretu Molla		
11:20	Validation of Muse® Auto CD4/CD4% Assay to Determine the Absolute Number and Percentages of CD4 T Cells Using Cameroonian Children and Adult Patients' Samples Francois-Xavier Mbopi-Keou, Florence Tanghu Mimo, Hortense Gonsu Kamga, Pierrette Omgba Bassega, Martin Samuel Sosso, Joseph Mindimi Nkodo, Alexis Ndjolo, Côme Ebana Mvogo, Maurice Aurelien Sosso, Laurent Bélec		
11:30	Technical Performance Evaluation of the Zyomyx MyT4 Point of Care Technology for CD4+ T Cell Enumeration Matilu Mwau, Silvia Kadima, Joy Mwende, Maureen Adhiambo, Catherine Akinyi, Marta Prescott, Judi Lusike, Jackson Hungu, Lara Vojnov		
11:40	Geospatial Analysis: A CD4 Referral Network Optimization and Strategic POC Integration Model Jason Williams		
11:50	Using Open Source Spatial Software to Analyze and Optimize Inter-laboratory CD4 Referral Patterns in South Africa CANCELLED Oriel Mahlatsi, Naseem Cassim, Lindi Marie Coetzee, Deborah K. Glencross		
ORAL SESSION 3.3: Advances in Early Infant Diagnosis CO-CHAIRS: Wendy Stevens and Charles Kasipo Auditorium 1			
11:00	Adherence to Early Infant HIV Diagnosis (EID) Testing Algorithm–Uganda's Experience Charles Kiyaga and Helen Lee		
11:10	Selection and Evaluation of a Third Rapid HIV Assay as a Tie Breaker to Enhance Early HIV Diagnosis and Linkage to Care in the Kingdom of Swaziland Rogers Kisame and Sindisiwe Susan Diamini		
11:20	Task Shifting Training for Point-of-Care Technologies: The SAMBA Experience in Zimbabwe Sekesai Mtapuri-Zinyowera, Douglas Mangwanya, Raiva Simbi, Neha Goel, Jose Paolo Magbanua, Peter Gumbo, Ellen Munemo, Lourdes M. Nadala, Angella Mushavi, Vasco Chikwasha, Helen Lee		
11:30	Evaluation of the Simple Amplification-Based Assay (SAMBA) Qualitative Point-of-Care HIV-1 Viral Detection Assay on Whole Blood Among HIV-exposed Infants in Western Kenya Collins Odhiambo, Clement Zeh, Kenneth Ouma,		
11:40	Improved Sensitivity of a Dual-Probe HIV-1 Qualitative Test for Plasma and Dried Blood Spots Robert Luo, Sergio Carmona, Stefanie Templer, Britta Seiverth, Paul Baum, Carole Devaux, Wendy Stevens		
11:50	Evaluation of the Alere q Point-of-Care system for Early Infant HIV Diagnosis Nei-yuan Hsiao, Lorna Dunning, Catherine Clary, Max Kroon, Landon Myer		

ORAL SESSION 3.4: Diagnostic Innovations CO-CHAIRS: Emmanuel Fajardo and Daniela Maria Cirillo	
11:00	Improved Performance of the New Prototype Automated Abbott RealTime HIV-1 DBS Viral Load Assay*: Potential Use in Expanded Viral Load Testing in Resource Limited Setting (*For Research Use Only) Shihai Huang, Sergio Carmona, Brian Erickson, John Salituro, Chadwick Dunn, Livhuwani Nxumalo, Jeffrey Wuitschick, Jens Dhein
11:20	Demonstration of the Idylla™ System for Rapid, Multiplexed Molecular Diagnosis of Infectious Diseases Kathleen Tietje, Carmen Forsman, Heather White, Mitra Singhal, David Fredricks, Daisy Ko, Tina Fiedler, Katrien Vermeiren, Erwin Sablon, Rudi Rossau
11:30	Performance of Xpert® HIV-1 Quant Compared to Roche CAP/CTM v2 and Abbott RealTime HIV-1 on a Prequalification Plasma Validation Panel Lesley Scott, Natasha Gous, Sergio Carmona, Wendy Stevens
11:40	Rapid Plasma Separation Device for Point-of-Care Viral Load Testing: A Proof-of-Concept Emmanuel Fajardo, Racheal Shamiso Mandishora, Oscar Tapera, Elton Mbofana, Sekesai Mtapuri-Zinyowera
	ESSION 3.5: The Journey to Laboratory Accreditation Wednesday, 3 December RS: Talkmore Maruta and Thomas Gachuki Roof Terrace Roon
11:00	Progress Made in the Implementation of the Stepwise Laboratory Improvement Process Jean-Bosco Ndihokubwayo, Talkmore Maruta, Nqobile Ndlovu, Sikhulile Moyo, Teferi Mekonen, Ali Ahmed Yahaya, Sheick Oumar Coulibaly
11:10	Using Scores in Checklist Sections to Identify Gaps in SLIPTA Implementation Lawrena Okoro and Anthony Emeribe
11:20	High-level Advocacy to Build Support for Laboratory Accreditation Ngobile Ndlovu
11:30	ISO Accreditation of First Public Laboratory in Kenya: Benefits and Experiences Thomas Gachuki and Mamo Umuro
11:40	Customer Service and Corrective Action Top List of Sustained Laboratory Improvements in Resource-Limited Countries Striving to Earn International Accreditation Cathy Robinson and Wendy Arneson
11:50	Rapid Ascent from Zero Quality to ISO Accreditation in 18 Months: A Case Study from Vietnam Kyle Bond, Cuong Duong, Hien Bui, Nhan Dang, Nhanh Bui
	SSION 3.6: The Role of the Laboratory in Outbreak Response RS: Amadou Sall and Peter Nsubaga Auditorium
11:00	Genetic Diversity of Sporothrix Species Isolated From Clinical and Environmental Sources from an Outbreak among Gold Miners in Barberton, Mpumalanga Tsidiso Gugu Maphanga, Thokozile G. Zulu, Nelesh P. Govender
11:10	Cholera Outbreak in Plateau State, Nigeria, 2011 Samuel Badung, Gbenga Ajani, Okeke A. Lilian, Elmina A. Abiayi, Ndadilnasiya E. Waziri, Elisha Pede, Peterside Kumbish, Tony M. Joannis, Adebola T. Olayinka Philip A. Okewole, Patrick Nguku
11:20	Re-emergence of Yellow Fever in Kedougou, Southeastern Senegal in 2010 – 2011 Abdourahmane Sow, Yamar Ba, Diawo Diallo, Oumar Faye, Rubin Chen, Kathryn A Hanley, Scott C Weaver, Mawlouth Diallo, Amadou A Sall
11:30	An Outbreak of Measles in Techiman Municipality, Brong-Ahafo Region – Ghana, 2014 Joseph Asamoah Frimpong, Gershon Kobla Anthony, Abdulai Marijanatu, Culbert Nuolabong, Iddrisah Florence, Kofi Mensah Nyarko
11:40	Mozambique Field Epidemiology and Laboratory Training Program (FELTP) – Strengthening Disease Detection through Laboratory Confirmation Cynthia Semá Baltazar, Cátia Taibo, Jahid Sacarlat, Lorna Gujral, Eduardo Samo Gudo
11:50	Ebola Epidemic: Laboratory Lessons Learned in Uganda – Are You Ready? Ali Elbireer

ORAL POSTER 3

DATE: Wednesday, 3 December

TIME: 13:00 - 14:30

	STERS 3.1: Testing and Health System Strengthening S: Christina Mwangi and Emmanuel Idigbe Ballroom East/West
13:00	3.11 Assessing Current Preanalytical Practices vs. Best Practices: A Benchmark for Improving Specimen Quality and Patient and Healthcare Worker Safety Samuel Kwame Opoku and Aparna Jha Ahuja
13:10	3.12 Applying the Integrated Tiered Service Delivery Model (ITSDM) in KwaZulu-Natal (KZN) Province to Identify Optimal Placement of CD4 Testing Facilities Lindi Marie Coetzee, Naseem Cassim, Deborah K. Glencross
13:20	3.13 Assessing the Impact of Implementing a Community CD4 Laboratory in a Rural Health District in South Africa Nassim Cassim, Lindi Marie Coetzee, Deborah K. Glencross
13:30	3.14 Modular Containment Laboratory-Hybrid (MCL-H): A Novel Design Combining BSL3 Infectious Disease and BSL2 Molecular Laboratories in a Single, Transportable Unit Barry Kosloff, Ingrid Terlouw, Gregers Chalker
13:40	3.15 Country-Based Testing Algorithms and Outcomes in a Blood Donation Setting: Implications on Cost and Future Testing CANCELLED Joseph Mwangi, Joyceline Kinyua, Nancy Lagat
13:50	3.16 Quantitative Reference Ranges for Fasting Profiles and Oral Glucose Tolerance Test for Healthy Adults from Metropolitan Region (Nairobi) of Kenya CANCELLED
14:00	Stanley Kinge Waithaka, Eliud N. Njagi, Joseph N. Ngeranwa, Daniel M. Muturi, Wilfred K. Gatua, Bernard M. Chiuri, Leonard J. Njagi 3.17 Stability of Complete Blood Count and 3-part White Cell Differential Parameters with Storage Time and Temperature Variation Using Cell Dyn 1800 Automated Hematology Analyzer Desalegn Tesema, Aster Tsegaye, Gonfa Ayana, Achamyeleh Mulugeta, Habtamu Asrat, Abnet Abebe
	Sters 3.2: Drug Resistance S: Chunfu Yang and William Ampofo Ballroom East/West
13:00	3.21 Bacteriological Profile and Antimicrobial Susceptibility Pattern of Blood Culture Isolates among Septicemia Suspected Children at Tikur Anbessa Specialized Hospital and Yekatit 12 Hospital Addis Ababa, Ethiopia CANCELLED Adugna Negussie, Gebru Mulugeta, Ahmed Bedru, Ibrahim Ali, Damte Shimeles, Tsehaynesh Lema, Abraham Aseffa
13:10	3.22 Drug Resistance Profile and Molecular Characterization of Extended Spectrum Beta-lactamase (ESBL) Producing Escherichia coli Isolated in Lomé CANCELLED Kodjovi Dodji Mlaga, Kodjovi D. Mlaga, Eugenie A. Anago, Ségla Togossou, Anoumou Y. Dagnra, Ambaliou Sanni
13:20	3.23 Optimization and Validation of an In-house HIV-1 Genotyping Protocol for Use on Dried Blood Spots in a South African Setting Michelle Bronze, Kim Steegen, Azwidowi Lukhwareni, Maria A Papathanasopoulos, Wendy Stevens, Sergio C Carmona
13:30	3.24 Genetic Context for the Transmissible Quinolone-resistance Gene qnrS1 in Nigeria Aaron Aboderin, Iruka Okeke, Eric Sumrall, Elizabeth Gallo, Adebayo Lamikanra
13:40	3.25 Resistance Pattern of Enterobacteriaceae Isolate from Urinary Tract Infections to Selected Quinolones in Yaoundé, Cameroon Emilia Enjema Lyonga, Michel Toukam, Celine Nkenfou, Marie-Claire Okomo-Assoumou, Martha Mesembe, Agnes Eyoh, Georges Ikomey, Valantine Ngum Ndze, Sinata Koulla-Shiro
13:50	3.26 Detection of Extended Spectrum β-Lactamases in Invasive Klebsiella Pneumoniae Isolates from the University Teaching Hospital, Lusaka, Zambia Enock Mulowa Mumbula, James C. L. Mwansa, Geoffrey Kwenda, Chileshe Lukwesa-Musyani
14:00	3.27 Persistence of Chloroquine-resistant Plasmodium Falciparum Mutant Haplotypes in Children with Uncomplicated Malaria in Lagos, Nigeria Four Years After Change of Chloroquine as First-line Antimalarial Drug Oladipo Oladosu, Oyibo Wellington, Colin Sutherland
	STERS 3.3: Laboratory-Based Surveillance and Epidemiology S: Omu Anzala and Richard Njouom Sallroom East/West
13:00	3.31 Plasmodium Ovale Curtisi and Plasmodium Ovale Wallikeri in North-West Ethiopia CANCELLED Abebe Alemu, Hans-Peter Fuehrer, Gebeyaw Getnet, Belay Tessema, Harald Noedl
13:10	3.32 Improving Blood Supply Safety & Adequacy in Developing Countries: Pan-African Blood Safety Perspectives CANCELLED Asa'ah Nkohkwo and Nigel Talboys
13:20	3.33 Evaluation of Laboratory-based Multi Drug Resistant Tuberculosis (MDR-TB) Surveillance System in Muhimbili (NIMR-CTRL) Tanzania, 2012 CANCELLED Mura Ngoi, Fausta Mosha, Ahmed Abade, Mecky Matee
13:30	3.34 Emerging Zoonotic Diseases in the Coastal and Nairobi Regions of Kenya CANCELLED Julius Oyugi, Antar Munira, Mike Drebot, Omu Anzala
13:40	3.35 Rift Valley Fever Sero-surveillance Using Recombinant Virus Nucleoprotein and Vesicular Stomatitis Virus Pseudotype-based Assays among Humans in Borno State, Nigeria CANCELLED David Bukbuk, Shuetsu Fukushi, Hideki Tani, Tomoki Yoshikawa, Satoshi Taniguchi, Koichiro Iha, Shigeru Morikawa, Masayuki Saijo, Francis Kasolo, Saka Saheed Baba
13:50	3.36 Caractérisation Génétique des Rhinovirus et Entérovirus Associés au Syndrome Grippal au Sénégal Mbayame Niang, David Kiori, Ousmane Kébé, Déborah Goudiaby, Ndongo Dia
14:00	3.37 The in vitro Susceptibility Pattern of Candida Blood Stream Isolates to 3 Antifungal Agents at Abuth Shika, Zaria, Nigeria CANCELLED Joan Ejembi, Ronke Suleiman, Adebola Olayinka

SYMPOSIUM 9

COMBATING ANTIMICROBIAL RESISTANCE IN AFRICA

SESSION OBJECTIVES:

Antimicrobials play a critical role in reducing the burden of communicable diseases all over the world. However, the curative power of infectious disease by drugs or drug efficacy is not infinite. Antimicrobial resistance threatens the effectiveness of successful treatment of infections and is a public health issue with national

DATE: Wednesday, 3 December

TIME: 14:45 - 16:15

LOCATION: Auditorium 2

and global dimensions. In low-income countries including the WHO African region, AMR frequently occurs in microorganisms that are likely to be transmitted in the community such as organisms causing pneumonia, diarrheal diseases, tuberculosis (TB), sexually transmitted diseases, and malaria. Drug resistance has dramatically increased the costs of fighting TB and malaria, and slowed gains against childhood dysentery and pneumonia. It also threatens the push to treat people living with HIV/AIDS effectively. While appearance of drug resistance is a continuous phenomenon in microorganisms, its amplification and spread is through the improper utilization of antimicrobial agents, the use of fake and counterfeit medicines, poor prescribing habits, and non-compliance to prescribed treatments. Drug resistance is a major public health problem that requires a range of interventions and multidisciplinary team approach. The recent improvement in TB diagnostics provides an opportunity to increase MDR-TB detection and early initiation of treatment in Africa. Thus, to maintain the useful life of antimicrobial agents in African countries there are needs to have improved access to diagnostic laboratories, improved surveillance of the emergence of resistance, better regulation, and better education of the public, clinicians/prescribers, and veterinarians in the appropriate use of antibiotics.

The purpose of this session is to share the current status of this public health problem in the African Region, raise awareness on the need to strengthen AMR surveillance and propose key actions for monitoring this phenomenon.

How countries and laboratory services in the WHO African region can contribute to overcoming this challenge?

This session aims at sharing countries experience on AMR in 3 diseases of public health importance including AIDS, TB and Malaria. It underlines the issues, challenges and proposes solutions to improve AMR surveillance and containment in the WHO African region.

SESSION OVERVIEW:

 AMR in the WHO African Region: Overview, Issues, Challenges and Solutions

Jean-Bosco Ndihokubwayo, WHO Regional Office for Africa, Republic of Congo

- Overview of Malaria Resistance in the African Region Sheick Oumar Coulibaly, WHO Regional Office for Africa, Mali
- Surveillance of TB Drug Resistance: Lessons from Uganda
 Moses Joloba, Makerere University, Uganda
- HIV Acquired and Transmitted Drug Resistance in Senegal
 Coumba Touré Kane, National Reference Centre for HIV and STD Laboratory, Senegal

CO-CONVENERS:

Jean-Bosco Ndihokubwayo, WHO Regional Office for Africa, Republic of Congo



Jean-Bosco Ndihokubwayo is a Medical Doctor specialized in Clinical Pathology and Public Health. Before joining WHO in 2001, Dr. Ndihokubwayo was Dean of School of Medicine of Bujumbura, University of Burundi. In his capacity as WHO staff Member in the Regional Office for Africa, based in Brazzaville, Congo, Dr. Ndihokubwayo coordinates the laboratory programmes for their coherent contribution to the strengthening of national health laboratory capacity through setting norms and standards, including national laboratory policies and plans and the provision of support to countries to implement the WHO/ AFRO Stepwise Laboratory Quality Improvement Process Towards Accreditation among others.

Dr. Ndihokubwayo also coordinates the strengthening of the integration of laboratory services in the African region to support countries in their efforts to move away from a disease-specific laboratory focus towards an integrated, coordinated health laboratory system, one that promotes efficient use of resources and improved laboratory service delivery, and ensures laboratories at all levels of the health system contribute to national disease prevention and control including biosafety and laboratory biosecurity. Dr. Ndihokubwayo spent 2 months (April and May 2014) on the ground in Guinea trying to coordinate the international ongoing efforts to control the Ebola virus disease outbreak.

Sheick Oumar Coulibaly, WHO Regional Office for Africa, Mali



S. O. Coulibaly recently joined the WHO/AFRO to reinforce activities on clinical laboratories and health technologies including the antimicrobial resistance which is becoming a more and more serious threat for disease control and prevention. Just before, he was an associate professor of medical parasitology and mycology at the faculty of health sciences, University of Ouagadougou, Burkina Faso, and director of the department of research and training, National Public Health Laboratory of Burkina Faso for more than ten years.

Dr. Coulibaly is a medical doctor, clinical biologist, with a master's degree in human biology (University of Cocody, Côte d'Ivoire) and a Ph.D degree in public health sciences (University of Copenhagen, Denmark). He gained experience in medical research on infectious diseases at the laboratory of parasitology — mycology, Centre Muraz of Bobo-Dioulasso, Burkina Faso. His research has focused on the resistance of malaria parasites that he studied both clinically and using PCR for the detection of plasmodial gene mutations conferring resistance. His last publications on the topic are about the relations between plasmodial resistance and mother and child malaria infection.

SPEAKERS:

Moses Joloba, Makerere University, Uganda



Moses L. Joloba, MBChB, M.S., Ph. D is an Assoc. Professor of Molecular Biology, Immunology and Microbiology in the School of Biomedical Sciences, College of Health Sciences at Makerere University. He is the director of the Uganda TB Supra National Reference Laboratory that has attained ISO 15189 accreditation. Since his training in Makerere University (MBChB) and Case Western Reserve University (Ms and PhD), Dr. Joloba has developed skills in setting up standard laboratories, supporting TB laboratory networks, developing training programmes, starting graduate and short courses, initiating and participating in successful North to South and South to South collaborations, conducting laboratory-based research

as well as training of graduate students. Dr. Joloba has trained 33 Masters and 14 Doctoral students and many non-degree students from the African region and internationally. Dr. Joloba has won over 12 grants and published over 120 peer reviewed papers; he is a reviewer for 6 journals and a book author. Dr. Joloba, a previous and founder member of the core group of the Global Laboratory Initiative (GLI), is very excited and optimistic to be part of the GLI-AFRICA

Coumba Touré Kane, National Reference Centre for HIV and STD Laboratory, Senegal



N. Coumba Toure Kane is a Pharm D PhD. She is the Head of the molecular biology Unit in the National reference Centre for HIV and STD laboratory, Dakar, Senegal. She was graduated at Dakar University and Pasteur Institute in Paris in fundamental virology and Immunology. Prior to joining Dakar University as Associate Professor in Bacteriology and Virology at the Polytechnic Sciences School Centre in the Department of Applied Biology and the Faculty of Medicine, Pharmacy, and Odontology, she completed her post-graduate training in Virology and molecular biology at the University of Montpelier I /IRD (Development Research Institute). Prof. Toure Kane is a leader in the field of HIV prevention, nationally and internationally

recognized for her contributions in applied research on the epidemiology and alternative monitoring tools for HIV patients under ARV. The laboratory that she is leading is a national/regional reference laboratory for drug resistance testing. The laboratory is also a collaborative centre for the African Society for of Laboratory Medicine. She is the supervisor of 10 PhD students and has authored or co-authored over 70 scientific publications in peer-reviewed journals.

SYMPOSIUM 10

INNOVATIVE SOLUTIONS FOR HIV DIAGNOSIS AND MONITORING

SESSION OBJECTIVES:

Adequate tools to diagnose HIV infection, in adults and in exposed infants, and to monitor patients on antiretroviral therapy are indispensable to ensure an effective and sustainable reponse to HIV/AIDS. Yet significant barriers remain and require innovative approaches and solutions, especially in resource-limited settings.

DATE: Wednesday, 3 December

TIME: **14:45 – 16:15** LOCATION: **Room 2.4**

This session will focus on innovative solutions to key barriers of delivery of diagnostics tools. It brings together four speakers who will present their data on very different aspects of this challenge: from self-testing for HIV diagnosis via pooled testing of dried blood spots for infant diagnosis and treatment monitoring and ensuring test quality and managing supplies through telematic tools to assure quality in point-of-care testing.

Participants will learn about innovative ways of ensuring affordable quality laboratory support for HIV programmes

SESSION OVERVIEW:

- Self-testing as a New Delivery Channel for HIV Diagnostics
 Geoffrey Chipungu, Centres for Disease Control and Prevention, Malawi
- Pooling of Dried Blood Spots for More Cost-Effective Means of Viral Load Monitoring and Early Infant Diagnosis

Wolfgang Preiser, Stellenbosch University, South Africa

The Use of Quality Corps Volunteers and Quality Assurance of HIV Testing

Juliana Ndasi, Global Health Systems Solution, Cameroon

CO-CONVENERS:

Wolfgang Preiser, Stellenbosch University, South Africa



During his training as a medical virologist in Germany and the UK, Wolfgang Preiser gained extensive experience in state-of-the-art diagnostic testing including molecular methods. He graduated with his second doctoral degree (Habilitation) while working as consultant virologist in Frankfurt. In 2005 he was appointed as Professor and Head of the Division of Medical Virology, Faculty of Medicine and Health Sciences, University of Stellenbosch/National Health Laboratory Service (NHLS) Tygerberg in Cape Town, South Africa.

His research aims to close gaps in clinical and diagnostic virology and to improve the management of viral diseases through developing new and improving existing laboratory tests and evaluating their optimal clinical use. Preiser has authored more than 100 Medline-listed publications. His research interests cover three areas: diagnosis and monitoring of HIV infection, using novel or improved diagnostic markers and addressing operational aspects; diagnosis and monitoring of opportunistic infections, especially hepatitis B virus, in HIV-infected and otherwise immunocompromised individuals; and potentially emerging and zoonotic viral diseases. He served as a temporary advisor to the World Health Organization on SARS in China during 2003 and led the Frankfurt group who, together with colleagues from Hamburg, were among the first to isolate the SARS-associated coronavirus in spring 2003.

Brenda Waning, UNITAID, Switzerland



Brenda Waning serves as Coordinator of Market Dynamics at UNITAID, a WHO-partnership based in Geneva. She leads UNTAID's technical team responsible for monitoring trends in HIV/AIDS, tuberculosis, and malaria markets; identifying strategic opportunities to intervene in these markets; developing new proposals for funding consideration; and assessing the public health and market impact of UNITAID's interventions. Prior to joining UNITAID, Dr. Waning served as Director of Pharmaceutical Policy at Boston University School of Medicine where she authored numerous peer-reviewed studies on pharmaceutical policy at local, national, and global levels. Dr. Waning serves on many expert advisory groups, including

the UNAIDS Diagnostics Access Initiative Steering Committee United Nations and the Medicines for Malaria Venture Access and Delivery Advisory Committee.

SPEAKERS:

Geoffrey Chipungu, Centres for Disease Control and Prevention, Malawi



Geoffrey Chipungu is a Malawian Medical Doctor and Clinical Microbiologist working with US CDC Malawi country office as a laboratory advisor. Dr. Chipungu gives technical assistance to the Ministry of Health diagnostic department and National Reference Laboratory. He also works as an activity manager on PEPFAR funded laboratory capacity building collaborative agreements.

The collaborative agreements involve improving quality management systems through SLMTA implementation, scale up of CD4 testing, Gene Xpert and Viral load, adverse event monitoring and opportunist infection diagnostics.

Dr. Chipungu studied his medical degree at University of Malawi's College of Medicine, specializing at the University of Cape Town, and attained a post-graduate Diploma in Tropical Medicine at University of Witwatersrand. He previously lectured and headed the Department of Pathology and Medical Laboratory Sciences at the University of Malawi's College of Medicine. Dr. Chipungu's research interests at the College of Medicine involved novel diagnostics for tuberculosis and capacity building for tuberculosis research.

Juliana Ndasi, Global Health Systems Solution, Cameroon



Juliana Ndasi is the Deputy Executive Director for Global Health Systems Solutions (GHSS). She obtained a Bachelor of Science in Biochemistry and a Master of Science in Pharmacology from Ahmadu Bello University Zaria, Nigeria, in 1998 and 2001, respectively. She also holds a PhD in Pharmacology and Toxicology from the University of Nigeria, Nsukka in 2008. Juliana has authored six publications in pharmacology and toxicology in the Asian Journal of Medical Sciences, West Africa Journal of Pharmacology and Drug Research and The Plant Scientist. Juliana was a lecturer at the Ebonyi State University for six years before being recruited as a Senior Lecturer at the University of Buea, Cameroon

where she lectured for three years. Dr. Ndasi is a SLMTA (Strengthening Laboratory Management towards Accreditation) Master Trainer, Laboratory Mentorship Trainer, and Public Health Laboratory Manager where she is currently coordinating and mentoring 14 laboratories towards WHO/AFRO SLIPTA accreditation, as well as supervising 25 technical staff in these laboratories. Juliana also currently coordinates the implementation of quality assurance activities in 340 health facilities spread over the 10 regions of the Republic of Cameroon.

SYMPOSIUM 11

THE ROLE OF ANATOMIC PATHOLOGY IN IMPROVING HEALTH CARE IN SUB-SAHARAN AFRICA

SESSION OBJECTIVES:

A transition from communicable to chronic diseases has occurred in many countries. As our knowledge of the pathogenesis of chronic diseases increases, the distinction between communicable and non-communicable disease blurs. A great example is cervical carcinoma caused by Human Papilloma virus (HPV),

DATE: Wednesday, 3 December

TIME: **14:45 – 16:15** LOCATION: **Room 1.4**

for which we now have diagnosis and prevention before the cancer occurs. For cancer, one of the barriers to increase access to treatment is lack of diagnosis. Similarly, for childhood mortality, diagnosis is paramount to provide prevention strategies. In both examples, establishing anatomic pathology services is indispensable to provide patient diagnosis and reliable data so that public health officials can act accordingly. Past efforts to improve and increase the capacity to provide these services have not had the attention or funding support that are needed. This has resulted in many gaps in our knowledge of which are the most frequent causes of childhood mortality and the neoplasias more frequently encountered in many countries in Sub-Saharan Africa. In addition, the integration of anatomic pathology and laboratory medicine is central to developing public health strategies related to non-communicable diseases. In this symposium we will discuss: 1) The need for clinical laboratory support in the care of patients with non-communicable diseases, particularly cancer, and how that needs to be integrated with anatomic pathology services; 2) The need to focus attention on the health care of women and children, with an emphasis on the need for anatomic pathology services for these populations; 3) The importance of autopsy services for quality control of diagnosis and treatment, particularly as new forms of diagnosis and treatment are introduced; and 4) A recent example from Kenya for how to develop a coordinated, multidisciplinary approach to improving cancer care.

SESSION OVERVIEW:

• The Need for Clinical Laboratory Support in the Care of Patients with Non-Communicable Diseases

Michael Wilson, Denver Health Medical Center, United States of America **Jeannette Guarner**, Emory University, School of Medicine, United States of America

 Role of Anatomic Pathology Services in the Health Care of Women and Children

Drucilla J Roberts, Massachusetts General Hospital, United States of America

- Role of Autopsy Services in Quality Control of Diagnosis and Treatment
 Ann Marie Nelson, US Department of Defense, Joint Pathology Center, United States of America
- Coordinated, Multidisciplinary Approach to Improving Cancer Care in Kenya

Shahin Sayed, College of Pathologists of East, Central and Southern Africa (COPECSA), Kenya

CO-CONVENERS:

Michael Wilson, Denver Health Medical Center, United States of America



Michael Wilson is Director of the Department of Pathology and Laboratory Services at Denver Health in Denver, Colorado. He is a Professor of Pathology at the University of Colorado School of Medicine in Aurora, Colorado. He is currently the Editor-in-Chief of the *American Journal of Clinical Pathology*. His academic interests are in the areas of Medical Microbiology, Infectious Diseases Pathology, and Public Health Microbiology. His research focus is in the areas of laboratory detection of bacteremia and fungemia and tuberculosis diagnostics. He is a founding member of InPaLa, a non-governmental organization based in the USA that works to coordinate efforts to build sustainable anatomic and clinical pathology/laboratory

medicine capacity in Sub-Saharan Africa (SSA). Prof. Wilson is currently involved in two major projects to improve anatomic and clinical pathology/laboratory medicine capacity in SSA, one in Eldoret, Kenya and the other in Juba, South Sudan.

Jeannette Guarner, Emory University, School of Medicine, United States of America



Jeannette Guarner was brought up in Mexico City where she obtained her medical degree from LaSalle University. She did her anatomic and clinical pathology residency training at Emory University in Atlanta, GA. Then she returned to Mexico City where she was the Director of the Clinical Laboratory at the National Cancer Institute. In 1997 she returned to Atlanta and worked at the Centers for Disease Control and Prevention (CDC) in the Infectious Disease Pathology Branch. During her 10-year tenure at CDC she was involved in the histopathologic study of high profile outbreaks including the US anthrax bioterrorism attack, the introduction of West Nile virus to the Americas, and the discovery of SARS coronavirus. In 2007

she joined the faculty at Emory University. She is Professor of Pathology and Laboratory Medicine and is currently the Medical Director of the Clinical Laboratory at Emory University Hospital in Midtown. She teaches medical students, residents and fellows. She has developed a curriculum to teach laboratory medicine to clinicians that has been used at Emory University and Addis Ababa University.

SPEAKERS:

Drucilla J Roberts, Massachusetts General Hospital, United States of America



Drucilla J Roberts is Associate Professor in the Department of Pathology at the Massachusetts General Hospital. She has been brought up in Harvard University as she did medical school, residency training, and fellowship there. She has special interest in gynecobstetric pathology, autopsy pathology, and cytopathology. She has taught extensively in Sub Saharan Africa (SSA). She has published on Pathology: functionality in resource-poor settings. Together with Michael Wilson she is involved in two major projects to improve anatomic and clinical pathology/laboratory medicine capacity in SSA, one in Eldoret, Kenya and the other in Juba, South Sudan. She is involved in four large projects in SSA including placental malaria, stillbirth, and respiratory mortality in children and adults.

Ann Marie Nelson, US Department of Defense Joint, Pathology Center, United States of America



Ann Marie Nelson did her medical school in Guadalajara, Mexico. Then she trained in anatomic pathology and got a Fullbright Scholarship working in Makerere College of Health Sciences in Uganda and Muhimbili University in Tanzania. During that year, Dr. Nelson worked with local pathologists, clinicians and international researchers to improve pathology capacity within the national institutions. When she returned to the US, she worked at the Armed Forces Institute of Pathology focusing on AIDS and infectious diseases. Currently she has a position at the US Department of Defense Joint Pathology Center. For her involvement in international work, particularly in Africa, she was awarded the Gold Medal in 2013 by the International

Academy of Pathology. Together with Dr. Wilson, she is a founding member of InPaLa, a non-governmental organization based in the USA that works to coordinate efforts to build sustainable anatomic and clinical pathology/laboratory medicine capacity in Sub-Saharan Africa (SSA).

Shahin Sayed, College of Pathologists of East, Central and Southern Africa (COPECSA), Kenya



Shahin Sayed is a pathologist from Kenya that works at Aga Khan University. Dr. Sayed is the Secretary General College of Pathologists of East, Central and Southern Africa (COPECSA). COPECSA is a regional and internationally recognized college that supports and informs medical and laboratory practice through the promotion of quality pathology and laboratory medicine services in Africa and the setting of standards in the education, training, and professional development of pathologists in the region.

SYMPOSIUM 12

EVIDENCE TO SUPPORT INFLUENZA VACCINATION IN AFRICA

SESSION OBJECTIVES:

Following the emergence of avian influenza in Africa in 2006 and of influenza A (H1N1) pdm in 2009, there has been a substantial expansion of influenza surveillance activities in Africa. However, influenza vaccine utilisation on the continent remains extremely low. Recently, the Global Alliance on Vaccines and Immunisations (GAVI) requested more evidence on influenza vaccination of

DATE: Wednesday, 3 December

TIME: **14:45 – 16:15** LOCATION: **Room 1.6**

pregnant women to prevent disease in pregnant women and their infants. Implementation of influenza vaccination programmes in African countries must be driven by robust data on burden of disease and groups at highest risk of severe infection and death. Influenza vaccines must be shown to be effective in high risk groups in Africa. Data on circulating viral strains in Africa are essential to guide production of effective vaccines. In addition, systems must be in place to ensure an adequate supply of vaccines for both seasonal and pandemic influenza. This session will provide an update on the above issues as well as suggestions for future research needs.

SESSION OVERVIEW:

Who is at Risk of Severe Influenza in Africa?

Cheryl Cohen, National Institute for Communicable Diseases, South Africa

 Influenza: The Role of a WHO Collaborating Centre within Global Influenza Surveillance and Response and Provision of Candidate Vaccine Viruses

Rodney Stuart Daniels, MRC-National Institute for Medical Research, England

- Maternal Influenza Vaccination, An Update from Africa
 Marta Nunes, University of the Witwatersrand, South Africa
- Progress Towards Influenza Vaccine Manufacture in Africa
 Patrick Tippoo, The Biovac Institute, South Africa

CO-CONVENERS:

Richard Njouom, Centre Pasteur, Cameroon



Richard Njouom has a PhD in Virology at the University of Toulouse III in France. He is now the Head of Virology Department at the Centre Pasteur of Cameroon and also the Head of the National Influenza Centre of Cameroon. He has set up a National sentinel surveillance system for ILI in all the 10 administrative regions of Cameroon and for SARI in the capital city. Dr. Njouom's research focused primarily on prevalence, genetic diversity, and dynamic of transmission of viral hepatitis in Central Africa. Since 2006, his research activities are also concerned with the epidemiology of influenza and other respiratory viruses in Cameroon. He has published about 45 peer-reviewed papers, one book, and has given more than 50 scientific presentations in international meetings.

Cheryl Cohen, National Institute for Communicable Diseases, South Africa



Cheryl Cohen has a background as a medical doctor with a specialisation in clinical microbiology and MSc in epidemiology. She is co-head of the Centre for Respiratory Diseases and Meningitis at the National Institute for Communicable Diseases in South Africa. In this position she works closely with the National and Provincal Department of Health to generate evidence to guide policy with regard to the control and management of infectious diseases. She led the establishment of a national surveillance programme for severe acute respiratory infections in South Africa in 2009. Simultaneously she directed the establishment of rotavirus surveillance at several sites throughout South Africa and has been intensively involved

in leading the epidemiology component of a national surveillance programme for invasive bacterial infections, specifically pneumococcus, meningococcus, and *Haemophilus influenzae*. She has also been involved in a number of studies related to describing the burden of vaccine-preventable diseases and assessments of vaccine effectiveness including a national case-control study aiming to estimate the effectiveness of pneumococcal conjugate vaccine in prevention of invasive pneumococcal disease. She has published more than 50 peer-reviewed papers.

SPEAKERS:

Rodney Stuart Daniels, MRC-National Institute for Medical Research, England



Rodney Stuart Daniels graduated from King's College, London in 1979 with a PhD in Biochemistry. His Post-Doctoral career has largely been spent in the Virology Division, MRC-National Institute for Medical Research, Mill Hill, London. He has 20 and 35 years of experience in the fields of HIV and Influenza research respectively, with a focus on the structure and function of the virus glycoproteins. Since 2006 he has held the post of Deputy Director of the WHO Collaborating Centre for Reference and Research on Influenza (WHO CC) and conducted surveillance as related to twice yearly WHO recommendations on vaccine composition, production of candidate vaccine viruses, potential emergence (zoonotic events)

of viruses with pandemic potential and monitoring of 'resistance' to antiviral drugs, notably neuraminidase inhibitors. From a research perspective his work focuses on understanding the interplay between receptor-binding and antigenicity of influenza haemagglutinin (HA) and how these are affected by changes in the neuraminidase (NA). In his role as a WHO CC he has strong collaborative interactions with \sim 40% of the WHO National Influenza Centres (NICs), notably those in the WHO EURO, AFRO and EMRO regions.

Marta Nunes, University of the Witwatersrand, South Africa



Marta Nunes is a senior scientist at Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand. Marta did her PhD thesis work at the Department of Neurology & Neuroscience, Weill Medical College of Cornell University, New York, NY, USA and obtained her PhD from the University of Lisbon, Medical College, Lisbon, Portugal. She has worked previously on the cellular mechanisms of malaria parasite infection and collaborated in various projects dedicated to identify new malaria vaccine candidates for malaria in pregnancy. Currently her research is focused on the prevention of respiratory diseases exploring the use of vaccines and other interventions particularly in populations burdened by

HIV infection. She was a co-investigator/laboratory scientist on a clinical trial that investigated the safety, immunogenicity, and efficacy of trivalent inactivated influenza vaccination of HIV-uninfected and HIV-infected pregnant women against early-childhood and maternal influenza-virus associated illness.

Patrick Tippoo, The Biovac Institute, South Africa



Patrick Tippoo heads up Product Development and Business Development at The Biovac Institute, a private public partnership aimed at re-establishing vaccine development and manufacturing capacity in South Africa. He has been with Biovac since its inception in 2003. Patrick's responsibilities include strategic alliances and local & international partnering opportunities with respect to product development and inbound and outbound technology transfer projects.

He is also the Interim Executive Director of the African Vaccine Manufacturing Initiative (AVMI), whose mission is to promote the establishment of sustainable human vaccine manufacturing capacity in Africa.

SYMPOSIUM 13

UPDATE ON VACCINE PREVENTABLE DISEASES LABORATORY NETWORKS IN AFRICA

SESSION OBJECTIVES:

WHO together with the member states of the African Region have adopted goals to eradicate polio, eliminate measles, control rubella, yellow fever, and bacterial diseases through intense vaccination efforts. Surveillance is a critical component to monitor the progress of any disease intervention. It serves as a method for

DATE: Wednesday, 3 December

TIME: 14:45 - 16:15

LOCATION: Roof Terrace Room

assessing the effectiveness of immunization strategies and as a tool for guiding efforts toward disease eradication, elimination or control. Surveillance is based on the detection, reporting, and analysis of suspect cases and laboratory confirmation of clinical diagnosis. With the adoption of a global goal to eradicate polio, WHO developed in the early 1990s a global network of laboratories to ensure high quality laboratory diagnosis of suspect cases of poliomyelitis. More recently, other laboratory networks were developed using the polio model and based on the experience of the Global Polio Laboratory Network, WHO has developed additional networks to support various vaccine-preventable disease programmes, including the measles-rubella elimination initiative, the introduction of new and underutilized vaccines like rotavirus, and invasive bacterial diseases, but also other vaccine-preventable disease programmes like yellow fever, Japanese encephalitis, as well as influenza, and tuberculosis. These laboratory networks have been developed to ensure coordination of routine activities in terms of laboratory investigation, confirmation analysis and reporting according to the guidelines set forward by WHO. This session intends to present a global overview and the African perspective on the roles and responsibilities of the Laboratory Networks, and how to ensure high quality testing for aforementioned diseases is warranted.

SESSION OVERVIEW:

- Global Laboratory Networks for Vaccine-preventable Diseases
 Mick Mulders, World Health Organization, Switzerland
- AFRO Regional Reference Laboratory for Measles and Rubella, Roles, Responsibilities and Challenges

Josephine Bwogi, Uganda Virus Research Institute, Uganda

 Roles, Responsibilities and Challenges of the Uganda Measles Regional Reference Laboratory

Berhane Beyene, Ethiopian Public Health Institute (EPHI), Ethiopia

 Ensuring High Quality Testing for Vaccine-Preventable Bacterial Diseases in AFRO LabNet

Linda De Gouveia, National Institute for Communicable Diseases, South Africa

CO-CONVENERS:

Ilesh Jani, National Health Institute, Mozambique



llesh V. Jani, MD, PhD, qualified as a medical doctor at the Eduardo Mondlane University in Mozambique and received a PhD in Immunology from the University of London in the United Kingdom. Dr. Jani has been a researcher at Mozambique's Instituto Nacional de Saúde (INS, National Institute of Health) since 1998, where he also served as the Head of the Department of Immunology from 2004 to 2009. Since 2009, he has been the Director General of the INS, the national research and public health institute in Mozambique which houses all major reference laboratories.

During his career Dr. Jani has lead efforts in the areas of research, public health, education and diagnostics with the objective of strengthening the health system in Mozambique. He is currently on the board of directors of the African Society for Laboratory Medicine (ASLM), a member of the executive board of the International Association of National Public Health Institutes (IANPHI), and a member of the Task Force on Immunization at the WHO-AFRO. His fields of research include diagnostic laboratory technologies and HIV/AIDS vaccines. He has authored several publications in peer-reviewed international journals.

Mick Mulders, World Health Organization, Switzerland



Mick Mulders is of Dutch nationality and obtained his PhD at the medical faculty of the University of Amsterdam, the Netherlands. The topic of his thesis was molecular detection and characterization of poliovirus. His studies were conducted at the WHO Global Specialized Polio laboratory CDC, Atlanta, under supervision of Dr. Olen Kew and at the Global Polio laboratory at the National Institute of Public Health and the Environment (RIVM) in the Netherlands. His post-doc was again at a WHO Global Specialized laboratory for polio at the National Public Health Institute of Finland with Prof. Tapani Hovi. In 2000 he took a senior scientist position at the WHO Regional Reference Laboratory for measles and rubella at the National Public

Health Laboratory in Luxembourg. In 2003 he joined WHO European Regional Office in Copenhagen as Regional Laboratory coordinator for measles and rubella. Between 2008 and 2010 he was programme manager antibiotic resistance back at RIVM, after which he rejoined WHO/EURO. Since 2012 he has been the global laboratory coordinator for vaccine-preventable diseases with WHO/Geneva.

SPEAKERS:

Josephine Bwogi, Uganda Virus Research Institute, Uganda



Josephine Bwogi is the head of EPI Laboratory at Uganda Virus Research Institute since 2002. This lab is a designated WHO Measles Regional Reference Laboratory serving eight countries: Kenya, Tanzania, Ethiopia, Eritrea, Rwanda, Burundi, Comoros, and Uganda.

Dr. Josephine Bwogi has a Bachelor's Degree in Medicine and Bachelor's Degree in Surgery. She has a Master of Science Degree in Clinical Epidemiology and Biostatistics. She is currently a PhD student at the College of Health Sciences, Makerere University. Her PhD Project is on rotaviruses. She is studying the molecular epidemiology of Rotaviruses and possibility of zoonotic transmission in under-fives and adults.

She is interested in surveillance and research on vaccine preventable diseases namely, but not limited to measles, rubella, polio, influenza, hepatitis B, and rotaviruses.

Berhane Beyene, Ethiopian Public Health Institute (EPHI), Ethiopia



Berhane Beyene is of Ethiopian nationality and obtained her BSc in Biology at Addis Ababa University, Ethiopia and Master of Business Administration in Health Care Administration at Century University in New Mexico, USA. Mrs. Berhane Beyene has worked in the African polio and measles laboratory network since 1998 – 2014 mainly on the polio eradication programme as head of the National Polio and Measles Laboratory which has been a WHO-accredited laboratory since 2001. She trained in molecular methods for the characterization of polioviruses from September 1996 to March 1997 conducted by the Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Her experience in surveillance and establishment

of a National Polio Laboratory licensed her as Chief Public Health Professional by the Federal Ministry of Health in Ethiopia. She was working at the associate researcher II level in public health bacteriology, and mycology, and shifted to the virology team as coordinator of polio, measles, rubella, yellow fever, rotavirus and influenza projects under Ethiopia's disease surveillance. She worked as a the National Immunization Days facilitator under WHO. She is a member of the national polio eradication expert committee and coordinator of National Polio containment committee in Ethiopia. She is working as the virology research team coordinator and Head of the National Polio and Measles Laboratory at Ethiopian Public Health Institute.

Linda De Gouveia, National Institute for Communicable Diseases, South Africa



Linda de Gouveia qualified as a medical microbiology technologist in 1986 and has vast experience in routine microbiology diagnostics and training of personnel in the laboratory component of communicable disease diagnosis and pathogen identification.

In 1999, she was involved in the setting up of national surveillance for laboratory-confirmed disease due to pneumococcus, meningoccus and Haemophilus influenzae and then became part of core founding team for the Group for Enteric, Respiratory and Meningeal Disease Surveillance (GERMS-SA). She is currently the laboratory manager of the Centre for Respiratory Diseases and Meningitis of the National Institute for

Communicable Diseases, and is actively involved in national laboratory surveillance for bacterial infections causing pneumonia and meningitis in South Africa .

She has been involved in the laboratory component of numerous research projects and many carriage studies. She has extensive experience and has played a pivotal role in hands-on teaching and training of pathologists, scientists and technologists, both here in South Africa and other African counties as part of an agreement with WHO AFRO in the Vaccine-Preventable Invasive Bacterial Diseases (VP-IBD) and Global Surveillance Network for the southern African region.

ROUND TABLE 10

A ROADMAP FOR LABORATORY STRENGTHENING IN AFRICA

SESSION OBJECTIVES:

Global health priorities are coalescing around a set of clear goals in the coming years, such as the new 90-90-90 HIV treatment targets announced by UNAIDS, global initiatives to combat TB and malaria and new efforts to tackle emerging epidemics and neglected diseases. Laboratory medicine is a critical partner in

DATE: Wednesday, 3 December

TIME: **16:30 – 18:00** LOCATION: **Room 1.6**

these global health priorities. In December 2012, ASLM convened African Ministers of Health to discuss laboratory challenges on the continent. Ministers of Health from across the continent have adopted and signed a Ministerial Call to Action for Laboratory Strengthening calling for governments to commit to support workforce development, laboratory quality improvement and accreditation, improved regulatory standards and harmonization, and laboratory network strengthening.

Tackling these and other laboratory strengthening priorities will take a strong and coordinated effort by governments, donors and implementing partners. Clear goals and a roadmap based on best practice are needed to ensure coordinated effort and efficient resource allocation and utilization. National laboratory programmes need well-designed strategic plans and effective assistance from partners.

A clear, prioritized roadmap for improvement and more effective utilization of implementing partners may enable Africa to achieve its laboratory strengthening goals quicker and more efficiently.

The Roundtable on the ASLM Roadmap for Laboratory Strengthening in Africa will provide a detailed framework of priority areas of focus and specific opportunities and mechanisms ensure access, equity and efficiency for laboratory services in Africa. The Roadmap will be based on well-established best practices and innovations and will provide a roadmap for lab improvement to achieve the ASLM2020 goals and other key strengthening priorities that ensure better health outcomes.

SESSION OVERVIEW:

- Health Priorities and the Role of Laboratory Medicine
 Trevor Peter, African Society for Laboratory Medicine, Ethiopia
- Looking Forward: A Roadmap for Laboratory Strengthening

Tsehaynesh Messele, African Society for Laboratory Medicine, Ethiopia

CO-CONVENERS:

Alash'le Abimiku, Institute of Human Virology, University of Maryland School of Medicine



Alash'le Abimiku, is an Associate Professor at the Institute of Human Virology, University of Maryland School of Medicine, Baltimore; and a the Director of office of Laboratory diagnostics and research at the Institute of Human Virology Nigeria. She has spent over 2 decades establishing laboratory infrastructure and science in Nigeria with long-term collaborations with the USA. Dr. Abimiku's research focuses on the role of HIV subtypes in disease pathogenesis using mother to child model to investigate the transmitting subtype/s and studying effects of co-infections on HIV pathogenesis. Dr. Abimiku's more recent grant funding allows Nigeria to epidemiologically characterize different cohorts and build capacity of government officials and

Nigerian researchers in preparation for the future conduct of HIV vaccine clinical trials. Dr. Abimiku also joined the effort by scientist in Africa in the field of genomic science through the NIH's H3Africa initiative. Dr. Abimiku has trained a cadre of pre and post doctoral Nigerian students who are engaged in advanced research as collaborators. She is internationally recognized for her leadership in HIV research and in her role as a member of the WHO Vaccine advisory committee and as a board member the African society of Laboratory medicine.

Sagie Pillay, ASLM2014 Conference Co-Chair



Sagie Pillay is currently CEO of the National Health Laboratory Services (NHLS) and was the former CEO at Charlotte Maxeke Johannesburg Academic Hospital. He has extensive leadership experience of Tertiary Hospitals and Laboratory Services. Mr. Pillay worked and consulted locally and internationally in health management, financing and planning. His academic background includes a Masters in Health Management, Policy and Planning from University of Leeds and a MBA from University of Liverpool. He is also an Honorary Lecturer at the school of Public Health at the University of Witwatersrand, South Africa.

SPEAKERS:

Trevor Peter, African Society for Laboratory Medicine, Ethiopia



Trevor Peter is the Chair of the Board of the African Society for Laboratory Medicine and is based in Botswana. He is also the Senior Scientific Director, Diagnostics at the Clinton Health Access Initiative where he has worked since 2005. Dr. Peter has over 20 years experience in the fields of diagnostics and infectious diseases research and public health. He has provided technical guidance in public laboratory strengthening across Africa, Asia, Eastern Europe, the Caribbean and South America. Before 2005, Dr. Peter was laboratory director at Botswana-Harvard HIV Reference Laboratory and conducted infectious disease epidemiology research.

Tsehaynesh Messele, African Society for Laboratory Medicine, Ethiopia



Tsehaynesh Messele joined ASLM as CEO in March 2011, following an extensive international candidate search. From 2004-2011, she served as Director General of the Ethiopian Health and Nutrition Research Institute. She has also served as Senior Technical Advisor for the Federal HIV Prevention and Control Office of Ethiopia. Over her distinguished career, Dr. Messele has published and co-authored over 60 publications in peer-reviewed journals as well as book chapters. She holds a PhD in Immunology from the University of Amsterdam, Netherlands.

DISCUSSANTS:

Wendy Stevens, NHLS, South Africa; Philip Onyebujoh, WHO; John Nkengasong, US CDC; Jessica Markby, WHO; Isatta Wurie, CDC Sierra Leone; Rosanna Peeling, LSHTM; Amadou Sall, Senegal; Sagie Pillay, ASLM2014 Conference Co-Chair; Anthony Emeribe, MLSCN; Ralph Timperi, APHL

ROUND TABLE 11

THE ROLE OF RAPID TESTS IN IMPROVING THE CLINICAL MANAGEMENT OF PATIENTS PRESENTING WITH CHRONIC FEVER, INTESTINAL AND NEUROLOGICAL DISORDERS

SESSION OBJECTIVES:

This session will present the first results of a large multi-centre clinical study (NIDIAG) addressing the diagnostic work up of persistent fever, intestinal and neurological syndromes (www.nidiag.org). The objectives were to generate evidence for a syndromatic approach, by improving current diagnostic algorithms.

DATE: Wednesday, 3 December

TIME: **16:30 – 18:00** LOCATION: **Room 1.4**

Evidence-based algorithms for the primary care level will be designed with a patient-centred approach, following guidance from disease-endemic countries stakeholders and making the best possible use of existing assays and treatments. Relevant innovative technology will be introduced when required and comprehensive diagnostic platforms will be developed according to the specific epidemiological contexts in Africa and South-Asia. The Session at ASLM will present preliminary results and exchange

SESSION OVERVIEW:

• The Role of Rapid Diagnostic Tests (RDTs) in Improving the Clinical Management of Patients Presenting with Chronic Fever

Sayda El Safi, University of Khartoum, Sudan

 The Role of RDTs in Improving the Clinical Management of Patients Presenting with Neurological Syndrome

Pascal Lutumba, Institute National de Recherche Biomedicale, Democratic Republic of the Congo **Moussa Sacko**, Institute National de la Recherche en Santé Publique, Mali

Quality Issues in RDTs for Neglected Infectious Diseases

Jan Jacobs, Institute of Tropical Medicine, Belgium

CO-CONVENERS:

Sayda El Safi, University of Khartoum, Sudan



Sayda El Safi is currently a professor of Immunology at the University of Khartoum, Sudan, teaching Immunology at undergraduate and postgraduate levels. She received the MB.BS degree from the Faculty of Medicine, Khartoum University, MSc degree in Clinical Tropical Medicine from London School of Hygiene and Tropical Medicine where she also obtained her PhD degree on Protozoal Immunology, in addition to a certificate of the Immunology Module of the Diploma in Clinical Pathology from The Royal Post — graduate Medical School, University of London. She worked as medical officer in several hospitals in Khartoum State, as a Researcher at the Institute of Tropical Medicine, Medical Research Council, Khartoum and eventually

she joined the Department of Microbiology and Parasitology, Faculty of Medicine, University of Khartoum in 1990. Since then she served as Head Department for six years and as Dean , Faculty of Medical Laboratory Sciences, University of Khartoum for nine years. She chaired several committees at the Ministry of Higher Education and Research and is a member of the Leishmaniasis Task Force at the Federal Ministry of Health. She is the Deputy Chairperson of the MD degree in Clincal Immunolgy at the Sudanese Medical Specialization Board. Her research interests focus mainly on infectious diseases with emphasis on leishmaniasis. She has fifty five publications in peer-reviewed journals and managed 15 internationally-funded research projects (funded a.o. by WHO, TDR and EU.)

Jan Jacobs, Institute of Tropical Medicine, Belgium



Jan Jacobs MD KULeuven, (Belgium 1984), Clinical Pathologist (Belgium, 1989), Medical Microbiologist (The Netherlands, 1991). From 1990 to 2005, he was working at the University Hospital of Maastricht and involved in diagnostic microbiology, infection control and teaching. Since 2006, he is appointed at the Institute of Tropical Medicine as Professor in Tropical Laboratory Medicine.

His research focuses on invasive bacterial infections and quality of diagnostics laboratories in resource limited tropical settings, including quality and appropriate use of in-vitro diagnostics. He is technical advisor for the World Health Organization's Prequalification of Diagnostics Program (test product review, ISO 13485).

manufacturing site inspections) and chair of the Procurement and Supply Working Group on Diagnostics from Roll Back Malaria Partnership.

SPEAKERS:

Pascal Lutumba. Institute National de Recherche Biomedicale. Democratic Republic of the Congo



Pascal Lutumba is the Head of the Epidemiology service at the Institut National de Recherche Biomédicale, Democratic Republic of Congo (DRC). He is a visiting professor, at the School of Public Health of Lubumbashi University/ DRC and a Professor at the Tropical Medicine department of Kinshasa University, DRC. His current research includes clinical trials on ACTs and quinine in malaria; surveillance of sleeping sickness by using filter paper, integration of control and surveillance of sleeping sickness in health facilities; schistosomiasis control strategy and epidemiology in DRC of today (with the agreement of financing by TDR/OMS); efficiency of diagnostic algorithms of malaria; neurocysticercosis and epilepsy in DR Congo.

Social determinants of effectiveness of human African trypanosomiasis control strategies and Knowledge, attitudes and practices of population about malaria control strategies.

Moussa Sacko, Institute National de la Recherche en Santé Publique, Mali



Moussa Sacko, MSc in Medical Parasitology (London School of Hygiene and Tropical Medicine) and PhD (DBL-Institute for Health Research Development, University of Copenhagen) has more than 20 years' experience in research and control of Infectious diseases. Currently he is the Head of Department of Diagnostic and biomedical Research at the INRSP and Coordinator of Neglected Tropical Diseases Research Programme. He has conducted a number of rigorous research studies, including research and control in Schistosomiasis and Soil Transmitted Helminthiasis (STH), Filariasis and malaria. He has actively been involved in operational research as well as dissemination and translation into policy. These included:

epidemiology, mapping of schistosomiasis and STH, morbidity assessment, monitoring and evaluation. In addition under his supervision the laboratory has conducted several other activities: evaluation of dipstick and its use at the district health centres for diagnostic and treatment of urinary schistosomiasis, field evaluation of antigen detection for schistosomiasis, evaluation of feasibility of treatment of out of school aged children, evaluation of the efficacy of different anthelminthic drugs in the treatment of STH. Sacko is a professor of Human Parasitology for MSc Students, Faculty of Science and Technique, University of Bamako and supervisor of several MD, PharmD, MSc and PhD Thesis.

ROUND TABLE 12

ENSURING THE QUALITY OF POINT-OF-CARE TESTING: NEED FOR INNOVATIVE APPROACHES

SESSION OBJECTIVES:

In this session, speakers will describe the need for innovative strategies in point-ofcare testing (POCT), discuss the role of site certification for effective management of POCT to ensure reliable and accurate results, share experiences in using innovative strategies for implementing the Quality Assured Cycle, and discuss current strategies and updates on evaluation of new POCT for HIV and CD4. DATE: Wednesday, 3 December

TIME: 16:30 - 18:00

I OCATION: Roof Terrace Room

SESSION OVERVIEW:

- Re-Setting the Testing Button The Changing Landscape of POCT
 John Nkengasong, Centers for Disease Control and Prevention, United States of America
- Site Certification for HIV POCT The Namibia Experience Gerhard van Rooyen, Namibia Institute of Pathology, Namibia
- Implementing the HIV Quality-Assured Cycle Using Innovative Strategies: Cameroon Perspective

Juliana Ndasi, Global Health Systems Solution, Cameroon

 Current Strategies and Updates on Evaluation of New POCT for HIV and CD4 Testing

Jonathan Lehe, Clinton Health Access Initiative, Kenya

CO-CONVENERS:

Fausta Mosha, National Public Health Laboratory, Tanzania



Fausta Mosha, is a medical microbiologist and epidemiologist working for the Ministry of Health and Social Welfare in Tanzania since 2005, currently as a Director for the National Public Health Laboratory since 2010. Before that she has been coordinating laboratory based trainings and also a Resident Advisor for the Tanzania Field Epidemiology and Laboratory Training Programme (FELTP). She holds an MD from the University of Dar es Salaam, Msc in Microbiology from the University of Leuven, Belgium, Msc in Epidemiology and Laboratory Management from the Jomo Kenyatta University, Kenya and PhD from the University of Leuven, Belgium. She is a Principal Investigator for the international Co-operative agreement

between the Centers for Disease Control and Prevention, (CDC), Atlanta and African Field Epidemiology Network (AFENET) on a project "Laboratory Biosafety and Quality Assurance involving several Countries in Africa and the Caribbean Region. She is also a Program Manager for the East African Public Health Laboratory Networking Project (EAPHLNP) in Tanzania and Secretary for the Board of Directors of African Society for Laboratory Medicine (ASLM).

Judith Shang, Centres for Disease Control and Prevention, Cameroon



Judith Shang is the current Laboratory Director for the CDC-Cameroon programme. She received a Masters in Medical Microbiology at the London School of Hygiene and Tropical Medicine, UK, and a Doctorate in Medical Sciences (Microbiology) from the United Medical and Dental Schools of Guy's and St Thomas's Hospitals, London, UK. From 1998-2001, she took up the position of assistant head of the Laboratoire de Santé Hygiene Mobile, Yaoundé, Cameroon. Between July 1999 — February 2000, she also served as an ORISE Fellow in a post-doctoral fellowship programme with the Food and Drug Administration (FDA), Center for Biologics, Evaluation and Research, USA. In 1999, she joined the University of Yaoundé 1,

Department of Biochemistry and Microbiology, as lecturer in Microbiology, Immunology and Molecular biology until 2007 when she joined CDC-Cameroon DHAP programme as the laboratory coordinator for the CDC-Cameroon research station in Mutengene and in October 2008, she joined CDC/DGHA-Cameroon. Dr. Shang has received several awards in recognition of her services, including a Centre for Global Health 2011 Director's leadership award and a US Department of State Meritorious Honor Award for superior management and leadership of the CDC Cameroon laboratory section resulting in a model laboratory programme under PEPFAR.

SPEAKERS:

John Nkengasong, Centers for Disease Control and Prevention, United States of America



John Nkengasong is the current Associate Director for Laboratory Science at the Division of Global HIV/ AIDS, Center for Global Health, CDC Atlanta. He is also the Chief of the International Laboratory Branch and co-chairs the President's Emergency Plan for AIDS Relief's (PEPFAR) Laboratory Technical Working Group. He joined CDC in 1995 as Chief of the Virology Laboratory, CDC Abidjan, Ivory Coast, and became Chief of the International Laboratory Branch, Global AIDS Program in 2005. He has received numerous awards for his work including, but not limited to, the US Secretary of Health and Human Services Award for excellence in Public Health Protection Research, the Sheppard Award, and Director's Recognitions Award. He is the founding chair of the board of directors of the African Society for Laboratory Medicine.

Gerhard van Rooyen, Namibia Institute of Pathology, Namibia



Gerhard van Rooyen is the Quality Manager at the Namibia Institute of Pathology (NIP). NIP is a wholly state owned entity providing medical laboratory services to all public health facilities in Namibia. Gerhard holds a B-Tech degree in Bio-Medical Laboratory Technology, and a Management Development Program (MDP) certificate.

He joined the Namibia Institute of Pathology in 2004 after starting his professional career with the Namibia Blood Transfusion Service. He has over 9 years' experience in implementing Quality Management Systems in medical laboratories leading to the achievement of international accreditation status.

He moved to the Quality Assurance department of NIP in 2009 to work on the HIV Counselling and Testing programme. This included the development of National Guidelines, Standards and Protocols for HIV Counselling and Testing in Namibia. Gerhard was also responsible for the evaluation of test devices, training and competency certification of point-of-care testers as well as the administration of the HIV proficiency testing programme.

Since December 2011, his responsibilities as the Quality Manager include the development and implementation of an effective quality management system within the organization's network of 40 laboratories. He is also responsible for the in-country roll-out of the SLMTA programme.



Juliana Ndasi, Global Health Systems Solution, Cameroon



Juliana Ndasi is the Deputy Executive Director for Global Health Systems Solutions (GHSS). She obtained a Bachelor of Science in Biochemistry and a Master of Science in Pharmacology from Ahmadu Bello University Zaria, Nigeria in 1998 and 2001, respectively. She also holds a PhD in Pharmacology and Toxicology from the University of Nigeria Nsukka in 2008. Juliana authors six publications in pharmacology and toxicology in Asian Journal of Medical Sciences, West Africa Journal of Pharmacology and Drug Research and The Plant Scientist. Juliana was a lecturer at the Ebonyi State University for six years before being recruited as a Senior Lecturer at the University of Buea, Cameroon where she lectured for three

years. Dr. Ndasi is a SLMTA (Strengthening Laboratory Management towards Accreditation) Master Trainer, Laboratory Mentorship Trainer and Public Health Laboratory Manager where she is currently coordinating and mentoring 14 laboratories towards WHO/AFRO SLIPTA accreditation, as well as supervising 25 technical staff in these laboratories. Juliana also currently coordinates the implementation of quality assurance activities in 340 health facilities spread over the 10 regions of the Republic of Cameroon.

Jonathan Lehe, Clinton Health Access Initiative, Kenya



Jonathan Lehe is the Senior Program Manager for Point-of-Care (POC) Diagnostics at the Clinton Health Access Initiative (CHAI), and a member of CHAI's global Laboratory Services Team. He is responsible for managing CHAI's work supporting Ministries of Health in Africa, Asia, and the Caribbean to improve access to innovative POC HIV diagnostics, bringing healthcare closer to the patient, especially in rural and low-resource settings without access to labs. He joined CHAI in 2008 and lived in Nairobi, Kenya for 5 years, focusing on expanding access to diagnostics services in East and Southern Africa. In 2013, he returned home to the United States and is currently based in Chicago. Prior to joining CHAI, he worked in the

management consulting industry, advising pharmaceutical companies on strategies to improve their marketing and procurement practices. He holds a degree in Economics from Harvard University

ROUND TABLE 13

A COLLABORATIVE APPROACH TO MARKET ENTRY AND PROCUREMENT OF DIAGNOSTIC PRODUCTS

SESSION OBJECTIVES:

The objectives of this session are to introduce the Global Diagnostic Working Group and share information about implementation of key mechanisms for quality assurance, market entry, and procurement of diagnostic products.

DATE: **Wednesday, 3 December**

TIME: **16:30 - 18:00**

LOCATION: Auditorium 2

This group of partners has been established in late 2012 with the objectives to strengthen communication, collaboration and coordination among its members for the optimal selection and use of quality-assured HIV-related in-vitro devices, to respond in a timely and coordinated manner to any quality related issues, to provide aligned messages to global, regional and country level users on quality assurance for product selection and procurement.

A question and answer session with representatives of all the constituencies of the Global Diagnostic Working Group (BMGF, CDC, CHAI, MSF, The Global Fund, UNICEF, UNITAID, USAID, USG/OGAC, WHO-EMP, WHO-HIV) will occur after speaker presentations.

SESSION OVERVIEW:

HIV Global Diagnostic Working Group

Myriam Henkens, Médecins Sans Frontières, Geneva

Quality Assurance for Diagnostics Products: Expert Review Panel for Diagnostics

Jöelle Daviaud, The Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria, Switzerland

Product Eligibility, Selection, Procurement and Market Dynamics:
 Ongoing Initiatives and Opportunities for Alignment

Irena Prat, World Health Organization, Switzerland
Joel Kuritsky, United States Agency for International Development, United States of America

CONVENER:

HIV Global Diagnostic Working Group



SPEAKERS:

Myriam Henkens, Médecins Sans Frontières, Geneva



For more than 6 years, Myriam Henkens worked in field positions with Médecins Sans frontiers (MSF) in several countries in Africa and Asia. After completing an MPH at Johns Hopkins University, Myriam became the director of the Medical Department at MSF in Brussels and is now in charge of MSF's international medical coordination.

Besides coordinating the medical departments of all MSF sections, Myriam continues to be involved in several medical topics such as tuberculosis, meningitis, cholera, vaccination, etc. Myriam represents MSF

at several interagency platforms such as the International Coordination Group for meningitis, yellow fever and cholera, among others. She has also been invited as an expert to several platforms on cholera vaccines, the WHO Essential Medicines List, etc.

Myriam is currently the leader of MSF intersection team for the Quality Assurance of medicines, medical devices including diagnostic tests, and therapeutic food. She represents MSF in related international platforms and is representing MSF as a founding member of the GDWG (Global Diagnostic Working Group).

Jöelle Daviaud, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland



Jöelle Daviaud graduated from France with a Doctorate degree in Pharmacy. She is the Quality Assurance Specialist for Health Products in Grant Management Support within the Grant Management Division at the Global Fund. Since 2006 she has been responsible for providing with expert support and guidance on quality assurance related matters for health products (pharmaceuticals, diagnostics, bednets, insecticides, condoms, throughout the grant lifecycle. She also manages the development, operationalization, and implementation of the Quality Assurance policies developed in close cooperation with technical partners including WHO Pregualification team, National Drugs regulatory authorities, manufacturers' representatives,

as well as with donors, such as UNITAID and USAID, working towards harmonization of policies.

Since the early nineties, she has worked in the field of Health Products Quality Assurance with the following continuous objective: ensuring that the end users receive the most appropriate formulation of safe, efficient and quality-assured products.

She started her carrier in the Quality Control Laboratory at the French Ministry of Health, working on diagnostics, pharmaceuticals, and vaccines dossier assessment and quality control. In 2002 she moved to Geneva to join WHO Headquarters to work with the team in charge of the pregualification of vaccines.

Irena Prat, World Health Organization, Switzerland REPLACED BY ANITA SANDS



Irena Prat is the Group Lead for the Diagnostics Assessment Team within the WHO Department of Essential Medicines and Health Products (EMP). Ms. Prat has joined WHO in 2008 when she became responsible for product dossier and regulatory work within the WHO Prequalification of diagnostics programme. Since early 2014 she is overall responsible for the WHO Prequalification of In Vitro Diagnostics Programme and is the focal point for all in vitro diagnostics related activities within the department. Before joining WHO she worked as a Counsellor in the field of medical devices, active implantable medical devices and in vitro diagnostic medical devices at the Agency for medicinal products and medical devices of the Republic of

Slovenia (2000-2007). Ms. Prat has contributed to the transposition of the EEC Directives into the national regulations as well as to the establishment of pre- and post-market surveillance procedures for medical devices.

Ms. Prat graduated from the University of Ljubljana (Slovenia), Faculty of pharmacy and holds a post graduate specialization in management from the University of Primorska (Slovenia), Faculty of management.

Joël Kuritsky, United States Agency for International Development, United States of America REPLACED BY ROBERT LUO



Joel Kuritsky is the Medical Advisor for the Supply for Health Division in the Office of HIV/AIDS at USAID. He is trained in infectious diseases and worked for the National Centers for Disease Control in Atlanta for 23 years before joining USAID. Dr. Kuritsky worked in Bolivia for CDC and USAID from 1988 to 1994 on child survival programmes, Chagas' disease and HIV/AIDS. From 1996-2000 he was the Director of the Immunization Services Division in the National Immunization Program at CDC. From 2003 to 2005 he worked in the Treatment and Care Branch for the Global AIDS Program at CDC and was co-chair of the Procurement Work Group, which helped design supply chain strategies for the PEPFAR programme. From

2006 to 2009, Dr. Kuritsky was the Deputy Director of the Pediatric Dengue Vaccine Initiative at the International Vaccine Institute in Seoul, South Korea.

ROUND TABLE 14

THE CHANGING ROLE OF THE LABORATORY IN SUPPORT OF SEXUALLY TRANSMITTED INFECTION CONTROL PROGRAMMES IN AFRICA

SESSION OBJECTIVES:

At the conclusion of this session, participants should be able to understand the role of both the clinical and reference laboratory in the control of sexually transmitted infections in resource-poor settings in Africa as well as the rationale for syndromic surveillance of STIs, including antimicrobial susceptibility testing. The session will

DATE: Wednesday, 3 December

TIME: **16:30 – 18:00**LOCATION: **Room 2.4**

also cover the limitations of syndromic management for STIs and the importance of STI screening for asymptomatic infection in resource-poor settings in Africa. Finally, this session will also help participants to recognize the need for laboratory support for external quality assurance programmes to ensure quality of point-of-care diagnostics at peripheral treatment sites and understand the complexities of syphilis serological testing in a region where syphilis coexists with the endemic treponematoses, yaws and bejel.

SESSION OVERVIEW:

 Syphilis or an Endemic Treponematosis? New Laboratory Tests to Help Solve the Puzzle

Ron Ballard, Centers for Disease Control and Prevention, United States of America

 Microbiological Surveillance of STI Syndromes in South Africa, 2006-2014

Frans Radebe, National Institute for Communicable Diseases, South Africa

 How the Laboratory Can Help Prevent the Emergence of Multidrug Resistant Gonococci in Africa

Venessa Maseko, National Institute for Communicable Diseases, South Africa

The Changing Role of the Laboratory in the Control of Syphilis

Yaw Adu Sarkodie, Kwame Nkrumah University of Science and Technology, Ghana

CO-CONVENERS:

Ron Ballard, Centers for Disease Control and Prevention, United States of America



Ron Ballard is currently the Associate Director for Laboratory Science in the Center for Global Health at the Centers for Disease Control and Prevention in Atlanta, GA, USA. For 10 years, he held the post of Chief of the Laboratory Reference and Research Branch within the Division of Sexually Transmitted Disease Prevention, also at CDC. In 1974, he moved from the MRC Trachoma Research Unit at the Lister Institute for Preventive Medicine, London, UK to South Africa where he subsequently became Director of the National Reference Centre for Sexually Transmitted Diseases at the South African Institute for Medical Research and University of the Witwatersrand in Johannesburg. He was also Associate Professor in the

Department of Medical Microbiology and Infectious Diseases. He is a past Secretary-general of the International Union against Sexually Transmitted Infections (IUSTI), member of the Board of the International Society for STD Research (ISSTDR) and Board of the American STD Association. His research interests include development and application of diagnostic tests for STDs including HIV and tropical infections. He has over 200 publications in the scientific literature.

Chewe Luo, UNICEF, United States of America



Chewe Luo is a Paediatrician, Tropical Child Health Specialist and Epidemiologist from Zambia, currently serving as a Senior Programme Advisor and Technical Leader for scaling up country programmes for UNICEF's Global HIV Programme in New York. Dr. Luo has over 15 years of extensive experience in both HIV research and programming.

Before transferring to her current position, she worked as a UNICEF Regional PMTCT Advisor for Eastern and Southern Africa in Nairobi, providing technical guidance to countries in policy and strategy formulation as well as programme design. Dr. Luo was also the UNICEF HIV Officer in Botswana at a time when the

government was rapidly scaling up its PMTCT programme.

Prior to joining UNICEF, Dr. Luo worked as a paediatrician in Zambia and the National Health Service in the UK. She holds a medical degree and has post-graduate training in paediatrics from the University of Zambia. She also has a Masters in Tropical Child Health and a PhD from the University of Liverpool.

SPEAKERS:

Frans Radebe, National Institute for Communicable Diseases, South Africa



Frans Radebe, MSc is a laboratory trained virologist who is currently Research Manager at the Centre for HIV and Sexually Transmitted Infections (STIs), at the NICD/NHLS in Johannesburg, South Africa. His work on STIs spans almost 25 years where he has conducted and participated in laboratory-based studies, therapeutic clinical trials and clinical evaluations of diagnostic tests for STIs, ranging from multiplex molecular techniques to point-of-care tests for syphilis. He is currently involved in the organization, planning and implementation of research within the centre which includes STI surveillance within the country and the SADC region. His main research interest is chlamydial infection and has co-published over

40 peer-reviewed scientific papers locally and internationally. He is currently President of the Sexually Transmitted Infections Society of Southern Africa (STISSA) and an executive committee member of the Federation of Infectious Diseases Societies of Southern Africa (FIDDSA).

Venessa Maseko, National Institute for Communicable Diseases, South Africa



Dumisile Venessa Maseko is Laboratory Manager at the Centre for HIV and Sexually Transmitted Infections (STIs) of the National Institute for Communicable Diseases (NICD) / National Health Laboratory Service (NHLS) in Johannesburg, South Africa. She trained as a medical technologist at the Tshwane University of Technology and has over 16 years of experience working in the Sexually Transmitted Diseases research.

During this period she has been involved in the development and application of new diagnostic technologies for the diagnosis of individual STIs, detection of antimicrobial resistance among bacterial STIs, These technologies elsewhere in southern Africa as a result of capacity building through training

of laboratory professionals, both in formal courses at NICD and in the field. She has continued to offer support to the southern African region in their STI surveillance programmes. She is has a passion for the maintenance of the Gonococcal Antimicrobial Surveillance Programme (GASP) activities in Africa.

Ms. Maseko is an expert advisor to the NHLS Syphilis Proficiency Testing scheme and also serves on the Council of the Federation of Infectious Diseases Societies of Southern Africa (FIDSSA) and as current treasurer of the STD Society of Southern Africa.

Yaw Adu Sarkodie, Kwame Nkrumah University of Science and Technology, Ghana



Yaw Adu-Sarkodie is the Professor of Clinical Micrbiology at the School of Medical Sciences, Kwame Nkrumah University of science and Technology, Ghana. He is also a consultant Clinical Microbiologist and Genitourinary Physician at the Komfo Anokye Teaching Hospital, Kumasi, Ghana. For a number of years, he has worked closely with the Ghana National AIDS/STD Control Programme and is a member of many of its technical working groups. His main research interests include STI clinical management, evaluation of STI diagnostic tests and detection of antimicrobial resistance among STI pathogens.

NOTES		

THURSDAY, 4 DECEMBER 2014

PLENARY 4

DISEASE SPECIFIC THREATS

DATE: Thursday, 4 December

TIME: 09:00 - 10:30

LOCATION: Auditorium 1

SESSION CO-CHAIRS: Anthony Emeribe, Medical Laboratory Science Council of Nigeria (MLSCN), Nigeria

Ilesh Jani, National Health Institute, Mozambique

Jordan Tappero, Centers for Disease Control and Prevention, United States of America

Global Health Security and Laboratory Medicine

Dr. Jordan W. Tappero is the Director of the Division of Global Health Protection, Center for Global Health (CGH) at the Centers for Disease Control and Prevention. He provides leadership and overall strategic direction for division activities. Prior to his current role, Dr. Tappero has served in several positions in global health: Associate Director for Science in CGH, providing scientific leadership and oversight for CGH's public health activities; director of CDC's Health Systems Reconstruction Office focused on post-earthquake public health reconstruction, inclusive of cholera prevention and control; and as CDC country director in Uganda and Thailand with portfolios that included HIV/AIDS and malaria. Dr. Tappero joined CDC in July 1992, as an Epidemic Intelligence Service (EIS) Officer with the Respiratory Diseases Branch.



Before joining CDC, Dr. Tappero was an Associate Professor with the University of California, San Francisco. Dr. Tappero is a Captain in the USPHS, has three American Board Certifications in Internal Medicine, Preventive Medicine and Dermatology, and earned a Master's in Public Health from the University of California. He continues to be clinically active as a Clinical Assistant Professor of Dermatology, Emory University, Atlanta, Georgia. Dr. Tappero has authored or co-authored over 200 peer-reviewed publications, as well as textbook chapters on HIV, TB, malaria, meningococcal disease, leptospirosis, Ebola and Marburg Hemorrhagic Fever, cholera and other emerging infections.

Chewe Luo, UNICEF, United States of America

Laboratory Medicine: Companion in Virtual Elimination of Pediatric HIV/AIDS

Dr. Chewe Luo is a Paediatrician, Tropical Child Health Specialist and Epidemiologist from Zambia, currently serving as a Senior Programme Advisor and Technical Leader for scaling up country programmes for UNICEF's Global HIV Programme in New York. Dr. Luo has over 15 years of extensive experience in both HIV research and programming.

Before transferring to her current position, she worked as a UNICEF Regional PMTCT Advisor for Eastern and Southern Africa in Nairobi, providing technical guidance to countries in policy and strategy formulation as well as programme design. Dr. Luo was also the UNICEF HIV Officer in Botswana at a time when the government was rapidly scaling up its PMTCT programme.



Prior to joining UNICEF, Dr. Luo worked as a paediatrician in Zambia and the National Health Service in the UK. She holds a medical degree and has post-graduate training in paediatrics from the University of Zambia. She also has a Masters in Tropical Child Health and a PhD from the University of Liverpool.

Amadou Sall, Institut Pasteur, Senegal

Frontline Experience in Fighting Ebola in Africa

Amadou Sall is currently the head of the Arboviruses and viral hemorrhagic fever unit, director of the WHO collaborating centre and member of the governing board at Institut Pasteur de Dakar. He is also the director and founder of the international course on "arboviruses and viral hemorrhagic fever diagnosis, prevention, control, and outbreak management" organized by Institut Pasteur de Dakar in partnership AMP, Ministry of Health of Senegal and University Cheikh Anta Diop Dakar.

Dr. Sall is a virologist and has a PhD in Public Health. He received his scientific education at Universities Paul Sabatier at Toulouse, Paris Orsay and Pierre et Marie Curie in France.



Dr. Sall's research focused primarily on ecology and evolution of arboviruses and viral hemorrhagic fever and diagnostics of the latter viruses is a priority in his laboratory. He has published more than 60 papers and book chapters and given more than 80 scientific communications in international meetings.

ORAL SESSION f 4

DATE: Thursday, 4 December

TIME: 11:00 - 12:45

	SSION 4.1: Impact of Surveillance S: Fausta Mosha and Alash'le Abimiku Room 1.4
11:00	Surveillance of Seasonal Influenza in Tanzania: Five years of Sentinel Surveillance 2009-2013 Miriam Matonya and Vida Mmbaga
11:10	Second Round National Anti-Tuberculosis Drug Resistance Surveillance — Ethiopia Eshetu Lemma, Beniam Feleke, Abebaw Kebede, Muluwork Getahun, Zelalem Yaregal, Ribka Fantu, Yetnebersh Fiseha, Abyot Meaza, Zekarias Dagne
11:20	Drug Resistance Testing in HIV Infected on Treatment and Naïve: Implications on Treatment Outcome Winfrida Cheriro, James Brooks, Ben Liang, Ji Hezhao, Raphael Lihana, Michael Kiptoo, Simeon Mining, Wilfred Emonyi, Elijah M. Songok
11:30	Supervision of Sexually Transmitted Infections in Senegal: a National Survey Conducted in 2006 and 2010 Respectively on 596 and 570 Female Sex Workers in Different STI Centres of Senegal Awa Ba Diallo, Pape A. Niang Diallo, Maimouna Diakhaté-Touré, Aissatou Gaye-Diallo, Ndeye Coumba Touré-Kane, Halimatou Diop-Ndiaye, Astou Guèye-Gaye, Souleymane Mboup
11:40	Use of Clinical Laboratory Data to Determine Disease Prevalence and Diagnostics Services Provided in Kenya Angela Amayo, John Mwihia, Benard Muture, Jedida Wachira, Matilu Mwau, Judy Mwangi
11:50	Uganda Viral Hemorrhagic Fever Surveillance, Laboratory and Outbreak Response Program, 2010-2014: A Model for Early Detection and Effective Outbreak Control Trevor Shoemaker, Stephen Balinandi, Alex Tumusiime, Joseph F. Wamala, Luke Nayakarahuka, Barbara Knust, Ilana Schafer, Julius Lutwama, Ute Ströher, Pierre Rollin, Stuart Nichol
	SSION 4.2: Influenza and Respiratory Infections S: Michael Owusu and Mpho Seleka Thursday, 4 December Room 1.6
11:00	A Fully Integrated Paper-based Assay for the Extraction, Isothermal Amplification, and Detection of Pandemic (H1N1) Influenza A RNA Catherine Kapperich, Natalia Rodriguez, Andy Fan, Jacqueline Linnes, Christopher Chen
11:10	Molecular Epidemiology of Influenza B Viruses and Antigenic Profiles in South Africa: 2005-2013 Mpho Seleka, Marietjie Venter, Florette K Treurnicht, Amelia Buys, Johanna McAnerney, Terry Besselaar, Orienka Hellferscee, Cheryl Cohen, Shabir A Madhi
11:20	Human Coronaviruses Associated with Upper Respiratory Tract Infections in Rural Areas of Ghana Michael Owusu, Augustina Annan, Yaw Adu-Sarkodie
11:30	Co-colonization of Group B Streptococci and Other Respiratory Pathogens during Early Infancy in West Africa Ebenezer Foster-Nyarko, Brenda Anna Kwambana, Jessica Mclellan, Ifedayo Adetifa, Odutola Aderonke, Fatima Ceesay, Abdoulie Bojang, James Jafali, Olatunde Ogundare, Martin M. O. Ota, Martin Antonio
11:40	Role of the Laboratory in a Cluster-randomized Trial: Effectiveness of Seasonal Influenza Vaccination of Children in Africa (Senegal) Mbayame-Ndiaye Niang, Chris Victor, Aldiouma Diallo
	SSION 4.3: HIV Proficiency Testing S: Mamo Umuro and Nadia Sitoe Thursday, 4 December Room 2.4
11:00	Monitoring the Quality of HIV-1 Viral Load Testing through Proficiency Testing Program using Dried Tube Specimens in Resource-limited Settings Shon Nguyen, Artur Ramos, Joy Chang, Bin Li, Vedapuri Shanmugam, Debrah Boeras, John Nkengasong, Chunfu Yang, Dennis Ellenberger
11:10	Inter-operator Comparison of the Elispot Assay Proficiency Testing in HIV-1 Clinical Trials in Kenya Bashir Farah, Robert Langat, Jackton Indangasi, Simon Ogola, Omu Anzala
11:20	Rapid HIV Testing, Going Beyond Numbers in the Era of Task Shifting to Non-laboratory Personnel while Maintaining Quality through Individual-based Proficiency Test Monitoring – The Kenyan Successful Experience Muchiri Njogu, Frankline Kitheka, Sophie Mwanyumba, Kipkerich Bera, Umuro Mamo
11:30	The Performance of POC CD4 Technologies in Quality Assurance Systems is Comparable to the Performance of Conventional Technologies in Mozambique Nadia Sitoe
11:40	Quality Assurance Monitoring of Pima CD4 Testing: Operator Errors Attributing to Higher Invalid Test Rates Larry Westerman, Nichole Arnett, Sehin Birhanu, Karen Chang, Mary Schmitz, Katie Tucker, Omotayo Bolu, John Nkengasong, Luciana Kohatsu, and Fausta Mosha
11:50	Does Laboratory Participation in EQA Programs have an Impact on Laboratory Performance? Results of Two Years Evaluation of Laboratories Performances in the National Proficiency Testing Scheme, Nigeria Oluwaseun Aladesanmi, Eric Lugada, Olusegun Busari, Olumide Okunoye, Okechukwu C. Nwanyanwu, Ali Onoja, Jelpe Tapdiyel

	SSION 4.4: Sustainable Laboratory Information Systems RS: Ralph Timperi and Amitabh Adhikari	Thursday, 4 December Roof Terrace Room
11:00	Review of Laboratory Information Management Systems in Mozambique: Quality Indicators Beth Skaggs, Janise Richards, Mark DeZalia	
11:10	Successful Utilization of Laboratory Information Systems in Establishing Quality Management System to ISO Accreditation Thomas Gachuki and Mamo Umuro	ns Leading
11:20	Rapid Scale up of the Basic Laboratory Information System (BLIS) in Ghana Philip Boakye, Bernard Nkrumah, Anthony Ofosu, Beatrice van der Puije, Samuel Duh, Ava Onalaja, Amitabh Adhikari, Reshr	na Kakkar, Celia Woodfill
11:30	Rift Valley Provincial General Hospital in Kenya Goes Paperless: Achieving 100% Automation of Labor Developing Countries Edwin Ochieng, Rufus Nyaga, Michael Mwangi, Winnie Migwi, Osborn Otieno	atory Data in
11:40	Towards Providing an Affordable and Sustainable Laboratory Information System for Developing Cour Implementation of BLIS-Kenya Open Source Laboratory Information System In Public Health Hospital Emmanuel Kweyu, Roy Rutto, Emmanuel Kitsao, Brian Kiprop, Edwin Ochieng, Osborn Otieno, Amitabh Adhikari, Ralph Timp	Laboratories In Kenya
	SSION 4.5: Improving Biosafety and Laboratory Equipment RS: Albert Bunyasi and James Olweny	Thursday, 4 December Auditorium 2
11:00	The Maputo Declaration on Strengthening of Laboratory Systems: Where is Uganda on Equipment Ha Standardization Six Years Down the Road? James Olweny, Eric Nabuguzi, Henry Oundo, Paul Lotay, Sheba Nakimera, Wilson Nyegenye, Rashid Settaala, Sowedi Muyir.	
11:10	Development of a New Laboratory Safety Evaluation Tool to Build Robust Safety Programs and Achiev Thomas Stevens, David Bressler, Shanna Nesby, John Nkengasong	ve QMS Accreditation
11:20	Laboratory Equipment Maintenance using Reagent Markup and Reagent Rental Strategy in Uganda Wilson Nyegenye, Christina Mwangi, Ida Namakula, Eileen Burke, Steven Aisu, Sunday Izidoro, Victor Bigira, Sam Wasike, Si	itra Mulepo, Philip Kasibante
11:30	Suivi des Stocks de Réactifs et Consommables de Laboratoire de Biologie Médicale : Développement de la Couverture en Guinée Mouslihou Mohamed, Howoro Loua, Sophie Ouvrard, Etienne Guillard	d'un Outil de Calcul
11:40	Biological Safety Cabinet Training for African Countries at Eagleson Institute USA Mary Ann Sondrini	
11:50	Partnering with Biosafety Associations in Africa to Strengthen Laboratory Biosafety Maureen Ellis and Tubi Abiola	
	SSION 4.6: Return on Investment in Laboratory RS: Edwin Shumba and Alaine Umubyeyi Nyaruhirira	Thursday, 4 December Auditorium 1
11:00	Laboratory Tests Use and Laboratory Test Costs in Sub-Saharan Africa: A Comprehensive Survey of Complexities in Kampala, Uganda Lee F. Schroeder, Ali Elbireer, Timothy K. Amukele	linical Laboratory Test
11:10	Cost Effective Mix of Point-of-Care (POC) and Conventional Instrument Deployment in Zambia Farouk Umaru and Fales Mwamba	
11:20	Weighing the Costs: Implementing the SLMTA Program in Zimbabwe Edwin Shumba, Phoebe Nzombe, Absolom Mbinda, Raiva Simbi, Douglas Mangwanya, Peter H. Kilmax, Elizabeth T. Luman,	Sibongile N. Zimuto
11:30	SLMTA Return on Investment for Finance Managers Kilian Songwe and Maryanne Otieno	
11:40	Financing the Introduction of New TB Diagnostics and Treatment: Reflections from Rwanda and Ugan Alaine Umubyeyi Nyaruhirira, S Chutima, F Matovu, M Gasana, C Mundy	da
11:50	A Market Assessment of HIV Immunological and Virological Testing Across Low- and Middle-Income Of Teri Roberts and Jennifer Cohn	Countries

ORAL POSTER $oldsymbol{4}$

DATE: Thursday, 4 December

TIME: **13:00 - 14:30**

	STERS 4.1: Diagnostic Innovations Thursday, 4 December
CO-CHAIR	S: Mark Ware and Teferi Mekonen Ballroom East/West
13:00	4.11 Comparison of SpeedOligo Test to Xpert MTB/Rif Test for Detection of Tuberculosis in Smear-Negative HIV-Infected Patients CANCELLED Simon Walusimbi, Alfred Okeng, Edgar Kigozi, Samuel Kyobe
13:10	4.12 Development of an Enzyme-linked Immunosorbent Assay to Measure VWF Propeptide Levels in Plasma Muriel Meiring and Precious Setlai
13:20	4.13 Quantitative Detection of <i>Plasmodium falciparum</i> Histidine Rich Protein 2 in Saliva CANCELLED Felix Botchway, Cecilia Lekpor, David Dosoo
13:30	4.14 Evaluation of Mycobacteria Growth Indictor Tube (MGIT) for Drug Susceptibility Testing of Mycobacterium Tuberculosis Isolates from Egypt CANCELLED Basan Motawi, Dalia Salem, Zeinab Mostafa, Yasser Mostafa, Randa El-Harizy
13:40	4.15 Preliminary Data on a New Flow Cytometry Assay for the Early Detection of Cryptococcal Antigenaemia <i>Keshendree Moodley, Lindi-Marie Coetzee, E. Shimp, B. Neary, B. Crider, D.K. Glencross</i>
13:50	4.16 Concentration of Lymph Node Aspirate Improves the Sensitivity of Acid Fast Smear Microscopy for the Diagnosis of Tuberculous Lymphadenitis in Jimma, Southwest Ethiopia CANCELLED Mulualem Tadesse Jano
14:00	4.17 Modalities of Prostate Specific Antigen Testing in Gauteng Clinics and Hospitals, South Africa Mpho Maphayi, Jaya George, Braimoh Bello
	STERS 4.2: Policy and Networking S: Charles Massambu and Jackson Amone Thursday, 4 December Ballroom East/West
13:00	4.21 An Essay on the Critical Role of Public-Private Partnerships in Strengthening Laboratory Medicine in Developing Countries Ritu Shrivastava, Andy C Wilson, Christina Mwangi, Renuka Gadde, John N. Nkengasong
13:10	4.22 One Health: An Approach to Strengthen the Future of Laboratory and Clinical Health Systems to Solve Health Challenges in Africa CANCELLED Faith Nawagi, Samuel George Okech, Cheryl Robertson, Samuel Majalija
13:20	4.23 Probable Human Rabies Death in an Urban Hospital in Kenya, August 2013 <i>Emmanuel Okunga, Oluoch David, Wako Boru, Gura Zeinab, Galgoro Tura, Amwayi Samuel, Wences Arvelo</i>
13:30	4.24 Partenariat Publique/Privé en RDC Pour l'Implémentation de l'Option B Plus chez les Femmes Enceintes HIV Positives: le Cas du Programme DREAM Julien Nzeze, Giovanni Guidotti, Stefano Capparucci, Anna Maria Doro Altan, Ceffa Susanna, Dirk Shaka, Leonardo Palomb, Essenge Freddy, Jacques-Devos Kabemba
13:40	4.25 Improving Surveillance of Neisseria gonorrhea Antimicrobial Drug Resistance Based on Efficient Laboratory Network: Case of Cameroon-GASP Ariane Nzouankeu, Marie-Christine Fonkoua, Gaëlle Tchouwa, Genevieve Tsobnang, Marcelle Abanda, Esther Sokeng, Antoinette Ngandjio
13:50	4.26 On-site Sensitization Meeting to Hospital Management Teams Enhance Implementation Laboratory Quality Systems through SLMTA Program to 5 Laboratories Funded Under East Africa Public Health Laboratories Network Project (EAPHLNP) in Tanzania Abdul Mwanja, Fausta Mosha, Charles Masambu, Dickson Majige, Angelika Luguru, Jacquline Mumba, Lawrence Lekashingo, Lugano Kyando
	STERS 4.3: External Quality Assurance Programmes Thursday, 4 December
13:00	S: Henry Mbah and Lawrena Okoro Ballroom East/West 4.31 Initiating an Innovative External Quality Assurance Programme for Xpert MTB/RIF Instrument in Ghana (Pilot Phase)
13:10	Alaine Umubyeyi Nyaruhirira, Catherine Mundy, Rhehab Chimzizi, Bismarck Adusei, Francesca Dzata, Sebaka Molabo, Lesly Scott, Pedro Suarez, Frank Bonsu 4.32 Improving Quality of Rapid HIV Testing Services in HIV Testing and Counseling Settings: Impact of Hands-On Refresher
10.10	Training Franklin Kitheka, Sophie Mwanyumba, Mamo Umuro
13:20	4.33 Use of Dried Tube Specimen Technology for Quality Assurance in Remote HIV Testing Sites Supported by FHI360 in Nigeria Emmanuel Ojo, Henry Mbah, Humphrey Musuluma, Olufunmilayo Ojo, Sunday Ashaolu, Michael Dada, Uche Okudo, Olubunmi Negedu-Momoh, Kwasi Torpey
13:30	4.34 Causes of Proficiency Testing Failures in CD4 Immune Monitoring in Nigerian Laboratories: Outcomes of Investigation and Corrective Action Onsite Visits to Unsatisfactory CD4 Proficiency Testing Laboratories in Nigeria CANCELLED Oluwaseun Aladesanmi, Eric Lugada, Olusegun Busari, Olumide Okunoye, Sulieman Aminu, Okechuku Ogueri, Gregory Uchuno, Tosan Erhabor, Eruona Etubi, Jelpe Tapdiyel, Okechukwu C. Nwanyanwu
13:40	4.35 Coagulation Factors Level in Fresh Frozen Plasma in Rwanda Schifra Uwamungu, Anthony Kebira Nyamache, Florance Masaisa, Serah Njoki Kaggia, Swaibu Katare
13:50	4.36 Are We Delivering the Wrong Results? Examining Misclassification of HIV Status and False Positive Test Results CANCELLED Cheryl Johnson
14:00	4.37 Implementation of a National EQA Program for the Rwanda Hospital Laboratory Network <i>Esther Gathinji, Jennifer Anderson, Janvier Serumondo, Emmy Rusanganwa, Claude Muvunyi, Anicet G. Dahourou, Sally Liska</i>

SYMPOSIUM 14

ADVANCING TOWARDS HIV DRUG RESISTANCE MONITORING IN RESOURCE-LIMITED SETTINGS: WHAT & HOW?

SESSION OBJECTIVES:

The introduction of antiretroviral therapy (ART) has averted 5.5 millions of deaths and prevented 34% of new HIV infections in sub-Saharan Africa (UNAIDS report 2013). However, treatment failure is a consequence of the ART scale-up, with the risk that HIV drug resistance (HIVDR) mutations emerge and accumulate. HIVDR

DATE: Thursday, 4 December

TIME: **14:45 – 16:15** LOCATION: **Room 1.4**

has the potential to limit response to subsequent treatment (acquired HIVDR) and to be transmitted (transmitted HIV DR) to newly infected individuals. Today, the need for unique measures to prevent the development and spread of HIVDR in order to sustain the effectiveness of large ART programmes in resource-poor settings is recognized.

How can countries and ART programmes in sub-Saharan Africa prepare for this challenge?

This session aims at highlighting key aspects pertaining to HIVDR monitoring at a population or at a patient level in resource-limited settings.

SESSION OVERVIEW:

 Overview of Long-term ART Outcome of Adults and Pediatric Patients Receiving ART in the PASER Programme, with a Focus on the Effect of Baseline HIVDR (Implications for HIVDR monitoring approaches will be discussed)

Tobias Rinke de Wit, Amsterdam Institute for Global Health and Development (AIGHD), The Netherlands

 Experience of Kenya in Implementing HIVDR Monitoring for the Clinical Management of Patients Failing Second-line ART

Clement Zeh, Kenya Medical Research Institute, Kenya **Irene Mukui**, Ministry of Health, Kenya

 Overview of the of the SATuRN Experience in Establishing a Regional HIVDR Clinical and HIVDR Sequence Database

Tulio de Oliveira, Wellcome Trust, Africa Centre for Health and Population Studies, South Africa

• Virological and HIV Drug Resistance Outcomes of Antiretroviral Therapy in Central and West Africa: Challenges to Improve Treatment Monitoring in Contexts of Generalised HIV Epidemic

Avelin F. Aghokeng, Institut de Recherche pour le Dévelopement (IRD), France

CO-CONVENERS:

Gillian Hunt, National Institute for Communicable Diseases, South Africa



Dr. Gillian Hunt is senior research scientist in the Centre for HIV and STI at the National Institute for Communicable Diseases. Dr. Hunt received her PhD in Virology from the University of the Witwatersrand in 2003, and has been working in the field of HIV since 1996. The Drug Resistance Surveillance Laboratory is accredited by the World Health Organization as Regional Drug Resistance Testing Laboratory and performs surveillance testing for South African and neighboring countries. In addition, the laboratory is involved in clinical research projects and assay development activities.

Pascale Ondoa, Amsterdam Institute for Global Health and Development (AIGHD), The Netherlands



Dr. Pascale Ondoa is a viro-immunologist currently serving as a senior laboratory scientist at the Amsterdam Institute for Global Health and development (AIGHD) (www.aighd.org) and has more than 15 years experience with HIV research. Pascale obtained her medical degree in 1992 from the *'Centre Universitaire des Sciences de la Santé'* (CUSS)' in Cameroon and worked a few years as a medical officer in a tuberculosis hospital in Yaoundé. She was trained in Molecular Biology at the Vrij Universiteit Brussels (1999) and obtained her PhD in Biomedical Sciences (Virology) from the University of Antwerp in 2001. She completed her post-doc training in the unit of Immunology at the Institute of Tropical Medicine in Antwerp

between 2002 and 2009. During this period, Dr. Ondoa was mainly involved in the development and evaluation of alternative and affordable methods to monitor HIV disease progression and antiretroviral therapy in resource-poor settings. She was also interested in studying (incomplete or inappropriate) immune restoration upon suppressive anti-HIV treatment. Presently, Dr. Ondoa works on several projects evaluating HIV drug resistance in Africa. She also conducts research on laboratory systems, with specific focus on alleviating barriers to the laboratory workforce and improving the contribution of laboratory screening tests to antenatal care in Sub Saharan Africa (www.aighd.org/projects/socialab)

SPEAKERS:

Tobias Rinke de Wit, Amsterdam Institute for Global Health and Development (AIGHD), The Netherlands



Since 2001 Professor Tobias Rinke de Wit (PhD) is Director Research at the PharmAccess group and is specifically affiliated with the Amsterdam Institute for Global Health and Development (AIGHD: www.aighd. org). Tobias is Principal Investigator at the Academic Medical Centre (AMC), University of Amsterdam. Originally trained as a molecular biologist, he has specialized in HIV/AIDS in Africa, in particular affordable diagnostics, HIV epidemiology and HIV drug resistance. Tobias is also performing operational research in the context of various PharmAccess operations, like SafeCare (http://www.safe-care.org/), and the Medical Credit Fund (http://www.medicalcreditfund.org/). Between 1990 and 2000 he was Senior Scientist and

Associated Professor in Addis Ababa, Ethiopia, working on tuberculosis, leprosy, leishmaniasis and HIV, mostly in the areas of immunology, virology and prevention. In 2005 he was awarded a professorship at the University of Amsterdam in Sustainable Healthcare, in particular Affordable Diagnostics. At the Department of Global Health of the AMC, under the umbrella of AIGHD he supports various health system research projects in Africa, including impact evaluations. Tobias is promotor of 10 PhD students and has published 135 articles in peer-reviewed journals.

Tulio de Oliveira, Wellcome Trust, Africa Centre for Health and Population Studies, South Africa



Prof. Tulio de Oliveira is a bioinformatician who has been working in the field since 1995. He received his PhD at the Nelson R Mandela School of Medicine, UKZN, South Africa in 2003 He was a Marie Curie research fellow at the University of Oxford, U.K. from 2004 to 2006, where he received in depth training on virus genetic analysis and molecular evolution. He is recognized as an expert on HIV genetic data and bioinformatics and has published some high-impact articles that describe bioinformatics tools and their applications to answer scientific questions related to molecular epidemiology and drug resistance. He is also very committed to capacity building and community engagement. He has trained over 2,500

researchers at his capacity building workshops and his group website, www.bioafrica.net interaction with the community via videos, blogs and tweets.

Clement Zeh. Kenya Medical Research Institute. Kenya



Dr. Clement Zeh is the current Director of the KEMRI/CDC HIV-Research Laboratory in Kisumu, Kenya and the acting HIV-Research Branch Chief. Dr. Zeh received his PhD from the University of Amsterdam, the Netherlands and has served CDC since 1999. He has over 15 years of experience in HIV/AIDS and STI research. He served as PI and co-PI in several clinical trials for PMTCT, Point-of-Care devices and HIV prevention programmes. Dr. Zeh has been instrumental in evaluation of HIV testing strategies, diagnostic and incidence tests. In 2011, Dr. Zeh was the lead author for an alternative algorithm and new frontiers for HIV diagnosis in Kenya and other resource constrained areas.

Dr. Zeh was the principal party responsible for establishing and provided strong leadership in developing a clinical laboratory that achieved ISO15189, DAIDS certification WHO-accredited as Kenyan National and Regional Reference Laboratory for HIV Drug Resistance and the first WHO accredited dried blood spot HIVDR laboratory in Africa. The laboratory is collaboration centre for the African Society of Laboratory Medicine. He is the acting coordinator for KEMRI/CDC multidisciplinary laboratories (malaria, HIV Research and Global AIDS, TB, and the International Emerging Infections Program) in Kisumu. Dr. Zeh has been honored with the CDC Director and US Ambassador's awards, excellence in Public Health Service.

Avelin Aghokeng, Institut de Recherche pour le Dévelopement (IRD), France



Dr. Avelin Aghokeng is a senior research scientist in the Institut de Recherche pour le Dévelopement (IRD) based in France and in many other countries including Cameroon, where Dr. Aghokeng conducts the majority of his research activities. Dr. Aghokeng then also acts as the Director of the IMPM-IRD-CREMER Virology Laboratory in Yaoundé Cameroon, a specialized laboratory for research on HIV genetic diversity and public health implications, emergence of new HIV strains, disease monitoring including access to viral load and surveillance of HIVDR in resource-limited settings. The CREMER lab is a WHO accredited laboratory for HIVDR surveillance since 2008 and supports programmes in Cameroon and in the sub-

region of Central Africa. Dr. Aghokeng also works with the French *Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS)*, where he co-coordinates a group of expect virologists, specifically focusing one key challenges to prevent HIVDR in sub-Saharan Africa.

Irene Mukui, Ministry of Health, Kenya



Dr. Irene Mukui has 14 years of management, clinical, and public health experience at facility, district, provincial, and national level in Kenya; she is currently the National HIV Care and Treatment Program manager in the Ministry of Health Kenya. She holds a Bachelor's degree In Medicine and a Masters in Public Health from University of Nairobi.

Dr. Mukui has worked in both health facilities providing clinical Care and has for the past 8 years spent most of her time in public health and management having served as a district medical officer of health, then as a provincial HIV AIDs and STI coordinator and is currently the managing the HIV care and Treatment

program in the Ministry of Health. As the national HIV Care and Treatment manager for the past 5 years, Dr Mukui has overseen rapid scale up of access to HIV treatment to over 680,000 currently receiving ART in Kenya, overseen the shift of HIV training from classroom based training to facility based training and establishment of mentorship structures for HIV care and Treatment. In addition Dr Mukui is intensely involved in operational research in HIV care in Kenya in various areas including treatment outcomes for children and adults, costing of HIV treatment, HIV drug resistance among others. She is has also participated in many global policy meetings including development of WHO Guidelines on use of ARVs as a guidelines development group member most recently in the 2013 guidelines.



SYMPOSIUM 15

ROLE OF LABORATORY IN SURVEILLANCE: FIELD EPIDEMIOLOGY LABORATORY TRAINING PROGRAM (FELTP)

SESSION OBJECTIVES:

The session will first describe the partnership needed between the public health laboratory and epidemiology in the performance of effective public health surveillance and response, and second, the pivotal role of FELTPs in training public health laboratory epidemiologists. This training is an important contribution to the

DATE: Thursday, 4 December

TIME: **14:45 – 16:15**L OCATION: **Room 2.4**

workforce for public health surveillance and response. The gainful collaborations and networking between the laboratory, animal, and human health sectors in the concept of one health will also be outlined. Lastly, in this session laboratory professionals will share ideas on the use of practical epidemiology, scientific research, and practice-based innovations that specifically address the needs and concerns of local health issues as well as identify challenges and potential solutions to effective public health laboratory surveillance strengthening using the FELTP strategy.

SESSION OVERVIEW:

• What is FELTP and How Does it Work for Effective Public Health Surveillance and Response in Africa?

Patrick Nguku, Nigeria FELTP

 How FELTPs Combine Public Health Laboratory and Epidemiology Skills to Solve Public Health Problems that Cross Animal and Human Health in Africa

Tura Galgalo, Kenya FELTP

 What is the Role of FELTP in Building a Public Health Laboratory Network?

Fausta Mosha, Tanzania FELTP, National Public Health Laboratory, Tanzania

• FELTP as a Strategy to Move Public Health Laboratory Surveillance Out of the Walls of the Laboratory

Elizabeth Prentice, AMPATH, South Africa

CO-CONVENERS:

Peter Nsubuga, Global Public Health Solutions, United States of America



Peter Nsubuga is a Medical Epidemiologist with a medical degree, and a public health degree from the University of California at Berkeley. Dr. Nsubuga is a graduate of the US Centers for Disease Control and Prevention (CDC) Epidemic Intelligence Service (EIS). Dr. Nsubuga worked at CDC in global health from 1998 to 2012 including a 7-year period where he oversaw the design development, and networking of Field Epidemiology and Laboratory Training Programs (FELTPs) in Africa. Dr. Nsubuga was one of the architects of the Integrated Disease Surveillance and Response strategy, and has published several peerreviewed papers and book chapters on TB and HIV, public health surveillance and response, and public

health systems development. Currently Dr. Nsubuga works as a Medical Epidemiologist in Global Public Health Solutions, public health consulting company based in Atlanta, GA, USA

Adebola Olayinka, ABU Teaching Hospital, Nigeria Inaugural Laboratory Resident Advisor, Nigeria FELTP



Adebola Olayinka served as the 1st Laboratory Resident Advisor to the Nigeria Field Epidemiology and Laboratory Training Program. She has a previous role as a laboratory director to one of the PEPFAR supported labs in Nigeria under the AIDS Prevention Initiative in Nigeria (APIN) management. She is keenly interested in Laboratory management realizing that the laboratory is key to proper diagnosis and effectiveness of interventions. She's also very interested in Medical microbiology especially the need to better understand microbes and their interaction with the human body such that prevention and treatment interventions against infectious diseases can be optimal. Her other interests include the epidemiology of

Dr. Olayinka is a Reader with the Ahmadu Bello University and a Consultant Clinical Microbiologist at the ABU Teaching Hospital, Zaria. She has a degree in medicine, a fellowship in Clinical Microbiology and a Masters in Public Health. Dr. Olayinka is a trainer, a supervisor and mentor to many. She has also served in various capacities in the University, the Teaching Hospital, various organisations and with the Federal Ministry of Health of Nigeria. She has presented at many conferences/workshops with many published journal articles.

infectious diseases, infection control and control of sexually transmitted infections, and capacity development.

SPEAKERS:

Patrick Nguku, Resident Advisor, Nigeria FELTP



Patrick Nguku is a medical epidemiologist by training, Dr. Patrick Mboya Nguku currently serves as the Resident Advisor of Nigeria FELTP (www.nigeria-feltp.net) since October 2008. He received his medical degree and PGD in HIV management from University of Nairobi in 2000 and 2003 respectively. He received his Field Epidemiology and Laboratory Program (FELTP) training from the Kenya FELTP between 2004-2006. He served as national coordinator of surveillance and response in Kenya in 2006-2008 and was instrumental to IDSR scale up and response to a multi-country rift valley fever outbreak. He also served in the multi-agency response to Ebola outbreak in Uganda in 2007. He has conducted trainings and

supported public health activities in Kenya, Uganda, South Sudan, Namibia, Botswana, Burkina Faso and Nigeria.

Since the inception of Nigeria FELTP, Patrick has supported the training of over 200 trainees in the long course and over 500 in the short course and helped develop its strategic plan. The Nigeria FELTP has three distinct tracks — medical, veterinary and laboratory and Patrick helps coordinate the 3. He also coordinates the FELTP response to polio in Nigeria through the National Stop Transmission of Polio (NSTOP). Dr. Nguku has interest and has published in epidemiology capacity building, childhood vaccine preventable diseases, surveillance and outbreak response, and one health.

Tura Galgalo, Laboratory Resident Advisor, Kenya FELTP



Tura Galgalo, a Kenyan, currently works for African Field Epidemiology Network (AFENET) as Laboratory Resident Advisor for Kenya Field Epidemiology and Laboratory Training Program (K-FELTP) based in Nairobi. He has over 15 years working experience in clinical, research and public health laboratory field. Tura started his laboratory career with Ministry of Health in Kenya as bench scientist. He later joined US Centers for Disease Control and Prevention (US CDC) and worked in both Kenya and Rwanda as laboratory technical for Global AIDS programme and the first laboratory resident advisor for Rwanda FELTP respectively.

Tura earned Masters Degree in applied epidemiology and public health laboratory management from Jomo Kenyatta University (KE) and Bachelors degree in Biomedical Sciences and Technology from Egerton University (KE). He is currently pursuing Masters in Health Policy and Planning at London School of Hygiene and Tropical Medicine (UK).

Fausta Mosha, National Public Health Laboratory, Tanzania Previously Laboratory Resident Advisor, Tanzania FELTP



Fausta Mosha, is a medical microbiologist and epidemiologist working for the Ministry of Health and Social Welfare in Tanzania since 2005, currently as a Director for the National Public Health Laboratory since 2010. Before that she has been coordinating laboratory based trainings and also a Resident Advisor for the Tanzania Field Epidemiology and Laboratory Training Program (FELTP). She holds an MD from the University of Dar es Salaam, MSc in Microbiology from the University of Leuven, Belgium, MSc in Epidemiology and Laboratory Management from the Jomo Kenyatta University, Kenya and PhD from the University of Leuven, Belgium. She is a Principal Investigator for the international Co-operative agreement between the Centers

for Disease Control and Prevention, (CDC), Atlanta and African Field Epidemiology Network (AFENET) on a project "Laboratory Biosafety and Quality Assurance involving several Countries in Africa and the Caribbean Region. She is also a Program Manager for the East African Public Health Laboratory Networking Project (EAPHLNP) in Tanzania and Secretary for the Board of Directors of African Society for Laboratory Medicine (ASLM).

Elizabeth Prentice, AMPATH, South Africa Previously Laboratory Track Coordinator, South African FELTP



Elizabeth Prentice trained as a medical doctor at the University of the Witwatersrand, South Africa, after which she worked as a Medical Officer in Infectious Diseases at Chris Hani Baragwanath Hospital. Having completed a Diploma in Tropical Medicine and Hygiene, she then embarked upon a specialisation in Clinical Microbiology and Infectious Diseases. She interrupted her registrar time to pursue an interest in the role of the Microbiology Laboratory in communicable disease control and facilitated the laboratory component of the South African Field Epidemiology Laboratory Program for the first three years of the programme under the auspices of the Centers for Disease Control and Prevention (USA) and the National Institute of

Communicable Diseases (RSA). Having returned to complete her specialist training she worked as a Medical Specialist in the National Department of Health, in the Communicable Disease Directorate. She is presently employed as a Clinical Microbiologist, in the private health care sector, working for a nation-wide pathology practice.

SYMPOSIUM 16

LABORATORY NETWORKS IN GLOBAL HEALTH SECURITY

SESSION OBJECTIVES:

Public health laboratories networks play an essential role in global health security for reference diagnostic services, research, surveillance, and coordination of outbreak responses. The Ebola epidemic and the threat of TB, HIV and antimicrobial resistance has highlighted the importance of laboratory networks. A panel of

DATE: Thursday, 4 December

TIME: 14:45 - 16:15

LOCATION: Roof Terrace Room

experts will discuss how to build laboratory networks to improve preparedness and response to global heath security threats.

SESSION OVERVIEW:

• The Role of Health Laboratories in the Control of Infectious Diseases in Ghana – West Africa

William Ampofo, Noguchi Memorial Institute for Medical Research

• The Evolution of the Uganda VHF Laboratory Programme from Pioneer to Role Model for Global Health Security

Trevor Shoemaker, Centres for Disease Control and Prevention, Uganda

• Laboratory Network and Global Health Security: Case Study of Ebola Virus Disease Crisis in West Africa

Amadou Sall, Institut Pasteur, Senegal

• Establishment and Operation of the NICD Ebola Diagnostic Mobile Laboratory in Sierra Leone, Freetown – Lessons Learned

Janusz Paweska, National Institute for Communicable Diseases, South Africa

CO-CONVENERS:

Beth Skaggs, Centers for Disease Control and Prevention, United States of America



Beth Skaggs holds a Bachelor of Arts degree from DePauw University, Greencastle Indiana and a PhD from Purdue University. She joined CDC's Mycotic Diseases Branch as a post-doctoral fellow and in 1999 was hired to stand up the Antifungal Drugs Investigation Unit within the Branch. She continued with the Mycotic Diseases Branch for the next eight years focusing on identification of genetic markers of antifungal drug resistance and the development of diagnostic assays to detect fungal pathogens with reduced drug susceptibility. In 2007, Dr. Skaggs joined CDC's Global HIV/AIDS Program in Mozambique Africa where she worked with the Ministry of Health to build the capacity and improve the quality of the public sector

laboratory service. In 2013, Dr. Skaggs returned to CDC Headquarters and currently serves as Laboratory Team Lead for the Global Disease Detection Branch, focusing on laboratory systems strengthening and workforce development to meet Global Health Security objectives of accurate and rapid detection and reporting of epidemic prone diseases.

Lucy Maryogo-Robinson, Association of American Public Health Laboratories (APHL), United States of America



Lucy Maryogo-Robinson has served as the Director of the Global Health Program at the Association of Public Health Laboratories (APHL) since 2009. In her current role she serves as the principal investigator for the APHL Cooperative Agreement with the Division of Global HIV/AIDS at the Centers for Disease Control and Prevention (CDC). She manages a portfolio of over \$12 million for the President's Emergency Plan for AIDS Relief (PEPFAR) to support laboratory strengthening initiatives in over 20 countries in Africa, Eastern Europe, Asia and the Caribbean. She works to implement PEPFAR country operational plan objectives including participating on laboratory assessments, coordinating national laboratory strategic planning

initiatives, managing diverse project teams, organizing complex technical assistance visits and implementing laboratory twinning initiatives. She collaborates with the APHL Global Health Committee to further programme goals and implement the association's global health strategic plan. Lucy holds a Masters in Public Health degree in International Health Promotion from the George Washington University, in Washington DC.

William Ampofo, Noguchi Memorial Institute for Medical Research



William Ampofo is Head of the Virology Department, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Accra, Ghana. His research interests include molecular and serological investigations of viruses, prevention of viral infections, anti-viral therapy and viral disease burden.

Career milestones include the laboratory discovery of the first Ghanaian case of HIV in 1986, first isolation of wild type poliovirus in Ghana, confirmation of first cases in 2007 of highly pathogenic avian influenza H5N1 virus in Ghanaian poultry and establishment of the National Influenza Centre in Ghana 2007. In

December 2011, he supervised the laboratory detection of the first ever cases of Lassa fever virus infection in humans and rodents in Ghana. He is also the focal point for HIV Drug Resistance Genotyping and Emerging Dangerous Pathogens Reference laboratories.

Recent collaborations include studies on Influenza, HIV, Viral Hemorrhagic fevers and investigations of plant extracts for antiviral activity. He has teaching responsibilities in the University of Ghana with about 50 publications covering medicine, immunology and microbiology.

Prof. Ampofo is a member of the WHO Global Action Plan for Influenza Vaccines Advisory Group and is the current chair of the WHO Pandemic Influenza Preparedness Framework Advisory Group. He is the Ambassador in Ghana for the African Society for Laboratory Medicine and the American Society for Microbiology and is also the President of the Ghana Cricket Association.

Trevor Shoemaker, Centres for Disease Control and Prevention, Uganda



Trevor Shoemaker is an epidemiologist with the Viral Special Pathogens Branch (VSPB) at CDC and is assigned to the CDC-Uganda country office. He serves as the viral hemorrhagic fever (VHF) surveillance and laboratory programme director. The VSPB Uganda programme specializes in the surveillance, investigation, laboratory diagnostics, and outbreak response for viral hemorrhagic fevers. He has been working in infectious disease epidemiology and public health for over 15 years. Prior to returning to VSPB, he served as an epidemiologist for the Biological Threat Reduction Program and worked in the countries of Armenia, Azerbaijan, Georgia, and Ukraine. His other previous work experience includes the

California Department of Public Health working on avian and pandemic influenza epidemiology, surveillance, and public health preparedness.

Amadou Sall, Institut Pasteur, Senegal



Amadou Sall is currently the head of the Arboviruses and viral hemorrhagic fever unit, director of the WHO collaborating centre and member of the governing board at Institut Pasteu de Dakar. He is also the director and founder of the international course on "arboviruses and viral hemorrhagic fever diagnosis, prevention, control, and outbreak management" organized by Institut Pasteur Dakar in partnership AMP, Ministry of Health of Senegal and University Cheikh Anta Diop Dakar.

Dr. Sall is a virologist and has a PhD in Public Health. He received his scientific education at Universities Paul Sabatier at Toulouse, Paris Orsay and Pierre et Marie Curie in France.

Dr. Sall's research focused primarily on ecology and evolution of arboviruses and viral hemorrhagic fever and diagnostics of the latter viruses is a priority in his laboratory. He has published more than 60 papers and book chapters and given more than 80 scientific communications in international meetings.

Janusz Paweska, National Institute for Communicable Diseases, South Africa



Janusz T. Paweska is a head of the Centre for Emerging and Zoonotic Diseases at the National Institute for Communicable Diseases of the National Health Laboratory Service, (NICD-NHLS) Sandringham, South Africa. He is also the regional director of the Global Viral Network and the deputy director of the Southern Centre for Infectious Diseases Surveillance. In 2001 he moved to become a Head of the Special Pathogens Unit of the NICD-NHLS and to manage the only maximum suite biosafety facility (BSL-4) on the African continent. From 2011 is a Head of the Centre for Zoonotic and Emerging Diseases at NICD/NHLS. He is also a Reader/Associate Professor at the School of Pathology, Faculty of Health Sciences, University of

Witwatersrand, and an Extraordinary Professor at the University of Pretoria and an NRF B2 rated scientist.

He authored or co-authored 130 articles published in peer reviewed journals and 12 book chapters. He is supervising a number of MSc, PhD and postdoc students.

Prof. Paweska has been a part of international research expeditions and international outbreak responses, including the investigations, controlling and diagnosis of the 2002 Ebola outbreaks in Gabon, the 2005 Marburg disease outbreak in Angola, the 2006 Rift Valley fever outbreak in Kenya, the 2009 Ebola outbreak in the Democratic Republic of Congo. During a highly fatal nosocomial outbreak of a viral haemorrhagic fever in Johannesburg in 2008 he led the discovery of a new Old World Arenavirus, he named Lujo virus. In 2010 and 2011 he led the Ebola ecology study in the Democratic Republic of Congo. In 2014 he established and managed the operation of Ebola mobile diagnostic laboratory in Sierra Leone as a part of the WHO-GOARN Ebola outbreak response in West Africa.

SYMPOSIUM 17

ADVANCES IN IMPLEMENTING QUALITY ASSURED POINT-OF-CARE TESTING

SESSION OBJECTIVES:

More than 118 million people received HIV tests in 124 low-and middle-income countries in 2012 (WHO, 2013). This expansion in HIV testing has largely been possible due to the scale up of rapid POC HIV testing. Similarly implementation and scale up of other HIV-related POCT, in particular CD4 has been rapid over the last

DATE: Thursday, 4 December

TIME: **14:45 – 16:45** LOCATION: **Room 1.6**

five years, with 23% CD4 testing in 2013 reportedly being performed using POC technologies (WHO, 2014). POCT provides an opportunity to greatly decrease test turnaround time and increase the availability, scope and coverage of testing beyond urban centres to reach the rural population. POCT has been shown to reduce patient loss to follow-up and increase access to ART (Wynberg, 2014).

Rapid scale-up of POC testing without simultaneous capacity building of quality assurance (QA) is counter-productive if service providers are unable to guarantee adherence to minimum standards and accuracy of results. In order to address common root causes of incorrect results and errors, it is imperative that a concerted effort is made at all levels to significantly step up efforts to systematically improve and assure quality of testing. Improving quality of testing will reduce the prevalence of incorrect results that negatively impact national HIV programmes (Moodley, 2008, Greig, 2011).

New guidance and associated tools that underscore the need for more effort, funding and leadership, advocacy, new innovations and better coordination is currently being launched by WHO/ CDC to set a new benchmark for quality improvement activities. Many countries have made commendable advancements in the scale up of QA programmes for POCT including increased training and supervision efforts, improved documentation and robust proficiency testing programmes. This session will highlight these advancements and provoke discussion on the way forward for improving the quality of POCT for HIV.

SESSION OVERVIEW:

• Update on Recent Guidelines for Quality Assurance for Point-of-Care Testing

John Nkengasong, Centers for Disease Control and Prevention, United States of America

 Misclassification of Data and Why it's Important for Quality Assurance Advances

Geoffrey Chipungu, Centres for Disease Control and Prevention, Malawi

 The Use of Remote Connectivity for Quality Monitoring of Instrument-Based Point-of-Care Testing

Leigh Berrie, National Health Laboratory Service, South Africa

• Standardisation of Material for Quality Assurance and External Quality Assurance Proficiency Testing

Lesley Scott, University of the Witwatersrand, South Africa

CO-CONVENERS:

Jessica Markby, World Health Organization, Switzerland



Dr. Jessica Markby currently holds the position of Diagnostics Advisor at the World Health Organization in Geneva. Her areas of interest include development and capacity building of HIV diagnostic and monitoring programmes in resource constrained countries, translational research of appropriate HIV diagnostics technologies and population health surveillance. Dr. Markby finished her PhD in Immunology and Pathology at Monash University, Australia in 2005, and subsequently obtained her Master of Public and Tropical Medicine. Dr. Markby has nine years post-doctoral field experience most of which was spent living in Papua New Guinea (PNG) and Cambodia. She completed her first post-doctoral fellowship at the University of

Melbourne in the Department of Biochemistry, followed by her first overseas posting at the PNG Institute of Medical Research, where she headed a high throughput molecular malaria laboratory. Subsequently, she worked with the National Institute of Public Health Laboratory (NIPHL) in Cambodia as a Technical Adviser. More recently, she spent four years working with Clinton Health Access Initiative (CHAI) PNG as the laboratory adviser, implementing the national EID programme, coordinating and implementing CD4 monitoring (Lab and POC) and viral load testing. She continued this work with the Burnet Institute managing a Global Fund project and conducting translational HIV research.

Wendy Stevens, National Health Laboratory Service, South Africa



Professor Wendy Stevens is currently Professor and Head of the Department of Molecular Medicine and Haematology at the University of the Witwatersrand and the National Health laboratory Service (NHLS) (2003-current), the largest Haematology department in South Africa. Her research efforts have been largely focused in HIV for the past 15 years; this can be supported by over 170 peer reviewed publications and 180 conference presentations. She has contributed significantly to the development of capacity for affordable, accessible HIV diagnosis and monitoring in South Africa and over 60 centres in sub-Saharan Africa. Research activities have included the expansion of early infant diagnosis of HIV, affordable viral

load, CD4 and investigation of HIV drug resistance. She has been an advisor to and investigator for the following HIV research networks: the International AIDS Vaccine Initiative (IAVI) (New York), the HIV Vaccine Trials Network (HVTN) (NIH funded, Seattle), the AIDS Clinical Trials Group (ACTG) (NIH funded) and the Microbicide Development Program (UK based funding), amongst others. Other funders of her research include: the Netherlands AIDS fund, Pharmaccess, the Gates Foundation, the Grand Challenges Canada, Global Fund, the CDC and USAID. Recently, since November 2010, she has been appointed head of National Priority Programs at the NHLS focusing on laboratory efforts related to priority diseases including HIV and TB. Her portfolio included the National Rollout of GeneXpert technology across microscopy centres in South Africa. This has involved establishing 207 centres that had by August 2014 conducted over 4 million Xpert MTB RIF assays. She has also won several innovation awards in 2013 and her Department was nominated as the Best Academic Pathology Department in South Africa.

SPEAKERS:

John Nkengasong, Centers for Disease Control and Prevention, United States of America



Dr. Nkengasong is the current Associate Director for Laboratory Science at the Division of Global HIV/AIDS, Center for Global Health, CDC Atlanta. He is also the Chief of the International Laboratory Branch and co-chairs the President's Emergency Plan for AIDS Relief's (PEPFAR) Laboratory Technical Working Group. He joined CDC in 1995 as Chief of the Virology Laboratory, CDC Abidjan, Ivory Coast, and became Chief of the International Laboratory Branch, Global AIDS Program in 2005. He has received numerous awards for his work including, but not limited to, the US Secretary of Health and Human Services Award for excellence in Public Health Protection Research, the Sheppard Award, and Director's Recognitions Award. He is the founding chair of the board of directors of the African Society for Laboratory Medicine.

Geoffrey Chipungu, Centres for Disease Control and Prevention, Malawi



Dr. Geoffrey Chipungu is a Malawian Medical Doctor and Clinical Microbiologist working with US CDC Malawi country office as a laboratory advisor. Dr. Chipungu gives technical assistance to the Ministry of Health Diagnostic department and National Reference laboratory. He also works activity manager on PEPFAR funded laboratory capacity building collaborative agreements.

The collaborative agreements involve improving quality management systems through SLMTA implementation, scale up of CD4 testing, Gene Xpert and Viral load, adverse event monitoring and opportunist infection diagnostics.

Dr. Chipungu studied his medical degree at University of Malawi's College of Medicine and specialized at the University of Cape Town and attained a post-graduate Diploma in Tropical Medicine at University of Witwatersrand. He previously lectured and headed the Department of Pathology and Medical Laboratory Sciences at the University of Malawi's College of Medicine. Dr. Chipungu's research interests at the College of Medicine involved novel diagnostics for Tuberculosis and capacity building for Tuberculosis research.

Leigh Berrie, National Health Laboratory Service, South Africa

Dr. Leigh Berrie is currently the Operations Manager for the National Priority Programmes of the NHLS (Sept 2012-current), with a portfolio focusing on HIV viral load and CD4 monitoring, Early Infant Diagnosis, and TB diagnosis through the roll-out of the GeneXpert technology. Her management, coordination and implementations of these programmes has contributed significantly to improving access to these services in South Africa.

Her research efforts have included evaluation of new technologies for HIV viral load and Early Infant Diagnosis which can be supported by various publications and conference presentations. She has vast expertise with current commercial molecular diagnostic technologies available for HIV and TB.

Lesley Scott, University of the Witwatersrand, South Africa



Professor Lesley Scott is an applied scientist in the Department of Molecular Medicine and Haematology at the University of the Witwatersrand in Johannesburg, South Africa. Lesley is head of Research and Development for the National Priority Program in South Africa with a focus on designing, developing, evaluating and implementing laboratory diagnostic technologies for HIV and TB infected individuals. Her experience extends from high throughput to point-of-care technologies. Lesley has over 50 publications and 100 abstracts at local and international conferences, and an inventor on three diagnostic patents and a trademark.

16:30-18:00 - Auditorium 1

Closing Session Chair:

❖ Prof. Emmanuel Idigbe, Immediate Past Director General of the Nigerian Institute of Medical Research (NIMR)

Special Guests:

- Sagie Pillay, ASLM2014 Conference Co-Chair, Sakhile Development and Research, South Africa
- ❖ Dr. Tsehaynesh Messele, African Society for Laboratory Medicine

Rapporteurs:

- Jonathan Lehe, Clinton Health Access Initiative
- Ndlovu Ngobile, African Society for Laboratory Medicine
- Dr. Lawrena Okoro, Medical Laboratory Science Council of Nigeria
- * Adebola Olayinka, Ahmadu Bello University and Teaching Hospital, Nigeria



Aleremq

It's a matter of life or death.



Globally, access to anti-retroviral treatment (ARV) for children under 15 years is only half that of adults.¹



One third of infants living with HIV die before their first birthday, and half die before the age of two years.¹



Currently Early Infant Diagnosis is one of the biggest challenges to get children on treatment.



Alere™ q HIV-1/2 Detect is a nucleic acid amplification test which provides next generation virological HIV-1 and HIV-2 results within 50 minutes.

To learn more about our range of technologies and their positive impact on patients' lives, visit **alerehiv.com**

 Global HIV/AIDS Response: Epidemic update and health sector progress towards Universal Access, WHO/UNAIDS/UNICEF Progress Report 2011.

Alere $^{\rm M}$ q HIV-1/2 Detect available for Investigational Use Only (IUO). Product availability varies by region.





SUPPORTERS AND CORPORATE SPONSORS

Conference Supporter

National Health Laboratory Service

The National Health Laboratory Service (NHLS) is the largest diagnostic pathology service in South Africa with the responsibility of supporting the national and provincial health departments in the delivery of healthcare. The NHLS provides



laboratory and related public health services to over 80% of the population through a national network of laboratories.

Strategic Partner Sponsor

Daktari Diagnostics

Daktari Diagnostics develops point-of-care diagnostics that address the needs of patients, healthcare providers, and institutions in resource limited settings. We strive to provide the highest quality diagnostics, at an affordable price, that can be used by anyone, anywhere in the world.



Official Airline Network Sponsor

STAR ALLIANCE

The Star Alliance network is the leading global airline network, with the highest number of member airlines, daily flights, destinations and countries flown to. It was established in 1997 as the first truly global airline alliance to offer customers convenient worldwide reach and a smoother travel experience.

Platinum Sponsors

Abbott

Abbott Molecular, leader in molecular diagnostics specializes in the analysis of DNA and RNA at molecular level. Abbott Molecular's tests detect subtle but key changes in patients' genes and chromosomes and have the potential to aid with early detection or diagnosis, which can influence the selection of appropriate therapies, and may assist with monitoring of disease progression.



Roche Diagnostics

Roche, a pharmaceutical company founded in Basel, Switzerland creates innovative medicines and diagnostic tests that help millions of patients globally. A leader in personalised healthcare, Roche was one of the first companies to bring targeted treatments to patients. Our purpose statement of "Doing now what patients need next" ensures we deliver medical solutions right now while we develop innovations



for the future. Our local South African organization is ISO 13485 certified and committed to capacity building initiatives through ongoing training of laboratory scientists at the Roche Scientific Campus and through our training partnership with African Centre for Integrated Laboratory Training (ACILT) ensuring highest quality and reliable results. http://www.roche.com

Gold Sponsors

Hologic

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women. The Company operates four core business units focused on breast health, diagnostics, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives.

Alere

Alere helps patients and healthcare professionals get timely and actionable information anywhere, anytime. From the hospital to the home, Alere's diagnostic products and services empower caregivers and patients with the data they need to make better decisions to achieve better health and economic outcomes.



Cepheid

Cepheid is a leading on-demand molecular diagnostics company that is dedicated to improving healthcare by developing fully-integrated systems and accurate yet easy-to-use molecular tests. The company is focusing on applications where rapid and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases and cancer.



BD

BD Biosciences, a segment of Becton, Dickinson and Company, is one of the world's leading businesses focused on bringing innovative tools to life science researchers and clinicians. Its product lines include: flow cytometers, monoclonal antibodies, research reagents, and diagnostic assays.



Silver Sponsor

bioMérieux

bioMérieux has been a world leader in in vitro diagnostics for more than 50 years. Our development has been driven by an unrelenting commitment to improve public health worldwide (clinical, agri-food, biopharmaceutical and veterinary applications). We are present in more than 150 countries through 41 subsidiaries and a network of distributors.



Travel Scholarship Sponsors

Cepheid

Cepheid is a leading on-demand molecular diagnostics company that is dedicated to improving healthcare by developing fully-integrated systems and accurate yet easy-to-use molecular tests. The company is focusing on applications where rapid and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases and cancer.



Daktari Diagnostics

Daktari Diagnostics develops point-of-care diagnostics that address the needs of patients, healthcare providers, and institutions in resource limited settings. We strive to provide the highest quality diagnostics, at an affordable price, that can be used by anyone, anywhere in the world.



Omega Diagnostics Limited

Omega Diagnostics Group PLC is a group of companies specialising in the testing for Allergies, Food Intolerance, Autoimmune and Infectious Disease. Omega Diagnostics GmbH, Genesis Diagnostics Ltd, Cambridge Nutritional Sciences and Omega Diagnostics Ltd are subsidiary companies of the Group. All manufacture and develop quality Immuno-Diagnostic tests for use in hospitals, clinics and laboratories.




Other Sponsors

The South African National Convention Bureau (SANCB)

The South African National Convention Bureau (SANCB) assists and promotes South Africa's business events and MICE industry.



EXHIBITORS



B00TH #	EXHIBITOR	B00TH #	EXHIBITOR
1	Daktari Diagnostic	30	HainLife Science
	HUMAN Diagnostics Worldwide	31	Fisher Scientific
6	GSS Health	32	Thermo Fisher Scientific
7/8	Air Filter Maintenance Services (AFMS)	33a	NHLS
	Merck Millipore	33b/33d	University of Cambridge (UK)/
10	CAVIDI		The Diagnostics Development Unit (DDU)
11	Perkin Elmer	33c	BioMerieux
12	Global Heath Network	34	-
13/14	Beckman Coulter	35	
15	International Diagnostics Centre	36	Alere
	Omega Diagnostics	37	Bio-Rad
	The Scientific Group	38	Siemens
	Beryl Laboratory Solutions	39	Abbott
	Clinical and Laboratory	40	Randox
	Standards Institute (CLSI)	41/42	ROCHE
21	Labstix Diagnostics	43	Laboratory Infrastructure Solutions (LIS)
22	Oneworld Accuracy	44	Kat Laboratory & Medical
23	Longhorn Vaccines & Diagnostics	45	Aldatu Biosciences
	MDG Health Solutions	46	FIND
24	Disa*Lab	47	American Society for Microbiology
25-28	Sysmex and Partec	48	QIAGEN
29	Cepheid		

Abbott B00TH #39

Abbott Molecular, leader in molecular diagnostics specializes in the analysis of DNA and RNA at



molecular level. Abbott Molecular's tests detect subtle but key changes in patients' genes and chromosomes and have the potential to aid with early detection or diagnosis, which can influence the selection of appropriate therapies, and may assist with monitoring of disease progression.

Air Filter Maintenance Services......B00TH #7 & 8

Providing CONTAINMENT solutions for the research and diagnostics labs across



all of Africa and other parts of the world — Services include, Design, construction of Bsl 1 — Bsl 3 ag Facilities. Modular MCL $^{\text{TM}}$ Facilities as well as traditional lab design. Mechanical installations for the required negative pressure, Certification of Biological safety cabinets and supply of all lab equipment.

Aldatu Biosciences B00TH #45

Aldatu Biosciences is applying proprietary innovations in genotyping technology (PANDAATM)



to the development of affordable diagnostic tools for HIV drug resistance detection in sub-Saharan Africa. Our focused approach quickly and sensitively captures clinically actionable drug resistance information that allows clinicians to prescribe the most effective ARVs at the lowest cost.

Alere helps patients and healthcare professionals get timely and actionable information anywhere, anytime. From the hospital to the home, Alere's diagnostic products and services empower caregivers



and patients with the data they need to make better decisions to achieve better health and economic outcomes.

American Society for Microbiology B00TH #47

The American Society for Microbiology is the oldest and largest single life science membership organization in the world. Membership has grown



from 59 scientists in 1899 to 43,000 members today, with nearly half located outside the United States. ASM's mission is to advance the microbiological sciences as a vehicle for understanding life processes and to apply and communicate this knowledge for the improvement of health, environmental, and economic well being worldwide.

Beckman Coulter B00TH #13 & 14

Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. Our diagnostic systems



are found in hospitals and other critical care settings around the world and produce information used by physicians to diagnose disease, make treatment decisions and monitor patients. Scientists use our life science research instruments to study complex biological problems including causes of disease and potential new therapies or drugs.

Beryl Labs B00TH #19

Beryl Labs provides turnkey laboratory solutions for companies looking to build new labs or renovate their existing labs -Simplifying to process for all. By



leveraging our international resources, we are able to build the best labs in Africa.

BD is a medical technology company that serves healthcare institutions, life science, researchers, clinical laboratories, industry and the



general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products.

bioMérieux B00TH #33c

bioMérieux has been a world leader in in vitro diagnostics for more than 50 years. Our development has been driven by an unrelenting commitment to improve public health worldwide (clinical, agri-food, biopharmaceutical



and veterinary applications). We are present in more than 150 countries through 41 subsidiaries and a network of distributors.

Bio-Rad Laboratories continues to play a leading role in the advancement of scientific discovery



by providing a broad range of innovative products to the life science research and clinical diagnostic markets.

Founded in 1952, Bio-Rad serves research and industry customers around the world through its global network of operations.

Cavidi B00TH #10

Cavidi is an HIV viral load specialist focusing on nearpatient decentralized testing. Our

manual test ExaVir Load has been used over 400,000 times in resource limited settings. We provide solutions to increase access to viral load and improve treatment of HIV. Learn more at our booth or at www.cavidi.se.

Cepheid is a leading on-demand molecular diagnostics company that is dedicated to improving healthcare by developing fully-integrated systems and accurate yet easy-to-



use molecular tests. The company is focusing on applications where rapid and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases and cancer.

Clinical and Laboratory Standards Institute (CLSI).... BOOTH #20

The Clinical and Laboratory Standards Institute (CLSI) sets the standard for quality in clinical laboratory testing worldwide by setting and



upholding standards that drive quality test results and improve health care. A not-for-profit membership organization, CLSI brings together the global laboratory community to foster excellence in laboratory medicine.

Daktari Diagnostics.....B00TH#1

Daktari Diagnostics develops point-of-care diagnostics that address the needs of patients, healthcare providers, and institutions in resource limited



settings. We strive to provide the highest quality diagnostics, at an affordable price, that can be used by anyone, anywhere in the world.

Disa*Lab is a comprehensive Laboratory Management Information System (LIMS) developed in Africa specifically to meet the challenges of developing countries in resource poor settings.



Find B00TH #46

Launched in 2003, FIND is an international non-profit organization that bridges local understanding, global expertise



and international partnerships to advance comprehensive diagnostic solutions and overcome diseases of poverty. including tuberculosis, malaria, sleeping sickness, Hepatitis C, Leishmaniasis and Chagas disease. FIND creates an enabling environment for innovative diagnostic developments through specimen banks, reagent development, and better market visibility, and we support uptake of diagnostic tests through implementation, quality assurance and lab strengthening work. FIND is a mobilizer to increase the impact of diagnostics: access to accurate treatment, disease control and eradication, efficient health care spending and empowered individuals, communities and countries.

Fisher Scientific B00TH #31

Fisher Scientific is a leading provider of laboratory products and services to the worldwide



scientific community. We are proud to serve global health initiatives by providing technologies products and services that enable our customers to make the world healthier, cleaner and safer. We are your single resource for today's research and tomorrow's discovery. www.fishersci.com

GSSHealth......B00TH #6

Global Scientific Solutions for Health (GSSHealth) serves international public health campaigns, providing management consulting and technical assistance services with a global



outlook and a passion for sustainable solutions. GSSHealth works to strengthen public health programmes, clinical and research laboratories and laboratory networks to support the provision of high quality, sustainable interventions, disease surveillance, diagnosis and therapeutic monitoring.

Hain Lifescience SA

Hain Lifescience SA (Ptv) Ltd is a leading supplier of a full range state of the art, molecular based, diagnostic tests for tuberculosis infections. We provide the Southern African market



with high quality, accurate and cost effective solutions, as well as molecular based diagnostic assays for microbiological, dental and genetic conditions.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and



surgical products, with an emphasis on serving the healthcare needs of women. The Company operates four core business units focused on breast health, diagnostics, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development programme, Hologic is committed to improving lives.

HUMAN Diagnostics Worldwide.....

..... B00TH #5

It is today one of the few global players in the in vitro diagnostics industry, maintaining what is perhaps



Diagnostics Worldwide

the broadest distribution and service & support network in



the world. We offer a variety of products and services from Clinical Chemistry to Molecular Diagnostics and from Manual Instruments to Fully Automated Analyzers.

International

The IDC facilitates the development, evaluation and implementation of accessible, quality assured IVDs for global health through information sharing



and advocacy. The IDC brings together diagnostic companies, developers and international partners to provide advocacy and a rich platform of information to assist those designing, developing and implementing IVDs for global health.

KAT Laboratory & Medical (Pty) Ltd B00TH #44

KAT Laboratory & Medical (Pty) Ltd is a diagnostic company supplying various



laboratories and clinics across Southern Africa. The sales teams are all qualified Medical technologists, with over 85 years of experience in the Medical diagnostic field. The company has nationwide coverage with the head-office in Gauteng, situated in Roodepoort, and branches in Kwazulu-Natal and Lesotho as well as Botswana. Our factory trained service engineers are always in contact with our suppliers to ensure our analysers are always up to date with any upgrades or services that may be need to be done.

Laboratory Infrastructure Solutions (LIS)..... . BOOTH #43

Laboratory Infrastructure Solutions offers custom deployment laboratory infrastructure solutions, entailing containerized BSL-3 laboratories, solar energy PCR-laboratories and mobile laboratories. Each



laboratory is engineer designed, factory tested and site certified. Laboratories are custom made in an ISO 900:2008 certified factory. Find us at stand 43, ASLM Conference. Contact us at http://lis-labs.com/contact-us/

Labstix Diagnostics B00TH #21

Labstix Diagnostics is a specialized diagnostic company providing in all



your diagnostic needs from rapid diagnostic tests, Point of Care analyses to Turnkey Laboratory projects. Labstix Diagnostics can advise, supply and even manage your Lab. Labstix Diagnostics partnered with esteemed suppliers, leading the way in Innovative Laboratory technology.

Longhorn Vaccines & Diagnostics/ MDG Health Solutions..... B00TH #23

Longhorn Vaccines & Diagnostics' PrimeSuite® of molecular diagnostic and NGS technologies are safe, reliable, accurate, collection-to-detection systems



for rapidly inactivating infectious biological pathogens while preserving genomic RNA/DNA integrity even at elevated temperatures, with samples transported at ambient temperature over extended time periods. Sales in Africa are through MDG Health Solutions.

Merck Millipore B00TH #9

Please visit the Merck Millipore booth at ASLM. Merck Millipore is the designer and manufacturer of the new, exciting Muse Auto CD4/CD4% system. The Muse Auto CD4/ CD4% system was developed especially to meet the T cell monitoring needs for the



African laboratory. Invest your time in a demonstration of the Muse Auto CD4/CD4% system!

National Health Laboratory Service B00TH #33a

The National Health Laboratory Service (NHLS) is the largest diagnostic pathology service in South Africa with the responsibility of



supporting the national and provincial health departments in the delivery of healthcare. The NHLS provides laboratory and related public health services to over 80% of the population through a national network of laboratories.

Omega Diagnostics Limited......B00TH #16

Omega Diagnostics Group PLC is a group of companies specialising in the testing for Allergies, Food Intolerance, Autoimmune and Infectious Disease. Omega Diagnostics GmbH, Genesis Diagnostics Ltd, Cambridge Nutritional Sciences and Omega Diagnostics Ltd are subsidiary companies of the Group.



All manufacture and develop quality Immuno-Diagnostic tests for use in hospitals, clinics and laboratories.

Oneworld Accuracy Inc. B00TH #22

The Oneworld Accuracy Collaboration empowers public health groups to



become national EQA providers as part of a stepwise strategy to achieve testing accuracy. We provide the tools they need to succeed: programmes, OASYS (Oneworld Accuracy System), training and the collective experience of more than 40 national Collaboration peers.

Perkin Elmer B00TH #11

PerkinElmer is a global leader focused on improving Human and Environmental Health, for the better. PerkinElmer develop, manufacture. sell and service innovative solutions



to meet needs of scientists and researchers who require fast, reliable and precise results. At PerkinElmer, we make a difference everyday – helping Scientists, Clinicians and Governments detect earlier and more accurately to improve the Health and Safety of Humans and the Environmental.

QIAGEN N.V. is a Netherlands holding company publically traded providing worldwide Sample & Assay Technologies used to isolate biological materials (DNA, RNA and proteins) from biological samples and provide



valuable molecular information. QIAGEN markets 500+ products such as consumable kits and automated workflow solutions used in: Molecular Diagnostics, Applied Testing (forensics, veterinary and food safety), Pharmaceutical/Biotechnology companies and Academia (life sciences research). Further information can be found at HYPERLINK "http://www.qiagen. com"www.qiagen.com

Randox Laboratories

Patient health is reliant on accurate and timely diagnosis but this can only be facilitated through the use of quality diagnostic testing solutions. The Randox range of reagents, quality controls and RX series of chemistry analysers offer the ultimate in quality and performance, ensuring accurate and

Roche Diagnostics.....B00TH #41 & 42

Roche, a pharmaceutical company founded in Basel, Switzerland creates innovative medicines and diagnostic tests that help millions of patients globally. A leader in personalised

reliable results are delivered.



healthcare. Roche was one of the first companies to bring targeted treatments to patients. Our purpose statement of "Doing now what patients need next" ensures we deliver medical solutions right now while we develop innovations for the future. Our local South African organization is ISO 13485 certified and committed to capacity building initiatives through ongoing training of laboratory scientists at the Roche Scientific Campus and through our training partnership with African Centre for Integrated Laboratory Training (ACILT) ensuring highest quality and reliable results. http://www.roche.com

is one of the world's largest



suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases. Siemens also makes healthcare faster, better and more cost-effective, www.siemens.com/ diagnostics

Sysmex and Partec B00TH #25-28

Sysmex Corporation is a global IVD manufacturer of haematology and other core lab diagnostic



solutions. Partec's Essential Healthcare division develops, manufactures and distributes dedicated diagnostic solutions in the global fight against HIV/AIDS, TB and Malaria. Both, Sysmex and Partec, are well known in their fields of business not only as experts and pioneers but also as stable, reliable partners having a long-term perspective for all their stakeholders. By joining forces in 2013, Sysmex and Sysmex Partec (formerly known as Partec) now offer advanced and integrated solutions and a best-in-class support network across a range of platforms, including (fluorescence) flow cytometry and microscopy to combat HIV/AIDS, TB and malaria together. Integrated solutions represent the best opportunity for effectively combating these co-interactive pandemics.

The Global Health Network .. BOOTH #12

The Global Health Network is a hub joining together a collection of websites to support research by sharing knowledge and methods. Global Health



Laboratories, one of these dedicated spaces, is a free, openaccess, online professional community designed for laboratory researchers and staff to help build collaborations, exchange resources and information.

Thermo Fisher Scientific BOOTH #32

Thermo Fisher Scientific is the world leader in serving science, with revenues of Thermo Fisher SCIENTIFIC

\$17 billion and 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our four premier brands — Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services — we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support.

The Scientific Group B00TH #17 & 18

The Scientific Group is a sales and distribution company with 31 year's experience in our industry. We sell, supply and service clinical diagnostics,



Bioscience and medical fields with both equipment and consumables through our exclusive agreements with our international principals. We are able to offer our customers "basket" products and technical support through a service department of 48 factory-trained engineers. This is also of great benefit in obtaining contracts throughout Sub-Saharan Africa. With 185 staff members, we are proud to be ISO 9001:2008 accredited and have a BEE status, thus reflecting our commitment to continually improve our footprint.

University of Cambridge (UK)/ The Diagnostics Development

University of Cambridge
(UK) was established
over a decade ago by
a group of industry scientists
from a multinational diagnostic
company. The goal of DDU is to

develop innovative tests specif-





ically for resource limited settings. The team has developed two technology platforms, SAS (signal Amplified System) for protein targets and SAMBA (Simple AMplification Based Assay) for nucleic acids. A spinout company, Diagnostics for the Real World Ltd (DRW), was established in the bay area (USA) in 2002, to support scale-up, validation and manufacturing of market ready tests. DRW is ISO 13485 certified to ensure that a high standard of quality management system is maintained in the design of its in vitro diagnostic medical devices.

NOTES		

CONFERENCE AT A GLANCE

	Sunday, 30 November	l	December	Tuesday, 2 December		Wednesay, 3 December		Thursday, 4 December		
	Registration 07:30 – 19:00	Registration	Registration 07:30 – 16:30 Registration 07:30 -		07:30 – 16:30	Registration 07:30 – 16:30		Registration 07:30 – 14:00		
		Exhibits 10:00 – 17:00		Exhibits 10:00 – 17:00		Exhibits 10:00 – 17:00		Exhibits 10:00 – 14:30		
07:00		Morning Seminars		Morning Seminars		Morning Seminars		Morning Seminars		
07:30										
08:00										
08:30										
09:00										
09:30		Laboratory I	ary 1: Medicine and s Disease	Plenary 2: Laboratory Medicine and Policy		Plenary 3: Innovation in Diagnostics		Plenary 4: Disease-Speciic Threats		
10:00	Seminars		s disease itrol							
10:30										
11:00				Oral Sessions		Oral Sessions		Oral Sessions		
11:30		Oral S	essions							
12:00										
12:30										
13:00			Doctoro	Mid-Day Seminars	Dootovo		Dootowo		Dantava	
13:30		Mid-Day Seminars	Posters and Oral Posters		Posters and Oral	Mid-Day Seminars	Posters and Oral	Mid-Day Seminars	Posters and Oral	
14:00					Posters		Posters		Posters	
14:30										
15:00	Opening Ceremony	Symposia		Symposia		Symposia		Symposia		
15:30										
16:00										
16:30		Special Session:								
17:00		Frontline Experience with the	Round Tables		und bles	Round Tables		Closing Ceremony		
17.00		Ebola Outbreak in West	rables	iai	DIES					
17:30	Opening Reception	Africa	n West Africa							
18:00										
18:30						Awards				
19:00		Evening Seminars		Evening Seminars		Ceremony				
19:30										
20:00							Awards Dessert Reception			
20:30										

35 million people are living with HIV. 70% of them live in remote areas with limited access to care.

Until now.





Bring everyone the care they need with the ultra-portable, wireless, battery-powered

DAKTARI CD4



Be Efficient

Start up and begin testing in one minute, delivering results while the patient is on-site.



Be Flexible

Run 50 tests per battery charge and spend more time where it matters most: with patients.



Be Connected

Securely transmit your results in real time to monitor performance, inventory, and patients remotely.



TODAY THERE IS NO PLACE OUT OF REACH.